<SEC-DOCUMENT>0001731122-21-000829.txt : 20210513
<SEC-HEADER>0001731122-21-000829.hdr.sgml : 20210513
<ACCEPTANCE-DATETIME>20210513162950
ACCESSION NUMBER:		0001731122-21-000829
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		39
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210513
DATE AS OF CHANGE:		20210513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANAVEX LIFE SCIENCES CORP.
		CENTRAL INDEX KEY:			0001314052
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				208365999
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37606
		FILM NUMBER:		21920081

	BUSINESS ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163
		BUSINESS PHONE:		800-689-3939

	MAIL ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Thrifty Printing Inc.
		DATE OF NAME CHANGE:	20050111
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>e2736_10-q.htm
<DESCRIPTION>10-Q
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-size: 14pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 18pt"><B>FORM 10-Q</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Mark
One)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 31.5pt"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&#9746;&nbsp;<FONT STYLE="font-size: 12pt">QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE&nbsp;ACT&nbsp;OF 1934</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
the quarterly period ended: <B><U>March 31, 2021</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&#9744;&nbsp;<FONT STYLE="font-size: 12pt">TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE&nbsp;ACT&nbsp;OF 1934</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
the transition period from _____to _____</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Commission
File Number: <U>001-37606</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 24pt"><B><U>ANAVEX
LIFE SCIENCES CORP.</U></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Nevada</U></B></FONT></TD>
<TD STYLE="width: 50%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>98-0608404</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction
of</FONT></TD>
<TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation or organization)</FONT></TD>
<TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification No.)</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>51
West 52<SUP>nd</SUP> Street, 7<SUP>th </SUP>Floor, New York, NY USA 10019</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Address
of principal executive offices) (Zip Code)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>1-844-689-3939</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Registrant&rsquo;s
telephone number, including area code)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>N/A</U></B><BR>
(Former name, former address and former fiscal year, if changed since last report)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Securities
Registered Pursuant to Section&nbsp;12(b) of the Act:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
<TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title
of Each Class</FONT></TD>
<TD STYLE="vertical-align: top; padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Trading
Symbol</FONT></TD>
<TD STYLE="vertical-align: top; padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name
of Each Exchange on Which Registered</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
<TD STYLE="width: 32%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common Stock Par Value $0.001</FONT></TD>
<TD STYLE="width: 1%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="width: 32%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">AVXL</FONT></TD>
<TD STYLE="width: 1%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="width: 34%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">NASDAQ Stock Market LLC</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;
<B>Yes&#9744; No</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&sect;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;
<B>Yes&#9744; No</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo;
&ldquo;smaller reporting company,&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 27%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated
filer</FONT></TD>
<TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
<TD STYLE="width: 41%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="width: 26%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</FONT></TD>
<TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9744;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;&nbsp;<B>Yes&nbsp;&#9746;
No</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
the number of shares outstanding of each of the issuer&rsquo;s classes of common stock, as of the latest practicable date: <FONT> </FONT><FONT STYLE="color: black">70,038,920
shares of common stock outstanding as of May <FONT>11, </FONT>2021</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 88%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>TABLE OF CONTENTS</B></FONT></TD>
<TD STYLE="text-align: right; width: 12%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_001">PART I - FINANCIAL INFORMATION</A></FONT></TD>
<TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_002">ITEM 1. FINANCIAL STATEMENTS</A></FONT></TD>
<TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_003">ITEM 2. MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</A></FONT></TD>
<TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">18</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_004">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS.</A></FONT></TD>
<TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">32</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_005">ITEM 4. CONTROLS AND PROCEDURES.</A></FONT></TD>
<TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">32</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_006">PART II&nbsp;&nbsp;&nbsp;OTHER INFORMATION</A></FONT></TD>
<TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">33</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_007">ITEM 1. LEGAL PROCEEDINGS.</A></FONT></TD>
<TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">33</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_008">ITEM 1A. RISK FACTORS</A></FONT></TD>
<TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">33</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_009">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.</A></FONT></TD>
<TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">34</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_010">ITEM 3. DEFAULTS UPON SENIOR SECURITIES.</A></FONT></TD>
<TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">35</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_011">ITEM 4. MINE SAFETY DISCLOSURES</A></FONT></TD>
<TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">35</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_012">ITEM 5. OTHER INFORMATION.</A></FONT></TD>
<TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">35</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_013">ITEM 6. EXHIBITS.</A></FONT></TD>
<TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">36</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_014">SIGNATURES</A></FONT></TD>
<TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">37</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><A NAME="a_001"></A>PART I - FINANCIAL
INFORMATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><A NAME="a_002"></A>Item 1. FINANCIAL
STATEMENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: center"><B>ANAVEX LIFE SCIENCES CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: center">INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: center">March 31, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ANAVEX LIFE SCIENCES
CORP.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">INTERIM CONDENSED CONSOLIDATED
BALANCE SHEETS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">March 31, 2021 and September 30, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45.45pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">March 31,</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">September 30,</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; text-align: center">2020</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">(Unaudited)</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Current</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 20pt; width: 56%; text-align: left; text-indent: -10pt">Cash and cash equivalents</TD><TD STYLE="width: 8%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 12%; font-weight: bold; text-align: right">75,859,339</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">29,249,018</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Incentive and tax receivables</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">7,328,090</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,849,340</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Prepaid expenses and deposits</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">386,809</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">443,839</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Assets</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">83,574,238</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">34,542,197</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Liabilities and Stockholders&rsquo; Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Current Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accounts payable</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">3,658,052</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,989,054</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accrued liabilities</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">3,618,779</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,316,574</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Deferred grant income</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">487,111</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Liabilities</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">7,763,942</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,305,628</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Commitments and Contingencies - Note 5</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Capital stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Authorized:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 30pt; text-indent: -10pt">10,000,000 preferred stock, par value $0.001 per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 30pt; text-indent: -10pt">100,000,000 common stock, par value $0.001 per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Issued and outstanding:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 30pt; text-indent: -10pt">70,030,620 common shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 30pt; text-indent: -10pt">(September 30, 2020 - 62,045,198)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">70,032</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">62,047</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Additional paid-in capital</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">251,427,781</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">186,851,752</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accumulated deficit</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(175,687,517</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(159,677,230</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Stockholders&rsquo; Equity</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">75,810,296</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">27,236,569</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Liabilities and Stockholders&rsquo; Equity</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">83,574,238</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">34,542,197</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: center">See Accompanying Notes to Condensed Consolidated Interim
Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 5; Value: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: center"><B>ANAVEX LIFE SCIENCES CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: center">INTERIM CONDENSED CONSOLIDATED
STATEMENTS OF OPERATIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: center">For the three and six months ended
March 31, 2021 and 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center">Three months ended March 31,</TD><TD>&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center">Six months ended March 31,</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">2020</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; text-align: left; text-indent: -10pt; padding-left: 10pt">General and administrative</TD><TD STYLE="width: 3%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">2,233,745</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,720,142</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">3,704,401</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3,072,176</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Research and development</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">6,720,841</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,053,047</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">14,646,360</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,401,715</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Total operating expenses</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(8,954,586</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,773,189</TD><TD STYLE="text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(18,350,761</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,473,891</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Other income (expenses)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Grant income</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">10,820</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">74,944</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">10,820</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">149,888</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Research and development incentive income</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">960,879</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">717,328</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">2,230,195</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,660,543</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Interest income, net</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">9,216</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,180</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">7,657</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">116,900</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Foreign exchange gain (loss), net</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(154,563</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(325,960</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">178,071</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(272,848</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Total other income, net</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">826,352</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">536,492</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,426,743</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,654,483</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Net loss before provision for income taxes</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(8,128,234</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,236,697</TD><TD STYLE="text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(15,924,018</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13,819,408</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Income tax expense, current</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(26,988</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(86,269</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(9,214</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Net loss and comprehensive loss</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(8,155,222</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(7,236,697</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(16,010,287</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(13,828,622</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">Net Loss per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 20pt">Basic and diluted</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(0.12</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.12</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(0.24</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.24</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">Weighted average number of shares outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 20pt">Basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">68,594,867</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">58,353,954</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">66,421,380</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">56,544,037</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: center">See Accompanying Notes to Condensed Consolidated Interim
Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 6; Value: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>ANAVEX LIFE SCIENCES
CORP.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">INTERIM CONDENSED CONSOLIDATED
STATEMENTS OF CASH FLOWS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">For the six months ended March 31, 2021 and 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 155.65pt 0 53.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Cash Flows used in Operating Activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Net loss</TD><TD STYLE="width: 8%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 12%; font-weight: bold; text-align: right">(16,010,287</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(13,828,622</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Adjustments to reconcile net loss to net cash used in operations:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Stock-based compensation</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">2,785,470</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,965,177</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Changes in non-cash working capital balances related to operations:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Incentive and tax receivables</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(2,478,750</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,509,202</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Prepaid expenses and deposits</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">57,030</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">195,439</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accounts payable</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(331,002</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">126,402</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accrued liabilities</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">302,205</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,062,755</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Deferred grant income</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">487,111</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net cash used in operating activities</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(15,188,223</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,988,051</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Cash Flows provided by Financing Activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Issuance of common shares</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">61,934,439</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,365,492</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Share issue costs</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(1,134,697</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Proceeds from exercise of stock options</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">998,802</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net cash provided by financing activities</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">61,798,544</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,365,492</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Increase in cash and cash equivalents during the period</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">46,610,321</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,377,441</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Cash and cash equivalents, beginning of period</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">29,249,018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">22,185,630</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Cash and cash equivalents, end of period</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">75,859,339</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">26,563,071</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">See Accompanying Notes to Condensed Consolidated Interim
Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 7; Value: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>ANAVEX LIFE SCIENCES
CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">INTERIM CONDENSED CONSOLIDATED
STATEMENT OF CHANGES IN STOCKHOLDERS&rsquo; EQUITY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">For the three months ended March 31, 2021 and 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="border-bottom: Black 1pt solid; text-align: center">Common Stock</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">Additional</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">Paid-in</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">Accumulated</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; text-align: center">Shares</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; text-align: center">Par Value</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; text-align: center">Capital</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; text-align: center">Deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; text-align: center">Total</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; width: 35%; text-indent: -10pt">Balance, January 1, 2021</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">66,962,957</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">66,964</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">213,766,108</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(167,532,295</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">46,300,777</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued under 2019 Purchase Agreement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Purchase shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">661,708</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">662</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,649,134</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,649,796</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Commitment shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,571</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(22</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Shares issued upon exercise of options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">346,900</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">347</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">998,455</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">998,802</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued under Sales Agreement, net of share issue costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,037,484</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,037</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,167,950</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,169,987</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Share based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,846,156</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,846,156</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(8,155,222</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(8,155,222</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Balance, March 31, 2021</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">70,030,620</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">70,032</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">251,427,781</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(175,687,517</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">75,810,296</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Balance, January 1, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">57,080,356</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">57,082</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">165,891,753</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(139,988,685</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">25,960,150</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued under 2019 Purchase Agreement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Purchase shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,570,424</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,571</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,365,969</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,367,540</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Commitment shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,166</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Share based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,700,753</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,700,753</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,236,697</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,236,697</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Balance, March 31, 2020</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">58,664,946</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">58,666</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">171,958,462</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(147,225,382</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">24,791,746</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See Accompanying Notes to Condensed Consolidated Interim
Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 8; Value: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>ANAVEX LIFE SCIENCES
CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">INTERIM CONDENSED CONSOLIDATED
STATEMENT OF CHANGES IN STOCKHOLDERS&rsquo; EQUITY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">For the six months ended
March 31, 2021 and 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="border-bottom: Black 1pt solid; text-align: center">Common Stock</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">Additional</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">Paid-in</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">Accumulated</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; text-align: center">Shares</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; text-align: center">Par Value</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; text-align: center">Capital</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; text-align: center">Deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; text-align: center">Total</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; width: 35%; text-indent: -10pt">Balance, October 1, 2020</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">62,045,198</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">62,047</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">186,851,752</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(159,677,230</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">27,236,569</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued under 2019 purchase agreement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Purchase shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,007,996</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,008</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,107,190</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,111,198</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Commitment shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">78,213</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">78</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(78</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Shares issued upon exercise of options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">346,900</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">347</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">998,455</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">998,802</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued under Sales Agreement, net of share issue costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,552,313</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,552</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,684,992</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,688,544</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Share based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,785,470</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,785,470</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(16,010,287</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(16,010,287</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Balance, March 31, 2021</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">70,030,620</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">70,032</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">251,427,781</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(175,687,517</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">75,810,296</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Balance, October 1, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">52,650,521</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">52,652</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">153,633,807</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(133,396,760</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">20,289,699</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued under 2019 Purchase Agreement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Purchase shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,964,584</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,965</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,359,527</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,365,492</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Commitment shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,841</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(49</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Share based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,965,177</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,965,177</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(13,828,622</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(13,828,622</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Balance, March 31, 2020</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">58,664,946</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">58,666</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">171,958,462</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(147,225,382</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">24,791,746</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See Accompanying Notes to Condensed Consolidated Interim
Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 9; Value: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40pt; text-align: left">Note 1</TD><TD STYLE="width: 2pt"></TD><TD STYLE="text-align: justify"><U>Business Description and Basis of Presentation</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 42pt; text-align: justify; text-indent: 0pt">Business</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">Anavex Life Sciences Corp. (&ldquo;Anavex&rdquo;
or the &ldquo;Company&rdquo;) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics
by applying precision medicine to central nervous system (&ldquo;CNS&rdquo;) diseases with high unmet need. Anavex analyzes genomic data
from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment
of neurodegenerative and neurodevelopmental diseases. The Company&rsquo;s lead compound ANAVEX<SUP>&reg;</SUP>2-73 is being developed
to treat Alzheimer&rsquo;s disease, Parkinson&rsquo;s disease and potentially other central nervous system diseases, including rare diseases,
such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein
2 (&ldquo;MECP2&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 42pt; text-align: justify; text-indent: 0pt">Basis of Presentation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">These unaudited interim condensed consolidated
financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&ldquo;SEC&rdquo;)
and accounting principles generally accepted in the United States of America (&ldquo;U.S. GAAP&rdquo;) for interim reporting. Accordingly,
certain information and note disclosures normally included in the annual financial statements in accordance with U.S. GAAP have been condensed
or omitted pursuant to such rules and regulations. In the opinion of management, the disclosures are adequate to make the information
presented not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">These accompanying unaudited interim condensed
consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management
are necessary for fair presentation of the information contained herein. The consolidated balance sheet as of September 30, 2020 was derived
from the audited annual financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited interim
condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes
thereto included in the Company&rsquo;s annual report on Form 10-K for the year ended September 30, 2020 filed with the SEC on December
28, 2020. The Company follows the same accounting policies in the preparation of interim reports.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">Operating results for the six months ended
March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending September 30, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">Liquidity</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">All of the Company&rsquo;s potential drug
compounds are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful
or, if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial
revenues. To date, we have not generated any revenues from our operations. The Company expects the business to continue to experience
negative cash flows for the foreseeable future and cannot predict when, if ever, our business might become profitable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40pt; text-align: left">Note 1</TD><TD STYLE="width: 2pt"></TD><TD STYLE="text-align: justify"><U>Business Description and Basis of Presentation</U> &ndash; (Continued)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">The Company believes that its existing
cash and cash equivalents, along with existing financial commitments from third parties, will be sufficient to meet its cash commitments
for up to three years after the date that these interim condensed consolidated financial statements are issued. The process of drug development
can be costly, and the timing and outcomes of clinical trials is uncertain.&nbsp;The assumptions upon which the Company has based its
estimates are routinely evaluated and may be subject to change.&nbsp;The actual amount of the Company&rsquo;s expenditures will vary depending
upon a number of factors including but not limited to the design, timing and duration of future clinical trials, the progress of the Company&rsquo;s
research and development programs and the level of financial resources available. The Company has the ability to adjust its operating
plan spending levels based on the timing of future clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">Other than our rights related to the Sales
Agreement (as defined below in Note 4), there can be no assurance that additional financing will be available to us when needed or, if
available, that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional financing on
a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and development activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">In December 2019, a novel strain of coronavirus,
COVID-19, was reported to have surfaced in Wuhan, China. In March 2020, the World Health Organization declared COVID-19 to be a global
pandemic as a result of the rapid spread of the virus beyond its point of origin.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">The global outbreak of COVID-19 continues
to rapidly evolve as of the date these interim condensed consolidated financial statements are issued. As such, it is uncertain as to
the full magnitude that the outbreak will have on the Company&rsquo;s financial condition and future results of operations. Management
is actively monitoring the global situation on its business, including on its clinical trials and operations and financial condition.
The effects of COVID-19 did not have a material impact on the Company&rsquo;s result of operations or financial condition for the period
ended March 31, 2021. However, given the daily evolution of the COVID-19 situation, and the global responses to curb its spread, the Company
is not able to estimate the effects COVID-19 may have on its future results of operations or financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 42pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-style: normal">Use
of Estimates</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify; color: gray"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">The preparation of financial statements
in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
at the date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly
evaluates estimates and assumptions related to accounting for research and development costs, valuation and recoverability of deferred
tax assets, asset impairment, stock-based compensation, and loss contingencies. The Company bases its estimates and assumptions on current
facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which
form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are
not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&rsquo;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40pt; text-align: left">Note 1</TD><TD STYLE="width: 2pt"></TD><TD STYLE="text-align: justify"><U>Business Description and Basis of Presentation</U> &ndash; (Continued)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">Principles of Consolidation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">These consolidated financial statements
include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited., a company incorporated
under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex Canada Ltd., a company
incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have been eliminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify"><FONT STYLE="font-style: normal">Fair
Value Measurements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify; color: gray"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">The fair value hierarchy under GAAP is
based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure
fair value which are the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">Level 1 - &#9;&nbsp;quoted
prices (unadjusted) in active markets for identical assets or liabilities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">Level 2 - &nbsp;&nbsp;observable
inputs other than Level 1, quoted prices for similar assets or liabilities in active &#9;&#9;markets, quoted prices for identical or similar
assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value
drivers are observable; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">Level 3 - &#9;&nbsp;assets
and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant to the fair
value of the assets or liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">The book value of cash and cash equivalents
and accounts payable and accrued liabilities approximate their fair values due to the short-term maturity of those instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">At March 31, 2021 and September 30, 2020,
the Company did not have any Level 3 assets or liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 42pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-style: normal">Basic
and Diluted Loss per Share</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify; color: gray"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">Basic income/(loss) per common share is
computed by dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during
the period. Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum
of (1) the weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of
options and warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes
of the diluted net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation
of diluted net loss per share because their effect would be anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">As of March 31, 2021, loss per share excludes
11,505,199 (September 30, 2020 &ndash; 10,576,266) potentially dilutive common shares related to outstanding options and warrants, as
their effect was anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40pt; text-align: left">Note 2</TD><TD STYLE="width: 2pt"></TD><TD STYLE="text-align: justify"><U>Recent Accounting Pronouncements</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><I>Recent Accounting Pronouncements Not
Yet Adopted</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The Company does not expect the adoption
of recently issued accounting pronouncements to have a significant impact on its results of operations, financial position or cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40pt; text-align: left">Note 3</TD><TD STYLE="width: 2pt"></TD><TD STYLE="text-align: justify"><U>Other Income</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify; background-color: white">Grant Income</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify; background-color: white">During the six months
ended March 31, 2021, the Company received $497,931 of a $995,862 research grant awarded by the Michael J. Fox Foundation for Parkinson&rsquo;s
Research. The grant will be used to fund a clinical trial in the Company&rsquo;s lead compound, ANAVEX<SUP>&reg;</SUP>2-73 for the treatment
of Parkinson&rsquo;s disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify; background-color: white">The grant income
is being deferred when received and amortized to other income as the related research and development expenditures are incurred. During
the three and six months ended March 31, 2021, the Company recognized $10,820 and $10,820, respectively (2020: $0 and $0, respectively)
of this grant on its statements of operations within grant income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify; background-color: white">During the year
ended September 30, 2017, the Company was awarded grant funding in the amount of $597,886. The grant was received in equal quarterly installments
over a period of two years ending during the year ended September 30, 2020, in exchange for a commitment to complete clinical testing
for a therapeutic drug candidate for the treatment of Rett syndrome.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify; background-color: white">The grant income
was deferred when received and amortized to other income as the related research and development expenditures were incurred. During the
three and six months ended March 31, 2020, the Company recognized $74,944 and $149,888, respectively of this grant on its statements of
operations within grant income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify; background-color: white">Research and Development
Incentive Income</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify; background-color: white">Research and development
incentive income represents the receipt by the Company&rsquo;s Australian subsidiary, of the Australian research and development incentive
credit, (the &ldquo;ATO R&amp;D Credit&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify; background-color: white">During
the three and six months ended March 31, 2021, the Company recorded research and development incentive income of $960,879 (AUD 1,244,133)
and $2,230,195 (AUD 2,980,095) (2020: $717,328 (AUD 1,203,000) and $1,660,543 (AUD 2,548,000)), respectively, in respect of the ATO R&amp;D
Credit for eligible research and development expenses incurred during the period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 13; Value: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40pt; text-align: left">Note 4</TD><TD STYLE="width: 2pt"></TD><TD STYLE="text-align: justify"><U>Equity Offering Agreements</U> &ndash; (Continued)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">2019 Purchase Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">On June 7, 2019, the Company entered into
a $50,000,000 purchase agreement (the &ldquo;2019 Purchase Agreement&rdquo;) with Lincoln Park, as amended on July 1, 2020, pursuant to
which the Company had the right to sell and issue to Lincoln Park, and Lincoln Park was obligated to purchase, up to $50,000,000 in value
of its shares of common stock from time to time over a three-year period until July 1, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">In consideration for entering into the
2019 Purchase Agreement, the Company issued to Lincoln Park 324,383 shares of common stock as a commitment fee during the year ended September
30, 2019 and agreed to issue up to 162,191 shares pro rata, when and if, Lincoln Park purchased, at the Company&rsquo;s discretion, the
$50,000,000 aggregate commitment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">During the six months ended March 31,
2021, the Company issued to Lincoln Park an aggregate of 4,086,209 (2020 &ndash; 6,014,425) shares of common stock under the 2019 Purchase
Agreement, including 4,007,996 (2020: 5,964,584) shares of common stock for an aggregate purchase price of $24,111,198 (2020: $15,365,492)
and 78,213 (2020: 49,841) commitment shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">At March 31, 2021, no amount remained
available under the 2019 Purchase Agreement (September 30, 2020: $24,111,198).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">Sales Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">The Company entered into a Controlled
Equity Offering Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020 (the &ldquo;Sales Agreement&rdquo;) with
Cantor Fitzgerald&nbsp;&amp; Co. and SVB Leerink LLC (together the &ldquo;Sales Agents&rdquo;), pursuant to which the Company may offer
and sell shares of common stock registered under an effective registration statement from time to time through the Sales Agents (the &ldquo;Offering&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">Upon delivery of a placement notice based
on the Company&rsquo;s instructions and subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell the Shares
by methods deemed to be an &ldquo;at the market offering&rdquo; offering, in negotiated transactions at market prices prevailing at the
time of sale or at prices related to such prevailing market prices, or by any other method permitted by law, including negotiated transactions,
subject to the prior written consent of the Company. The Company is not obligated to make any sales of Shares under the Sales Agreement.
The Company or Sales Agents may suspend or terminate the offering of Shares upon notice to the other party, subject to certain conditions.
The Sales Agents will act as agent on a commercially reasonable efforts basis consistent with their normal trading and sales practices
and applicable state and federal law, rules&nbsp;and regulations and the rules&nbsp;of Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 42pt; text-align: justify">The Company has
agreed to pay the Sales Agents commissions for their services of up to 3.0% of the gross proceeds from the sale of the Shares pursuant
to the Sales Agreement. The Company also agreed to provide the Sales Agents with customary indemnification and contribution rights. During
the six months ended March 31, 2021, 3,552,313 shares were sold pursuant to the Offering for gross proceeds of $37,823,241 (net proceeds
of $36,688,544 after deducting offering expenses).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Value: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40pt; text-align: left">Note 5</TD><TD STYLE="width: 2pt"></TD><TD STYLE="text-align: justify"><U>Commitments and Contingencies</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-size: 10pt; font-style: normal">a)</FONT></TD><TD><FONT STYLE="font-size: 10pt; font-style: normal">Leases </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; color: gray"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 60pt; text-align: justify"><FONT STYLE="font-weight: normal">During the
three and six months ended March 31, 2021, the Company incurred office lease expense of $29,903 and $98,290, respectively (2020: $60,861
and $110,915, respectively).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-size: 10pt; font-style: normal">b)</FONT></TD><TD><FONT STYLE="font-size: 10pt; font-style: normal">Litigation</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; color: gray"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 60pt; text-align: justify"><FONT STYLE="font-weight: normal">The Company
is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there
can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter
will not have a material adverse effect upon the Company&rsquo;s consolidated financial statements. The Company does not believe that
any of such pending claims and legal proceedings will have a material adverse effect on its consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-size: 10pt; font-style: normal">c)</FONT></TD><TD><FONT STYLE="font-size: 10pt; font-style: normal">Share Purchase Warrants</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; color: gray"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 60pt; text-align: justify">A summary of the status of the Company&rsquo;s
outstanding share purchase warrants is presented below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <TR STYLE="vertical-align: bottom">
  <TD COLSPAN="2" STYLE="padding: 0pt; text-indent: 0pt; text-align: center">&nbsp; &nbsp; &nbsp; &nbsp;</TD>
  <TD STYLE="padding: 0pt; text-align: center; text-indent: 0pt">&nbsp; &nbsp; &nbsp; &nbsp;</TD>
  <TD COLSPAN="3" STYLE="padding: 0pt; text-indent: 0pt; text-align: center">Number of Shares</TD>
  <TD STYLE="padding: 0pt; text-align: center; text-indent: 0pt">&nbsp; &nbsp; &nbsp; &nbsp;</TD>
  <TD COLSPAN="3" STYLE="padding: 0pt; text-align: center; text-indent: 0pt">Weighted Average Exercise Price ($)</TD>
</TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; width: 49%; text-align: left; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Balance, September 30, 2019</FONT></TD><TD STYLE="padding: 0pt 0pt 0pt 10pt; width: 1%; text-align: left; text-indent: -10pt">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">350,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">4.19</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Granted</FONT></TD><TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">150,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3.17</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Balance, September 30, 2020 and March</FONT> <FONT STYLE="font-size: 10pt">31, 2021</FONT></TD><TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">500,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3.88</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 60pt; text-align: justify">At March 31, 2021,
the Company had share purchase warrants outstanding as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 60pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; text-align: center">Number</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; text-align: center">Exercise Price</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">Expiry Date</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">350,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">4.19</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 50%">June 30, 2021</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">150,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3.17</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-bottom: 1pt">May 6, 2024</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">500,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 15; Value: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40pt; text-align: left">Note 5</TD><TD STYLE="width: 2pt"></TD><TD STYLE="text-align: justify"><U>Commitments</U> &ndash; (Continued)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-size: 10pt; font-style: normal">d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-style: normal">Stock&ndash;based Compensation Plan</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-align: justify; color: gray"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 60pt; text-align: justify">2015 Stock Option Plan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 60pt; text-align: justify">On September 18, 2015, the Company&rsquo;s
board of directors approved a 2015 Omnibus Incentive Plan (the &ldquo;2015 Plan&rdquo;), which provided for the grant of stock options
and restricted stock awards to directors, officers, employees and consultants of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 60pt; text-align: justify">The maximum number of our common shares reserved
for issue under the plan was 6,050,553 shares, subject to adjustment in the event of a change of the Company&rsquo;s capitalization. At
March 31, 2021, 146,371 (September 30, 2020: 146,371) options remain available for issue under the 2015 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 60pt; text-align: justify">2019 Stock Option Plan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 60pt; text-align: justify">On January 15, 2019, the Board approved the
2019 Omnibus Incentive Plan (the &ldquo;2019 Plan&rdquo;), which provides for the grant of stock options and restricted stock awards to
directors, officers, employees, consultants and advisors of the Company. Under the terms of the 2019 Plan, 6,000,000 additional shares
of Common Stock are available for issuance under the 2019 Plan, in addition to the shares available under the 2015 Plan. Any awards outstanding
under the 2015 Plan or the Company&rsquo;s 2007 Stock Option Plan (the &ldquo;2007 Plan&rdquo;) will remain subject to and be paid under
the 2015 Plan or the 2007 Plan, respectively, and any shares subject to outstanding awards under the 2015 Plan or the 2007 Plan that subsequently
cease to be subject to such awards (other than by reason of settlement of the awards in shares) will automatically become available for
issuance under the 2019 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 60pt; text-align: justify">The 2019 Plan provides that it may be administered
by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined by the board of directors
at the time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date,
then the exercise price shall not be less than 110% of fair market value of the Company&rsquo;s shares of common stock on the grant date.
Stock options may be granted under the 2019 Plan for an exercise period of up to ten years from the date of grant of the option or such
lesser periods as may be determined by the board, subject to earlier termination in accordance with the terms of the 2019 Plan. At March
31, 2021, 1,856,665 (September 30, 2020: 3,161,665) options remain available for issue under the 2019 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Note 5&#9;<U>Commitments</U> &ndash; (Continued)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-style: normal">d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-style: normal">Stock-based Compensation Plan &ndash; (Continued)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-align: justify; color: gray"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 60pt; text-align: justify">A summary of the status of Company&rsquo;s
outstanding stock purchase options is presented below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 88%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; text-align: center">Number of Shares</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price ($)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; text-align: center">Weighted Average Grant Date Fair Value ($)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; text-align: center">Aggregate intrinsic value ($)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; width: 35%; text-align: left; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Outstanding, September 30, 2019</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">8,462,933</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">3.58</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">4,115,032</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Granted</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,695,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.96</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.27</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Forfeited</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(68,332</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.01</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Exercised</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(13,335</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3.15</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Outstanding, September 30, 2020</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10,076,266</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3.48</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">14,982,581</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Granted</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,305,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.93</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.47</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Forfeited</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(29,167</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.44</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"></FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Exercised</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(346,900</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2.88</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Outstanding, March 31, 2021</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">11,005,199</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3.79</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">122,805,858</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Exercisable, March 31, 2021</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,513,533</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3.65</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">84,890,710</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  </TABLE><BR STYLE="clear: both">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 60pt; text-align: justify">The aggregate intrinsic value is calculated
as the difference between the exercise price of the underlying awards and the quoted market price of the Company&rsquo;s stock for the
options that were in-the-money at March 31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 60pt; text-align: justify">During the three and six months ended March
31, 2021, the Company recognized stock-based compensation expense of $1,846,156 and $2,785,470, respectively (2020: $1,700,753 and $2,965,177,
respectively) in connection with the issuance and vesting &#9;of stock options and warrants in exchange for services. These amounts have
been included in general and &#9;administrative expenses and research and development expenses on the Company&rsquo;s statements of &#9;operations
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 88%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center">Three months ended March 31,</TD><TD>&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center">Six months ended March 31,</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; text-align: center">2021</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; text-align: center">2020</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; text-align: center">2021</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; text-align: center">2020</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36%; text-align: left">General and administrative</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">793,957</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">810,309</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,216,780</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,291,410</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Research and development</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,052,199</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">890,444</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,568,690</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,673,767</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total share based compensation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,846,156</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,700,753</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,785,470</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,965,177</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  </TABLE><BR STYLE="clear: both">


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 60pt; text-align: justify">An amount of approximately $7,091,142 in stock-based
compensation is expected to be recorded over the remaining term &#9;of such options through fiscal 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 60pt; text-align: justify">The fair value of each option
award granted during the six months ended March 31, 2021 and 2020 is estimated on the date of grant using the Black Scholes option pricing
model based on the following weighted average assumptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 88%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; text-align: center">2021</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; text-align: center">2020</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left">Risk-free interest rate</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">0.64</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1.68</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected life of options (years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.64</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.44</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Annualized volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">96.26</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">97.61</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Dividend rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE><BR STYLE="clear: both"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 17; Value: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><A NAME="a_003"></A>Item 2. Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Forward-Looking Statements</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Quarterly Report on Form 10-Q includes
forward-looking statements. All statements other than statements of historical facts contained in this Quarterly Report on Form
10-Q, including statements regarding our anticipated future clinical and regulatory milestone events, future financial position,
business strategy and plans and objectives of management for future operations, are forward-looking statements. The words &ldquo;believe,&rdquo;
&ldquo;may,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;expect&rdquo;
&ldquo;should,&rdquo; &ldquo;forecast,&rdquo; &ldquo;could,&rdquo; &ldquo;suggest,&rdquo; &ldquo;plan&rdquo; and similar expressions,
as they relate to us, are intended to identify forward-looking statements. Such forward-looking statements include, without limitation,
statements regarding:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 20.65pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="width: 18pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">volatility in our stock and in the markets
in general;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our ability to successfully conduct clinical
and preclinical trials for our product candidates;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our ability to raise additional capital
on favorable terms and the impact of such activities on our stockholders and stock price;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the impact of the COVID-19 outbreak and
its effect on us;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our ability to generate any revenue or
to continue as a going concern;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our ability to execute our research and
development plan on time and on budget;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our products ability to demonstrate efficacy
or an acceptable safety profile of our product candidates;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our ability to obtain the support of qualified
scientific collaborators;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our ability, whether alone or with commercial
partners, to successfully commercialize any of our product candidates that may be approved for sale;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our ability to identify and obtain additional
product candidates;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our reliance on third parties in non-clinical
and clinical studies;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our ability to defend against product liability
claims;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our ability to safeguard against security
breaches;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our ability to obtain and maintain sufficient
intellectual property protection for our product candidates;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our ability to comply with our intellectual
property licensing agreements;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our ability to defend against claims of
intellectual property infringement;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our ability to comply with the maintenance
requirements of the government patent agencies;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our ability to protect our intellectual
property rights throughout the world;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">competition;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the anticipated start dates, durations
and completion dates of our ongoing and future clinical studies;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the anticipated designs of our future clinical
studies;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the impact of fast track designation on
receipt of actual FDA approval;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our anticipated future regulatory submissions
and our ability to receive regulatory approvals to develop and market our product candidates, including any orphan drug or fast
track designations; and </FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our anticipated future cash position.</FONT><FONT STYLE="font: 11pt Times New Roman, Times, Serif">
</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have based these forward-looking statements
largely on our current expectations and projections about future events, including the responses we expect from the U.S. Food and
Drug Administration, (&ldquo;FDA&rdquo;), and other regulatory authorities and financial trends that we believe may affect our
financial condition, results of operations, business strategy, preclinical and clinical trials, and financial needs. These forward-looking
statements are subject to a number of risks, uncertainties and assumptions including without limitation the risks described in
&ldquo;Risk Factors&rdquo; in Part I, Item 1A of our Annual Report on Form 10-K filed with the Securities and Exchange Commission
on December 28, 2020. These risks are not exhaustive. Other sections of this Quarterly Report on Form 10-Q include additional factors
which could adversely impact our business and financial performance. Moreover, we operate in a very competitive and rapidly changing
environment. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor
can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause
actual results to differ materially from those contained in any forward-looking statements. You should not rely upon forward-looking
statements as predictions of future events. We cannot assure you that the events and circumstances reflected in the forward-looking
statements will be achieved or occur and actual results could differ materially from those projected in the forward-looking statements.
Except as required by applicable laws including the securities laws of the United States, we assume no obligation to update or
supplement forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18; Value: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As used in this Quarterly Report on Form 10-Q,
the terms &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; and &ldquo;Anavex&rdquo; mean Anavex Life Sciences Corp., unless
the context clearly requires otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Current Business</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex Life Sciences Corp. is a clinical stage
biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous
system (&ldquo;CNS&rdquo;) diseases with high unmet need. We analyze genomic data from clinical studies to identify biomarkers,
which we use to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental
diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our lead compound, ANAVEX<SUP>&reg;</SUP>2-73,
is being developed to treat Alzheimer&rsquo;s disease, Parkinson&rsquo;s disease and potentially other central nervous system diseases,
including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked
gene, methyl-CpG-binding protein 2 (&ldquo;MECP2&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We currently have two core programs and two
seed programs. Our core programs are at various stages of clinical and preclinical development, in neurodegenerative and neurodevelopmental
diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes key information about our programs:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;<IMG SRC="e2736_10-qimg001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex has a portfolio of compounds varying
in sigma-1 receptor (S1R) binding activities. The SIGMAR1 gene encodes the S1R protein, which is an intracellular chaperone protein
with important roles in cellular communication. S1R is also involved in transcriptional regulation at the nuclear envelope and
restores homeostasis and stimulates recovery of cell function when activated. In order to validate the ability of our compounds
to activate quantitatively the S1R, we performed, in collaboration with Stanford University, a quantitative Positron Emission Tomography
(PET) imaging scan in mice, which demonstrated a dose-dependent ANAVEX<SUP>&reg;</SUP>2-73 target engagement or receptor occupancy
(RO) with S1R in the brain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19; Value: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 9pt Sans-Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: Red"><B><IMG SRC="e2736_10-qimg002.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Cellular Homeostasis</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Many diseases are possibly directly caused
by chronic homeostatic imbalances or cellular stress of brain cells. In pediatric diseases like Rett syndrome or infantile spasms,
the chronic cellular stress is possibly caused by the presence of a constant genetic mutation. In neurodegenerative diseases, such
as Alzheimer&rsquo;s and Parkinson&rsquo;s diseases, chronic cellular stress is possibly caused by age-correlated buildup of cellular
insult and hence chronic cellular stress. Specifically, defects in homeostasis of protein or ribonucleic acid (&ldquo;RNA&rdquo;)
lead to the death of neurons and dysfunction of the nervous system. The spreading of protein aggregates resulting in a proteinopathy,
a characteristic finding in Alzheimer&rsquo;s and Parkinson&rsquo;s diseases that results from disorders of protein synthesis,
trafficking, folding, processing or degradation in cells. The clearance of macromolecules in the brain is particularly susceptible
to imbalances that result in aggregation and degeneration in nerve cells. For example, Alzheimer&rsquo;s disease pathology is characterized
by the presence of amyloid plaques, neurofibrillary tangles, which are aggregates of hyperphosphorylated Tau protein that are a
marker of other diseases known as tauopathies as well as inflammation of microglia. With the SIGMAR1 activation through SIGMAR1
agonists like ANAVEX<SUP>&reg;</SUP>2-73, our approach is to restore cellular balance, i.e. homeostasis. Therapies that correct
defects in cellular homeostasis might have the potential to halt or delay neurodevelopmental and neurodegenerative disease progression.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>ANAVEX</I></B><SUP>&reg;</SUP><B><I>2-73-specific Biomarkers</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A full genomic analysis of Alzheimer&rsquo;s
disease (AD) patients treated with ANAVEX<SUP>&reg;</SUP>2-73 resulted in the identification of actionable genetic variants. A
significant impact of the genomic biomarkers SIGMAR1, the direct target of ANAVEX<SUP>&reg;</SUP>2-73 and COMT, a gene involved
in memory function, on the drug response level was identified, leading to an early ANAVEX<SUP>&reg;</SUP>2-73-specific biomarker
hypothesis. It is expected that <I>excluding</I> patients with these two identified biomarker variants (approximately 10%-20% of
the population) in prospective studies would identify approximately 80%-90% patients that would display clinically significant
improved functional and cognitive scores.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 20; Value: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consistency between the identified DNA
and RNA data related to ANAVEX<SUP>&reg;</SUP>2-73, which are considered independent of AD pathology, as well as multiple endpoints
and time-points, provides support for precision medicine clinical development of ANAVEX<SUP>&reg;</SUP>2-73 by using genetic biomarkers
identified within the study population itself to target patients who are most likely to respond to ANAVEX<SUP>&reg;</SUP>2-73 treatment
in AD as well as indications like Parkinson&rsquo;s disease dementia (PDD) or Rett syndrome (RTT) in which ANAVEX<SUP>&reg;</SUP>2-73
is currently studied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Clinical Studies Overview</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Alzheimer&rsquo;s Disease</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2016, we completed a Phase 2a clinical
trial, consisting of PART A and PART B, which lasted a total of 57 weeks, for ANAVEX<SUP>&reg;</SUP>2-73 in mild-to-moderate Alzheimer&rsquo;s
patients. This open-label randomized trial met both primary and secondary endpoints and was designed to assess the safety and exploratory
efficacy of ANAVEX<SUP>&reg;</SUP>2-73 in 32 patients. ANAVEX<SUP>&reg;</SUP>2-73 targets sigma-1 and muscarinic receptors, which
have been shown in preclinical studies to reduce stress levels in the brain believed to restore cellular homeostasis and to reverse
the pathological hallmarks observed in Alzheimer&rsquo;s disease. The Phase 2a trial demonstrated positive pharmacokinetic (PK)
and pharmacodynamic (PD) data, which established a concentration-effect relationship between ANAVEX<SUP>&reg;</SUP>2-73 and study
measurements. These measures obtained from all patients who participated in the entire 57 weeks include exploratory cognitive and
functional scores as well as biomarker signals of brain activity. Additionally, the study appears to show that ANAVEX<SUP>&reg;</SUP>2-73
activity is enhanced by its active metabolite (ANAVEX19-144), which also targets the sigma-1 receptor and has a half-life approximately
twice as long as the parent molecule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Two consecutive trial extensions for the Phase
2a trial have allowed participants who completed the 52-week PART B of the study to continue taking ANAVEX<SUP>&reg;</SUP>2-73,
providing an opportunity to gather extended safety data for a cumulative time period of five years. In August 2020, patients completing
these Phase 2a trial extensions were granted continued access to treatment with ANAVEX<SUP>&reg;</SUP>2-73 through the Australian
Government Department of Health &ndash; Therapeutic Goods Administration (TGA) compassionate use Special Access Scheme.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A larger Phase 2b/3 double-blind, placebo-controlled
study of ANAVEX<SUP>&reg;</SUP>2-73 in Alzheimer&rsquo;s disease commenced in August 2018. The Phase 2b/3 study will enroll approximately
450 patients for 48 weeks, randomized 1:1:1 to two different ANAVEX<SUP>&reg;</SUP>2-73 doses or placebo. The trial commenced in
Australia; and additional regions have been added in the United Kingdom, The Netherlands, Germany and Canada. The ANAVEX<SUP>&reg;</SUP>2-73
Phase 2b/3 study design incorporates genomic precision medicine biomarkers identified in the ANAVEX<SUP>&reg;</SUP>2-73 Phase 2a
study. Primary and secondary endpoints will assess safety and both cognitive and functional efficacy, measured through Alzheimer&rsquo;s
Disease Assessment Scale &ndash; Cognition (ADAS-Cog), ADCS-ADL and Clinical Dementia Rating &ndash; Sum of Boxes for cognition
and function (CDR-SB).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">In October 2019,
we initiated a long-term open label extension study of ANAVEX<SUP>&reg;</SUP>2-73, entitled the ATTENTION-AD study, for patients
who have completed the 48-week Phase 2b/3 placebo-controlled trial referenced above. This study is expected to last two years and
will give patients the opportunity to continue their treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Rett Syndrome </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, we presented positive preclinical
data for ANAVEX<SUP>&reg;</SUP>2-73 in Rett syndrome, a rare neurodevelopmental disease. The study was funded by the International
Rett Syndrome Foundation (&ldquo;Rettsyndrome.org&rdquo;). In January 2017, we were awarded a financial grant from Rettsyndrome.org
of a minimum of $0.6 million to cover some of the costs of a multicenter Phase 2 clinical trial of ANAVEX<SUP>&reg;</SUP>2-73 for
the treatment of Rett syndrome. This award was received in quarterly instalments which commenced during fiscal 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2019, we commenced the first Phase
2 clinical trial in a planned Rett syndrome program of ANAVEX<SUP>&reg;</SUP>2-73 for the treatment of Rett syndrome. The studies
are being conducted in a range of patient age demographics and geographic regions, utilizing a convenient oral liquid once-daily
formulation of ANAVEX<SUP>&reg;</SUP>2-73.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21; Value: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The first Phase 2 study, which took place in
the United States, was completed in December 2020. This trial was a randomized double-blind, placebo-controlled safety, tolerability,
pharmacokinetic and efficacy study of oral liquid ANAVEX<SUP>&reg;</SUP>2-73 formulation in 25 adult female patients with Rett
syndrome over a 7-week treatment period including ANAVEX<SUP>&reg;</SUP>2-73-specific genomic precision medicine biomarkers. The
primary endpoint of the trial was safety. The dosing of 5 mg ANAVEX<SUP>&reg;</SUP>2-73 was well-tolerated and demonstrated dose-proportional
PK (pharmacokinetics). All secondary efficacy endpoints of the trial showed statistically significant and clinically meaningful,
drug exposure-dependent response in the Rett Syndrome Behaviour Questionnaire (RSBQ) Total scores, when compared to placebo, in
the ITT cohort (all participants, p = 0.048). 66.7% of ANAVEX<SUP>&reg;</SUP>2-73 treated subjects showed a statistically significant
improvement in drug exposure-dependent RSBQ response as compared to 10% of the subjects on placebo in the ITT cohort (all participants,
p = 0.011). ANAVEX<SUP>&reg;</SUP>2-73 treatment resulted in a sustained improvement in Clinical Global Impression Improvement
(CGI-I) scores throughout the 7-week study, when compared to placebo in the ITT cohort (all participants, p = 0.014). 86.7% of
ANAVEX<SUP>&reg;</SUP>2-73 treated subjects showed a statistically significant CGI-I response, defined as sustained improvement
to treatment, as compared to 40% of the subjects on placebo in the ITT cohort (all participants, p = 0.014). Consistent with previous
ANAVEX<SUP>&reg;</SUP>2-73 clinical trials, patients carrying the common form of the SIGMAR1 gene treated with ANAVEX<SUP>&reg;</SUP>2-73
experienced stronger improvements in the prespecified efficacy endpoints.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The second Phase 2 study of ANAVEX<SUP>&reg;</SUP>2-73
for the treatment of Rett syndrome, called the AVATAR study, commenced in June 2019. This study is taking place in Australia and
the United Kingdom using a higher dose than the U.S. based Phase 2 study for Rett syndrome. The study will evaluate the safety
and efficacy of ANAVEX<SUP>&reg;</SUP>2-73 in approximately 33 patients over a 7-week treatment period including ANAVEX<SUP>&reg;</SUP>2-73
specific precision medicine biomarkers. All patients who participate in the study will be eligible to receive ANAVEX<SUP>&reg;</SUP>2-73
under a voluntary open label extension protocol.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2020, we commenced the third study
of ANAVEX<SUP>&reg;</SUP>2-73 for the treatment of Rett syndrome, called the EXCELLENCE study. This Phase 2/3 study in pediatric
patients with Rett syndrome will evaluate the safety and efficacy of ANAVEX<SUP>&reg;</SUP>2-73 in at least 69 pediatric patients,
aged 5 to 18, over a 12-week treatment period incorporating ANAVEX<SUP>&reg;</SUP>2-73 specific precision medicine biomarkers.
All patients who participate in the study will be eligible to receive ANAVEX<SUP>&reg;</SUP>2-73 under a voluntary open label extension
protocol.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Parkinson&rsquo;s Disease</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2016, we presented positive preclinical
data for ANAVEX<SUP>&reg;</SUP>2-73 in an animal model of Parkinson&rsquo;s disease, which demonstrated significant improvements
on behavioral, histopathological, and neuroinflammatory endpoints. The study was funded by the Michael J. Fox Foundation. Additional
data announced in October 2017 indicates that ANAVEX<SUP>&reg;</SUP>2-73 induces robust neurorestoration in experimental parkinsonism.
The encouraging results we have gathered in this model, coupled with the favorable profile of this compound in the Alzheimer&rsquo;s
disease trial, support the notion that ANAVEX<SUP>&reg;</SUP>2-73 is a promising clinical candidate drug for Parkinson&rsquo;s
disease dementia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2020, we completed a double-blind,
randomized, placebo-controlled proof-of-concept Phase 2 trial with ANAVEX<SUP>&reg;</SUP>2-73 in Parkinson&rsquo;s Disease Dementia
(PDD), to study the effect of the compound on both the cognitive and motor impairment of Parkinson&rsquo;s disease. The Phase 2
study enrolled approximately 132 patients for 14 weeks, randomized 1:1:1 to two different ANAVEX<SUP>&reg;</SUP>2-73 doses, 30mg
and 50mg, or placebo. The ANAVEX<SUP>&reg;</SUP>2-73 Phase 2 PDD study design incorporated genomic precision medicine biomarkers
identified in the ANAVEX<SUP>&reg;</SUP>2-73 Phase 2a Alzheimer&rsquo;s disease study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Within this study ANAVEX<SUP>&reg;</SUP>2-73
was safe and well tolerated in oral doses up to 50mg once daily. The results show clinically meaningful, dose-dependent, and statistically
significant improvements in the Cognitive Drug Research (CDR) computerized assessment system analysis. The study confirmed the
precision medicine approach of targeting SIGMAR1 as a genetic biomarker in response to ANAVEX<SUP>&reg;</SUP>2-73.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2020, we announced a financial commitment
by Shake It Up Australia Foundation for Parkinson&rsquo;s Research to fund up to 50% of the costs of an Australian clinical study
to develop ANAVEX<SUP>&reg;</SUP>2-73 for the disease modifying treatment of Parkinson&rsquo;s disease. The financial commitment
would be made through private placement purchases of our common stock at 200% of the fair market value on the purchase date and
will be contingent upon the completion of certain clinical trial milestones relating to the proposed clinical trial. The proposed
clinical trial will use a convenient, once-daily oral ANAVEX<SUP>&reg;</SUP>2-73 formulation to confirm the potential disease modifying
features of ANAVEX<SUP>&reg;</SUP>2-73 in an animal model of Parkinson&rsquo;s disease. Safety and efficacy will be investigated
in an appropriately powered placebo-controlled clinical study of Parkinson&rsquo;s disease patients over at least 48-weeks including
ANAVEX<SUP>&reg;</SUP>2-73-specific precision medicine biomarkers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 22; Value: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2021, we announced we were awarded
a research grant of $1.0 million from&nbsp;<FONT STYLE="text-underline-style: none; color: windowtext">The Michael J. Fox Foundation
for Parkinson&rsquo;s Research</FONT>&nbsp;(MJFF) to develop ANAVEX<SUP>&reg;</SUP>2-73 for the treatment of Parkinson&rsquo;s
disease. The award will explore utilization of PET imaging biomarkers to enable measurement of target engagement and pathway activation
of the sigma-1 receptor (SIGMAR1) with clinically relevant doses in people with Parkinson&rsquo;s disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Frontotemporal Dementia</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2020, we commenced the First-in-Human
Phase 1 clinical trial of ANAVEX<SUP>&reg;</SUP>3-71, which was previously granted orphan drug designation for the treatment of
Frontotemporal Dementia (FTD) by the FDA. ANAVEX<SUP>&reg;</SUP>3-71 is an orally administered small molecule targeting sigma-1
and M1 muscarinic receptors that is designed to be beneficial for neurodegenerative diseases. In preclinical studies, <FONT STYLE="background-color: white">ANAVEX<SUP>&reg;</SUP>3-71
demonstrated disease-modifying activity against the major hallmarks of Alzheimer&rsquo;s disease in transgenic (3xTg-AD) mice,
including cognitive deficits, amyloid and tau pathologies, as well as beneficial effects on mitochondrial dysfunction and neuroinflammation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">The Phase
1 clinical trial will be a prospective double-blind, randomized, placebo-controlled study. A total of at least 36 healthy male
and female subjects will be included. Single escalating doses of ANAVEX<SUP>&reg;</SUP>3-71 will be administered in order to evaluate
the safety, tolerability, and pharmacokinetics (PK) of ANAVEX<SUP>&reg;</SUP>3-71 and the effects of food and gender on its PK
in healthy volunteers. This study is expected to be followed by longer duration dosing including patients with FTD or other dementia
indications with unmet medical need, incorporating exploratory efficacy and disease biomarker measures<FONT STYLE="color: #1F1F1F">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our Pipeline</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our research and development pipeline includes
ANAVEX<SUP>&reg;</SUP>2-73 currently in three different clinical study indications, and several other compounds in different stages
of clinical and pre-clinical study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our proprietary SIGMACEPTOR&trade; Discovery
Platform produced small molecule drug candidates with unique modes of action, based on our understanding of sigma receptors. Sigma
receptors may be targets for therapeutics to combat many human diseases, both of neurodegenerative nature, including Alzheimer&rsquo;s
disease, as well as of neurodevelopmental nature, like Rett syndrome. When bound by the appropriate ligands, sigma receptors influence
the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease. Multiple
viruses including SARS-CoV-2 (COVID-19) induce cellular stress by intrinsic mitochondrial apoptosis and other related cellular
processes, in order to ensure survival and replication. Hence, it is possible that S1R could play a role in modulating the cellular
response to viral infection and ameliorate pathogenesis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Compounds that have been subjects of our research
include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<SUP>&reg;</SUP>2-73 <I>(blarcamesine)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<SUP>&reg;</SUP>2-73 may offer a disease-modifying
approach in neurodegenerative and neurodevelopmental diseases by activation of sigma-1 receptors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In Rett syndrome, administration of ANAVEX<SUP>&reg;</SUP>2-73
resulted in both significant and dose related improvements in an array of behavioral paradigms in the MECP2 HET Rett syndrome disease
model. In addition, in a further experiment sponsored by Rettsyndrome.org, ANAVEX<SUP>&reg;</SUP>2-73 was evaluated in automatic
visual response and respiration tests in 7-month old mice, an age at which advanced pathology is evident. Vehicle-treated MECP2
mice demonstrated fewer automatic visual responses than wild-type mice. Treatment with ANAVEX<SUP>&reg;</SUP>2-73 for four weeks
significantly increased the automatic visual response in the MECP2 Rett syndrome disease mouse. Additionally, chronic oral dosing
daily for 6.5 weeks of ANAVEX<SUP>&reg;</SUP>2-73 starting at ~5.5 weeks of age was conducted in the MECP2 HET Rett syndrome disease
mouse model assessed the different aspects of muscular coordination, balance, motor learning and muscular strengths, some of the
core deficits observed in Rett syndrome. Administration of ANAVEX<SUP>&reg;</SUP>2-73 resulted in both significant and dose related
improvements in an array of these behavioral paradigms in the MECP2 HET Rett syndrome disease model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 23; Value: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2019, we commenced the first Phase
2 clinical trial in a planned Rett syndrome program of ANAVEX<SUP>&reg;</SUP>2-73 for the treatment of Rett syndrome. This study,
which took place in the United States, was completed in December 2020, however two other clinical trials in Rett syndrome, the
AVATAR study and the EXCELLENCE study, are still underway. The studies are being conducted in a range of patient age demographics
and geographic regions, as more fully described above under <I>Clinical Studies Overview &ndash; Rett Syndrome</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2016 and June 2016, the FDA granted
Orphan Drug Designation to ANAVEX<SUP>&reg;</SUP>2-73 for the treatment of Rett syndrome and infantile spasms, respectively. In
November 2019, the FDA granted to ANAVEX<SUP>&reg;</SUP>2-73 the Rare Pediatric Disease (RPD) designation for the treatment of
Rett syndrome. The RPD designation provides priority review by the FDA to encourage the development of treatments for rare pediatric
diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Further, in February 2020, the FDA granted
Fast Track designation for the ANAVEX<SUP>&reg;</SUP>2-73 clinical development program for the treatment of Rett syndrome. The
FDA Fast Track program is designed to facilitate and expedite the development and review of new drugs to address unmet medical
needs in the treatment of serious and life-threatening conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For Parkinson&rsquo;s disease, data demonstrates
significant improvements and restoration of function in a disease modifying animal model of Parkinson&rsquo;s disease. Significant
improvements were seen on all measures tested: behavioral, histopathological, and neuroinflammatory endpoints. In October 2020,
we completed a double-blind, randomized, placebo-controlled proof-of-concept Phase 2 trial with ANAVEX<SUP>&reg;</SUP>2-73 in Parkinson&rsquo;s
Disease Dementia (PDD), to study the effect of the compound on both the cognitive and motor impairment of Parkinson&rsquo;s disease.
The Phase 2 study enrolled approximately 132 patients for 14 weeks, randomized 1:1:1 to two different ANAVEX<SUP>&reg;</SUP>2-73
doses, 30mg and 50mg, or placebo. The ANAVEX<SUP>&reg;</SUP>2-73 Phase 2 PDD study design incorporated genomic precision medicine
biomarkers identified in the ANAVEX<SUP>&reg;</SUP>2-73 Phase 2a Alzheimer&rsquo;s disease study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The study found that ANAVEX<SUP>&reg;</SUP>2-73
was safe and well tolerated in oral doses up to 50mg once daily. The results show clinically meaningful, dose-dependent, and statistically
significant improvements in the Cognitive Drug Research (CDR) computerized assessment system analysis. We anticipate conducting
further clinical trials of ANAVEX<SUP>&reg;</SUP>2-73 in Parkinson&rsquo;s disease dementia after submitting the results of the
study to the FDA to obtain regulatory guidance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In Alzheimer&rsquo;s disease (AD) animal models,
ANAVEX<SUP>&reg;</SUP>2-73 has shown pharmacological, histological and behavioral evidence as a potential neuroprotective, anti-amnesic,
anti-convulsive and anti-depressive therapeutic agent, due to its potent affinity to sigma-1 receptors and moderate affinities
to M1-4 type muscarinic receptors. In addition, ANAVEX<SUP>&reg;</SUP>2-73 has shown a potential dual mechanism which may impact
amyloid, tau pathology and inflammation. In a transgenic AD animal model Tg2576, ANAVEX<SUP>&reg;</SUP>2-73 induced a statistically
significant neuroprotective effect against the development of oxidative stress in the mouse brain, as well as significantly increased
the expression of functional and synaptic plasticity markers that is apparently amyloid-beta independent. It also statistically
alleviated the learning and memory deficits developed over time in the animals, regardless of sex, both in terms of spatial working
memory and long-term spatial reference memory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on the results of pre-clinical testing,
we initiated and completed a Phase 1 single ascending dose (SAD) clinical trial of ANAVEX<SUP>&reg;</SUP>2-73. In this Phase 1
SAD trial, the maximum tolerated single dose was defined per protocol as 55-60 mg. This dose is above the equivalent dose shown
to have positive effects in mouse models of AD. There were no significant changes in laboratory or electrocardiogram (ECG) parameters.
ANAVEX<SUP>&reg;</SUP>2-73 was well tolerated below the 55-60 mg dose with only mild adverse events in some subjects. Observed
adverse events at doses above the maximum tolerated single dose included headache and dizziness, which were moderate in severity
and reversible. These side effects are often seen with drugs that target CNS conditions, including AD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 24; Value: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2014, a Phase 2a clinical trial
was initiated for ANAVEX<SUP>&reg;</SUP>2-73, for the treatment of Alzheimer&rsquo;s disease. The open-label randomized trial was
designed to assess the safety and exploratory efficacy of ANAVEX<SUP>&reg;</SUP>2-73 in 32 patients with mild-to-moderate Alzheimer&rsquo;s
disease. ANAVEX<SUP>&reg;</SUP>2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1
and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer&rsquo;s.
The Phase 2a study met both primary and secondary objectives of the study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In July 2018, we presented
the results of a genomic DNA and RNA evaluation of the participants in the Phase 2a study. More than 33,000 genes were analyzed
using unbiased, data driven, machine learning, artificial intelligence (AI) system for analyzing DNA &amp; RNA data in patients
exposed to ANAVEX<SUP>&reg;</SUP>2-73. The analysis identified genetic variants that impacted response to ANAVEX<SUP>&reg;</SUP>2-73,
among them variants related to the Sigma-1 receptor (SIGMAR1), the target for ANAVEX<SUP>&reg;</SUP>2-73. Results showed that study
participants with the common SIGMAR1 wild type gene variant, which is about 80 percent of the population worldwide, demonstrated
improved cognitive (MMSE) and the functional (ADCS-ADL) scores. The results from this evaluation have been used to establish a
precision medicine approach in subsequent clinical trials, since these signatures can now be applied to neurological indications
tested in clinical studies with ANAVEX<SUP>&reg;</SUP>2-73 including Alzheimer&rsquo;s disease, Parkinson&rsquo;s disease dementia
and Rett syndrome.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">ANAVEX<SUP>&reg;</SUP>2-73
data presented met prerequisite information in order to progress into a Phase 2b/3 placebo-controlled study. On July 2, 2018, the
Human Research Ethics Committee in Australia approved the initiation of our Phase 2b/3, double-blind, randomized, placebo-controlled
48-week safety and efficacy trial of ANAVEX<SUP>&reg;</SUP>2-73 for the treatment of early Alzheimer&rsquo;s disease. Clinical
trial sites in Canada, the United Kingdom, the Netherlands and Germany were also added. This Phase 2b/3 study design incorporates
inclusion of genomic precision medicine biomarkers identified in the ANAVEX<SUP>&reg;</SUP>2-73 Phase 2a study. The Phase 2b/3
study, which is expected to enroll approximately 450 patients, randomized 1:1:1 to either two different ANAVEX<SUP>&reg;</SUP>2-73
doses or placebo, commenced in October 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Preclinical data also validates ANAVEX<SUP>&reg;</SUP>2-73
as a prospective platform drug for other neurodegenerative diseases beyond Alzheimer&rsquo;s disease, Parkinson&rsquo;s disease
or Rett syndrome, more specifically, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis and,
more recently, tuberous sclerosis complex (TSC). ANAVEX<SUP>&reg;</SUP>2-73 demonstrated significant improvements in all of these
indications in the respective preclinical animal models.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In a study sponsored by the Foundation for
Angelman Syndrome, ANAVEX<SUP>&reg;</SUP>2-73 was assessed in a mouse model for the development of audiogenic seizures. The results
indicated that ANAVEX<SUP>&reg;</SUP>2-73 administration significantly reduced audiogenic-induced seizures. In a study sponsored
by FRAXA Research Foundation regarding Fragile X syndrome, data demonstrated that ANAVEX<SUP>&reg;</SUP>2-73 restored hippocampal
brain-derived neurotrophic factor (BDNF) expression to normal levels. BDNF under-expression has been observed in many neurodevelopmental
and neurodegenerative pathologies. BDNF signaling promotes maturation of both excitatory and inhibitory synapses. ANAVEX<SUP>&reg;</SUP>2-73
normalization of BDNF expression could be a contributing factor for the positive data observed in both neurodevelopmental and neurodegenerative
disorders like Angelman and Fragile X syndromes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Preclinical data presented also indicates that
ANAVEX<SUP>&reg;</SUP>2-73 demonstrates protective effects of mitochondrial enzyme complexes during pathological conditions, which,
if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Preclinical data on ANAVEX<SUP>&reg;</SUP>2-73
related to multiple sclerosis indicates that ANAVEX<SUP>&reg;</SUP>2-73 may promote remyelination in multiple sclerosis disease.
Further, data also demonstrates that ANAVEX<SUP>&reg;</SUP>2-73 provides protection for oligodendrocytes (&ldquo;OL&rsquo;s&rdquo;)
and oligodendrocyte precursor cells (&ldquo;OPC&rsquo;s&rdquo;), as well as central nervous system neurons in addition to helping
repair by increasing OPC proliferation and maturation in tissue culture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2018, we presented preclinical data
of ANAVEX<SUP>&reg;</SUP>2-73 in a genetic mouse model of tuberous sclerosis complex (&ldquo;TSC&rdquo;). TSC is a rare genetic
disorder characterized by the growth of numerous benign tumors in many parts of the body with a high incidence of seizures. The
new preclinical data demonstrates that treatment with ANAVEX<SUP>&reg;</SUP>2-73 significantly increases survival and reduces seizures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 25; Value: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>ANAVEX<SUP>&reg;</SUP>3-71</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<SUP>&reg;</SUP>3-71 is a clinical drug
candidate with a novel mechanism of action via sigma-1 receptor activation and M1 muscarinic allosteric modulation, which has been
shown to enhance neuroprotection and cognition in Alzheimer&rsquo;s disease models. ANAVEX<SUP>&reg;</SUP>3-71 is a CNS-penetrable
potential disease modifying treatment for cognitive impairments. It is highly effective in very small doses against the major Alzheimer&rsquo;s
hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also has beneficial effects
on inflammation and mitochondrial dysfunctions. ANAVEX<SUP>&reg;</SUP>3-71 indicates extensive therapeutic advantages in Alzheimer&rsquo;s
and other protein-aggregation-related diseases given its ability to enhance neuroprotection and cognition via sigma-1 receptor
activation and M1 muscarinic allosteric modulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A preclinical study examined the response of
ANAVEX<SUP>&reg;</SUP>3-71 in aged transgenic animal models and showed a significant reduction in the rate of cognitive deficit,
amyloid beta pathology and inflammation with the administration of ANAVEX 3-71. In April 2016, the FDA granted Orphan Drug Designation
to ANAVEX<SUP>&reg;</SUP>3-71 for the treatment of Frontotemporal dementia (FTD).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During pathological conditions ANAVEX<SUP>&reg;</SUP>3-71
demonstrated the formation of new synapses between neurons (synaptogenesis) without causing an abnormal increase in the number
of astrocytes. In neurodegenerative diseases such as Alzheimer&rsquo;s and Parkinson&rsquo;s disease, synaptogenesis is believed
to be impaired. Additional preclinical data presented also indicates that in addition to reducing oxidative stress, ANAVEX<SUP>&reg;</SUP>3-71
demonstrates protective effects of mitochondrial enzyme complexes during pathological conditions, which, if impaired, are believed
to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2020, we commenced the first Phase
1 clinical trial of ANAVEX<SUP>&reg;</SUP>3-71, with focus on the treatment of Frontotemporal Dementia (FTD) and <FONT STYLE="background-color: white">other
dementia indications with unmet medical need</FONT>. The study is more fully described above under <I>Clinical Studies Overview
&ndash; Frontotemporal Dementia</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>ANAVEX<SUP>&reg;</SUP>1-41</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<SUP>&reg;</SUP>1-41 is a sigma-1 receptor
agonist. Pre-clinical tests revealed significant neuroprotective benefits (i.e., protects nerve cells from degeneration or death)
through the modulation of endoplasmic reticulum, mitochondrial and oxidative stress, which damages and impairs cell viability.
In addition, in animal models, ANAVEX<SUP>&reg;</SUP>1-41 prevented the expression of caspase-3, an enzyme that plays a key role
in apoptosis (programmed cell death) and loss of cells in the hippocampus, the part of the brain that regulates learning, emotion
and memory. These activities involve both muscarinic and sigma-1 receptor systems through a novel mechanism of action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Preclinical data presented also indicates that
ANAVEX<SUP>&reg;</SUP>1-41 demonstrates protective effects of mitochondrial enzyme complexes during pathological conditions, which,
if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>ANAVEX<SUP>&reg;</SUP>1066</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<SUP>&reg;</SUP>1066, a mixed sigma-1/sigma-2
ligand is designed for the potential treatment of neuropathic and visceral pain. ANAVEX<SUP>&reg;</SUP>1066 was tested in two preclinical
models of neuropathic and visceral pain that have been extensively validated in rats. In the chronic constriction injury model
of neuropathic pain, a single oral administration of ANAVEX<SUP>&reg;</SUP>1066 dose-dependently restored the nociceptive threshold
in the affected paw to normal levels while leaving the contralateral healthy paw unchanged. Efficacy was rapid and remained significant
for two hours. In a model of visceral pain, chronic colonic hypersensitivity was induced by injection of an inflammatory agent
directly into the colon and a single oral administration of ANAVEX<SUP>&reg;</SUP>1066 returned the nociceptive threshold to control
levels in a dose-dependent manner. Companion studies in rats demonstrated the lack of any effects on normal gastrointestinal transit
with ANAVEX<SUP>&reg;</SUP>1066 and a favorable safety profile in a battery of behavioral measures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26; Value: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>ANAVEX<SUP>&reg;</SUP>1037 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<SUP>&reg;</SUP>1037 is designed for
the treatment of prostate and pancreatic cancer. It is a low molecular weight, synthetic compound exhibiting high affinity for
sigma-1 receptors at nanomolar levels and moderate affinity for sigma-2 receptors and sodium channels at micromolar levels. In
advanced pre-clinical studies, this compound revealed antitumor potential. It has also been shown to selectively kill human cancer
cells without affecting normal/healthy cells and also to significantly suppress tumor growth in immune-deficient mice models. Scientific
publications highlight the possibility that these ligands may stop tumor growth and induce selective cell death in various tumor
cell lines. Sigma receptors are highly expressed in different tumor cell types. Binding by appropriate sigma-1 and/or sigma-2 ligands
can induce selective apoptosis. In addition, through tumor cell membrane reorganization and interactions with ion channels, our
drug candidates may play an important role in inhibiting the processes of metastasis (spreading of cancer cells from the original
site to other parts of the body), angiogenesis (the formation of new blood vessels) and tumor cell proliferation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our compounds are in the clinical and pre-clinical
testing stages of development, and there is no guarantee that the activity demonstrated in pre-clinical models will be shown in
human testing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We continue to identify and initiate discussions
with potential strategic and commercial partners to most effectively advance our programs and realize maximum shareholder value.
Further, we may acquire or develop new intellectual property and assign, license, or otherwise transfer our intellectual property
to further our goals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our Target Indications</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have developed compounds with potential
application to two broad categories and several specific indications. including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Central Nervous System Diseases</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 24px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="width: 24px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Alzheimer&rsquo;s disease &ndash; In 2020, an estimated 5.8 million
Americans were suffering from Alzheimer&rsquo;s disease. The Alzheimer&rsquo;s Association<SUP>&reg;</SUP> estimates that by 2050,
this number will rise to nearly 14 million Americans. Medications on the market today treat only the symptoms of Alzheimer&rsquo;s
disease and do not have the ability to stop its onset or its progression. There is an urgent and unmet need for both a disease
modifying cure for Alzheimer&rsquo;s disease as well as for better symptomatic treatments.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Parkinson&rsquo;s disease &ndash; Parkinson&rsquo;s disease is a progressive
disease of the nervous system marked by tremors, muscular rigidity, and slow, imprecise movement. It is associated with degeneration
of the basal ganglia of the brain and a deficiency of the neurotransmitter dopamine. Parkinson&rsquo;s disease afflicts more than
10 million people worldwide, typically middle-aged and elderly people. The Parkinson&rsquo;s disease market is expected to expand
to $3.2 billion by 2021, according to business intelligence provider GBI Research.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Rett syndrome &ndash; Rett syndrome is a rare X-linked genetic neurological
and developmental disorder that affects the way the brain develops, including protein transcription, which is altered and as a
result leads to severe disruptions in neuronal homeostasis. It is considered a rare, progressive neurodevelopmental disorder and
is caused by a single mutation in the MECP2 gene. Because males have a different chromosome combination from females, boys who
have the genetic MECP2 mutation are affected in devastating ways. Most of them die before birth or in early infancy. For females
who survive infancy, Rett syndrome leads to severe impairments, affecting nearly every aspect of the child&rsquo;s life; severe
mental retardation, their ability to speak, walk and eat, sleeping problems, seizures and even the ability to breathe easily.
Rett syndrome affects approximately 1 in every 10,000-15,000 females.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Depression &ndash; Depression is a major cause of morbidity worldwide
according to the World Health Organization. Pharmaceutical treatment for depression is dominated by blockbuster brands, with the
leading nine brands historically accounting for approximately 75% of total sales. However, the dominance of the leading brands
is waning, largely due to the effects of patent expiration and generic competition.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Epilepsy &ndash; Epilepsy is a common chronic neurological disorder
characterized by recurrent unprovoked seizures. These seizures are transient signs and/or symptoms of abnormal, excessive or synchronous
neuronal activity in the brain. According to the Centers for Disease Control and Prevention, in 2015 epilepsy affected 3.4 million
Americans. Today, epilepsy is often controlled, but not cured, with medication that is categorized as older traditional anti-epileptic
drugs and second generation anti-epileptic drugs. Because epilepsy afflicts sufferers in different ways, there is a need for drugs
used in combination with both traditional anti-epileptic drugs and second generation anti-epileptic drugs.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify">Neuropathic Pain &ndash; We define neuralgia, or neuropathic pain, as pain that is not related to activation of pain receptor cells in any part of the body. Neuralgia is more difficult to treat than some other types of pain because it does not respond well to normal pain medications. Special medications have become more specific to neuralgia and typically fall under the category of membrane stabilizing drugs or antidepressants.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 27; Value: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cancer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 24px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="width: 24px">&#9679;</TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Malignant Melanoma &ndash; Predominantly a skin cancer, malignant melanoma
can also occur in melanocytes found in the bowel and the eye. Malignant melanoma accounts for 75% of all deaths associated with
skin cancer. The treatment includes surgical removal of the tumor, adjuvant treatment, chemo and immunotherapy, or radiation therapy.
According to IMS Health the worldwide malignant melanoma market is expected to grow to $4.4 billion by 2022.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD>&#9679;</TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Prostate Cancer &ndash; Specific to men, prostate cancer is a form
of cancer that develops in the prostate, a gland in the male reproductive system. The cancer cells may metastasize from the prostate
to other parts of the body, particularly the bones and lymph nodes. Drug therapeutics for prostate cancer are expected to increase
to nearly $13.5 billion in 2024 according to Datamonitor Healthcare.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT>&#9679;</TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pancreatic Cancer &ndash; Pancreatic cancer is a malignant neoplasm
of the pancreas. In the United States, approximately 55,000 new cases of pancreatic cancer will be diagnosed this year and approximately
44,000 patients will die as a result of their cancer, according to the American Cancer Society. Sales predictions by GBI Research
forecast that the market for the pharmaceutical treatment of pancreatic cancer in the United States and five largest European
countries will increase to $2.9 billion by 2021.</FONT></TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Patents, Trademarks and Intellectual
Property </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We hold ownership or exclusive rights to thirteen
U.S. patents, seventeen U.S. patent applications, and various PCT or ex-U.S. patent applications relating to our drug candidates,
methods associated therewith, and to our research programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We own one issued U.S. patent entitled &ldquo;ANAVEX<SUP>&reg;</SUP>2-73
and certain anticholinesterase inhibitors composition and method for neuroprotection&rdquo; claims a composition of matter of ANAVEX<SUP>&reg;</SUP>2-73
directed to a novel and synergistic neuroprotective compound combined with donepezil and other cholinesterase inhibitors. This
patent is expected to expire in June 2034, absent any patent term extension for regulatory delays. We own two issued U.S. patents
each with claims directed to crystalline forms of ANAVEX<SUP>&reg;</SUP>2-73. The first of these two patents claims crystalline
forms of ANAVEX<SUP>&reg;</SUP>2-73, dosage forms and compositions containing crystalline ANAVEX<SUP>&reg;</SUP>2-73, and methods
of treatment for Alzheimer&rsquo;s disease using them. This patent is expected to expire in July 2036, absent any patent term extension
for regulatory delays. The second of these two patents claims pharmaceutical compositions containing a crystalline form of ANAVEX<SUP>&reg;</SUP>2-73,
and methods of treatment for Alzheimer&rsquo;s disease using the compositions. This patent is expected to expire in June 2037,
absent any patent term extension for regulatory delays. We also own two issued U.S. patents on seizure treatment. The first of
these two patents claims methods and dosage forms for treating seizures, the dosage forms containing a low-dose anti-epilepsy drug
combined with either: (i) ANAVEX<SUP>&reg;</SUP>2-73 and its active metabolite ANAVEX<SUP>&reg;</SUP>19-144; or (ii) ANAVEX<SUP>&reg;</SUP>19-144.
The second of these two patents further claims the seizure treatment being co-timely or coordinated administration of anti-epilepsy
drugs and (i) ANAVEX 19-144<SUP>&reg;</SUP> or (ii) ANAVEX 19-144<SUP>&reg;</SUP> with ANAVEX 2-73<SUP>&reg;</SUP>. Both patents
are expected to expire in October 2035, absent any patent term extension for regulatory delays. We also own two issued U.S. patents
with claims directed to treating neurodevelopmental disorders. These patents claim methods for treating a neurodevelopmental disorder
or multiple sclerosis by administering ANAVEX<SUP>&reg;</SUP>2-73, ANAVEX<SUP>&reg;</SUP>19-144, and/or ANAVEX<SUP>&reg;</SUP>1-41
(another sigma receptor ligand similar to ANAVEX<SUP>&reg;</SUP>2-73), or compositions thereof. Both patents are expected to expire
in January 2037, absent any patent term extension for regulatory delays. In addition, we own one issued U.S. Patent with claims
directed to methods of treating melanoma with a compound related to ANAVEX<SUP>&reg;</SUP>2-73. This patent is expected to expire
in February 2030, absent any patent term extension for regulatory delays. We also own an issued U.S. patent that claims crystalline
forms of ANAVEX<SUP>&reg;</SUP>19-144, dosage forms and compositions containing the crystalline forms of ANAVEX<SUP>&reg;</SUP>19-144,
and methods of treatment for Alzheimer&rsquo;s disease. This patent is expected to expire in July 2036, absent any patent term
extension for regulatory delays.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 28; Value: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also own two issued U.S. patents related
to ANAVEX<SUP>&reg;</SUP>1066. The first of these two patents claims methods for treating or preventing pain using (+) ANAVEX<SUP>&reg;</SUP>1066
isomer. The second patent claims methods for treating or preventing pain using (-) ANAVEX<SUP>&reg;</SUP>1066 isomer Both patents
are expected to expire in November 2036, absent any patent term extension for regulatory delays.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For ANAVEX<SUP>&reg;</SUP>2-73, ANAVEX<SUP>&reg;</SUP>19-144,
ANAVEX<SUP>&reg;</SUP>1-41, and ANAVEX<SUP>&reg;</SUP>1066, we also have granted or pending applications in Australia, Canada,
China, Europe, Japan, and Hong Kong, and are expected to expire after 2035.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With regard to ANAVEX<SUP>&reg;</SUP>3-71,
we own exclusive rights to two issued U.S. patents with claims respectively directed to the ANAVEX<SUP>&reg;</SUP>3-71 compound
and methods of treating various diseases including Alzheimer&rsquo;s with the same. These patents are expected to expire in April
2030, and January 2030, respectively, absent any patent term extension for regulatory delays. We also own exclusive rights to related
patents or applications that are granted or pending in Australia, Canada, China, Europe, Japan, Korea, New Zealand, Russia, and
South Africa, and are expected to expire in January 2030.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also own other patent applications directed
to enantiomers, crystals, formulations, uses, and patient selection methods that may provide additional protection for one or more
of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We regard patents and other intellectual property
rights as corporate assets. Accordingly, we attempt to optimize the value of intellectual property in developing our business strategy
including the selective development, protection, and exploitation of our intellectual property rights. In addition to filings made
with intellectual property authorities, we protect our intellectual property and confidential information by means of carefully
considered processes of communication and the sharing of information, and by the use of confidentiality and non-disclosure agreements
and provisions for the same in contractor&rsquo;s agreements. While no agreement offers absolute protection, such agreements provide
some form of recourse in the event of disclosure, or anticipated disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our intellectual property position, like that
of many biomedical companies, is uncertain and involves complex legal and technical questions for which important legal principles
are unresolved. For more information regarding challenges to our existing or future patents, see &ldquo;Risk Factors&rdquo; &ldquo;
in Part I, Item 1A of our Annual Report on Form 10-K filed with the Securities and Exchange Commission on December 28, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial Highlights</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">At March 31, 2021, our cash position
had increased to $75.9 million, from $29.2 million at our fiscal year end of September 30, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Operating expenses for the second quarter of
fiscal 2021 were $9.0 million, compared to $7.8 million for the comparable quarter in fiscal 2020. The operating expenses include an
aggregate of $1.8 million, as compared to $1.7 million in the second quarter of fiscal 2020, in non-cash charges related to the issuance
and vesting of stock options. Our research and development expenses for the second quarter of fiscal 2021 were $6.7 million, compared
to $6.1 million in the comparable period in fiscal 2020. The increase is attributable to the continued advancement of our ongoing clinical
trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Net loss for the second quarter of fiscal
2021 was $8.2 million, or $0.12 per share, as compared to $7.2 million, or $0.12 per share in the comparative quarter of fiscal
2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 29; Value: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Results of Operations</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-style: normal">We
are in the development stage and have not earned any revenues since our inception and we do not anticipate earning any revenues
until we can establish an alliance with other companies to develop, co-develop, license, acquire or market our products.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-style: normal"><B>Three
and six months ended March 31, 2021 compared to three and six months ended March 31, 2020.</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-style: normal"><B>&nbsp;</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Operating Expenses</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: black">Total operating
expenses for the second quarter of fiscal 2021 were $9.0 million, compared to $7.8 million for the comparable quarter of fiscal
2020.</FONT> <FONT STYLE="color: black">Total operating expenses for the first half of fiscal 2021 were $18.4 million compared
to $15.5 million for the same period in fiscal 2020. This represents an increase of $1.2 million for the three-month period and
$2.9 million for the six-month period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: black">Research and development
expenses for the second quarter of fiscal 2021 were $6.7 million, compared to $6.1 million for the second quarter of fiscal 2020
and $14.6 million for the six-month period ended March 31, 2021, as compared to $12.4 million for the applicable prior year period.
This increase in both the current quarter and the year-to-date period is attributable to the continued advancement of our ongoing
clinical trials, most notably, the </FONT>expansion of our Phase 2b/3 Alzheimer&rsquo;s disease trial internationally, as well
as the international Rett syndrome program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">General and administrative expenses have increased
to $2.2 million for the three months ended March 31, 2021, as compared to $1.7 million for the second quarter of fiscal 2020. Similarly,
general and administrative expenses increased to $3.7 million for the six-month period ended March 31, 2021, as compared to $3.1
million for the applicable prior year period. The increase in general and administrative expenses was primarily related to an increase
in professional and consulting fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Other income </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The net amount of other income was $0.8 million
for the three-month period ended March 31, 2021 as compared to $0.5 million for the three-month period ended March 31, 2020 and
$2.4 million for the six-month period as compared to $1.7 million for the comparable six-month period in fiscal 2020. The increase
in other income is attributable to an increase in Australian research and development incentive income in connection with the increase
in eligible clinical activities in Australia over the comparable period. Foreign exchange gains&nbsp;and losses during the period were related
to the fluctuations in the Australian dollar against the US dollar and its related impact on Incentive and tax receivables during
the period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Liquidity and Capital Resources</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Working Capital</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding: 0 0 0 10; text-indent: -10">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2021</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, 2020</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: left; padding: 0 0 0 10; text-indent: -10">Current Assets</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 20%; text-align: right">83,574,238</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 20%; text-align: right">34,542,197</TD><TD STYLE="width: 2%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding: 0 0 0 10; text-indent: -10">Current Liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,763,942</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,305,628</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0 0 0 10; text-indent: -10">Working Capital</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">75,810,296</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">27,236,569</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><BR>
At March 31, 2021, we had $75.9 million in cash and cash equivalents, an increase of $46.6 million from September 30, 2020. During
the six-month period ended March 31, 2021, we received cash of $61.8 million, net of issuance costs,&nbsp;primarily from the issuance of shares
of common stock under the 2019 Purchase Agreement and through the Sales Agreement, as more fully described elsewhere in this Quarterly
Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 30; Value: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash Flows</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0 0 1pt 10; text-align: center; text-indent: -10">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months ended March 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0 0 1pt 10; text-align: center; text-indent: -10">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left; padding: 0 0 0 10; text-indent: -10">Net cash flows used in operating activities</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(15,188,223</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(10,988,051</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding: 0 0 0 10; text-indent: -10">Net cash flows from financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">61,798,544</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,365,492</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0 0 0 10; text-indent: -10">Increase in cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">46,610,321</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,377,441</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash flow used in operating activities</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in operating activities
for the <FONT STYLE="color: black">first six months of fiscal 2021 </FONT>was $15.2 million, compared to $11.0 million during
the comparable period of fiscal 2020. The principal reason for this increase in net cash used from operating activities in the
current period is due to an increase in research and development expenses and an increase in research and development incentive
income receivable, as compared to the comparable period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash flow provided by financing activities</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash provided by financing activities for the <FONT STYLE="color: black">first
six months in fiscal 2021 </FONT>was $61.8 million, primarily attributable to cash received from the issuance of common shares at
various market prices under the 2019 Purchase Agreement and the Sales Agreement, net of financing costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash provided by financing activities
for the <FONT STYLE="color: black">first six months in fiscal 2020 </FONT>was $15.4 million, attributable to cash received from
the issuance of common shares at various market prices under the 2019 Purchase Agreement<FONT STYLE="color: black">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other Financing</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B>Purchase Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On June 7, 2019, we
entered into a Purchase Agreement (the &ldquo;2019 Purchase Agreement&rdquo;) with Lincoln Park Capital Fund, LLC (&ldquo;Lincoln
Park&rdquo;), as amended on July 1, 2020, pursuant to which Lincoln Park committed to purchase up to $50,000,000 of our common
stock. Concurrently with the execution of the 2019 Purchase Agreement in 2019, we issued 324,383 shares of our common stock to
Lincoln Park as a fee for its commitment to purchase shares of our common stock under the 2019 Purchase Agreement and became obligated
to issue up to 162,191 shares pro rata, when and if Lincoln Park purchased, at our discretion, the $50,000,000 aggregate commitment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended March 31, 2021,
the Company issued to Lincoln Park an aggregate of 4,086,209 shares of common stock under the 2019 Purchase Agreement, including
4,007,996 shares of common stock for an aggregate purchase price of $24,111,198 and 78,213 commitment shares. As of<FONT STYLE="color: black">
March 31, 2021, no shares of our common stock remain available for purchase by Lincoln Park under the 2019 Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Controlled Equity Offering Sales Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">On May
1, 2020, we entered into an Amended and Restated&nbsp;Sales Agreement (the &ldquo;Sales Agreement&rdquo;) with Cantor Fitzgerald
&amp; Co. and SVB Leerink LLC (the &ldquo;Sales Agents&rdquo;), pursuant to which we may offer and sell shares of common stock
registered under an effective registration statement from time to time through the Sales Agents (the &ldquo;At-the-Market Offering&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon delivery of a placement notice based on
our instructions and subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell shares of common stock
by methods deemed to be an &ldquo;at the market offering&rdquo;, in negotiated transactions at market prices prevailing at the
time of sale or at prices related to such prevailing market prices, or by any other method permitted by law, including negotiated
transactions, subject to our prior written consent. We are not obligated to make any sales of shares under the Sales Agreement.
We or the Sales Agents may suspend or terminate the At-the-Market Offering upon notice to the other party, subject to certain conditions.
The Sales Agents will act as agents on a commercially reasonable efforts basis consistent with their normal trading and sales practices
and applicable state and federal law, rules&nbsp;and regulations and the rules&nbsp;of Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 31; Value: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have agreed to pay the Sales Agents commissions
for their services of 3.0% of the gross proceeds from the sale of the Shares pursuant to the Sales Agreement. We have also agreed
to provide the Sales Agents with customary indemnification and contribution rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended March 31, 2021,
3,552,313 shares were sold pursuant to the Offering for gross proceeds of $37,823,241 (net proceeds of $36,688,544 after deducting
commissions and offering expenses).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-style: normal">Off-Balance
Sheet Arrangements</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal">We
have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition,
changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources
that are material to our stockholders.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>CRITICAL ACCOUNTING POLICIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">We prepare our interim condensed
consolidated financial statements in accordance with accounting principles generally accepted in the United States of America,
and make estimates and assumptions that affect our reported amounts of assets, liabilities, revenue and expenses, and the related
disclosures of contingent liabilities. We base our estimates on historical experience and other assumptions that we believe are
reasonable in the circumstances. Actual results may differ from these estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">There have been no significant
changes in the critical accounting policies and estimates described in our Annual Report on Form 10-K for the year ended September
30, 2020 as filed with the SEC on December 28, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in"><B>RECENT ACCOUNTING PRONOUNCEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">Please refer to Note 2 &ldquo;Recent
Accounting Pronouncements&rdquo; in notes to our Interim Condensed Consolidated Financial Statements included in this Form 10-Q.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><A NAME="a_004"></A>Item 3. Quantitative
and Qualitative Disclosures about Market Risks.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Not applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><A NAME="a_005"></A>Item 4. Controls
and Procedures.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Disclosure Controls and Procedures
</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We maintain disclosure controls and procedures
that are designed to provide reasonable assurance that material information required to be disclosed in our periodic reports filed
under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&rsquo;s rules
and forms and to provide reasonable assurance that such information is accumulated and communicated to our management, our chief
executive officer and our principal financial officer, to allow timely decisions regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We carried out an evaluation, under the supervision
and with the participation of our management, including our principal executive officer and principal financial officer, of the
effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rule 13a 15(e) under the Exchange
Act, as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our principal executive
officer and principal financial officer concluded that our disclosure controls and procedures were effective as of March 31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Changes in Internal Control over Financial
Reporting</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 32; Value: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the quarter ended March 31, 2021, there
were no changes in our internal control over financial reporting identified in management&rsquo;s evaluation pursuant to Rules
13a 15(d) or 15d 15(d) of the Exchange Act that materially affected, or are reasonably likely to materially affect, our internal
controls over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><A NAME="a_006"></A>PART II &ndash;
OTHER INFORMATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><A NAME="a_007"></A>Item 1. Legal
Proceedings.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">We
know of no material pending legal proceedings, other than ordinary routine litigation incidental to our business, to which our
Company or our subsidiary is a party or of which any of their property is subject. There are no proceedings in which any of our
directors, officers or affiliates, or any registered or beneficial stockholder holding more than 5% of our shares, is an adverse
party or has a material interest adverse to our or our subsidiary&rsquo;s interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><A NAME="a_008"></A>Item 1A. Risk
Factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There have been no material changes to the
risk factors discussed in &ldquo;Risk Factors&rdquo; in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended
September 30, 2020 filed with the SEC on December 28, 2020 except for the following new risks:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our stock price has recently been volatile
and may be volatile in the future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our stock price has recently been volatile
and may be volatile in the future. For example, on February 1, 2021, the price of our common stock closed at $6.53 per share while
on February 9, 2021, the price of our common stock closed at $14.99 per share without disclosure of news or other developments
by us. On February 4, 2021, the opening price of our common stock was $19.94 and the intra-day sales price of our common stock
fluctuated between a reported low sale price of $13.80 and a reported high sales price of $28.70, closing at $14.91. Our volume
on this day was 116,590,800, which was a substantial increase from the volume of 18,086,230 and 3,161,525 on the two days immediately
preceding February 4, 2021. We may incur rapid and substantial increases or decreases in our stock price in the foreseeable future
that are do not coincide in timing with the disclosure of news or developments by us. The stock market in general, and the market
for biotechnology and pharmaceutical companies in particular, has experienced extreme volatility that has often been unrelated
to the operating performance of particular companies. The market price for our common stock may be influenced by many factors,
including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 24px">&nbsp;</TD>
<TD STYLE="width: 24px">&#9679;</TD>
<TD STYLE="text-align: justify">announcements of new data, clinical trial results or those of companies that are perceived to be similar to us;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&#9679;</TD>
    <TD STYLE="text-align: justify">announcements related to any delays in any preclinical or clinical trials related to our products;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 24px">&nbsp;</TD>
<TD STYLE="width: 24px">&#9679;</TD>
<TD STYLE="text-align: justify">announcements related to our products&rsquo; ability to demonstrate efficacy or an acceptable safety profile of our product candidates or similar announcements by companies that are perceived to be similar to us;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&#9679;</TD>
    <TD STYLE="text-align: justify">our ability to meet or exceed expectations of analysts or investors;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 24px">&nbsp;</TD>
<TD STYLE="width: 24px">&#9679;</TD>
<TD STYLE="text-align: justify">news that the number of patients required for clinical trials for our drug candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, participants may drop out of these clinical trials at a higher rate than we anticipate or the duration of these clinical trials may be longer than we anticipate;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&#9679;</TD>
    <TD STYLE="text-align: justify">actions taken by regulatory agencies with respect to our product candidates or the progress of our clinical studies, including with respect to any fast track or orphan drug designations;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&#9679;</TD>
    <TD STYLE="text-align: justify">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us, our strategic collaboration partners or our competitors;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&#9679;</TD>
    <TD STYLE="text-align: justify">grants awarded to us or companies that are perceived to be similar to us from outside entities;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 33; Value: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 24px">&nbsp;</TD>
<TD STYLE="width: 24px">&#9679;</TD>
<TD STYLE="text-align: justify">variations in our financial results or those of companies that are perceived to be similar to us;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&#9679;</TD>
    <TD STYLE="text-align: justify">trading volume of our common stock;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&#9679;</TD>
    <TD STYLE="text-align: justify">developments concerning our collaborations or partners;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&#9679;</TD>
    <TD STYLE="text-align: justify">the impact of the COVID-19 outbreak and its effect on us;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&#9679;</TD>
    <TD STYLE="text-align: justify">the perception of the biotechnology or pharmaceutical industries by the public, legislatures, regulators and the investment community;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&#9679;</TD>
    <TD STYLE="text-align: justify">developments or disputes concerning intellectual property rights;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&#9679;</TD>
    <TD STYLE="text-align: justify">significant lawsuits, including patent or stockholder litigation;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&#9679;</TD>
    <TD STYLE="text-align: justify">our ability or inability to raise additional capital and the terms on which we raise it;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&#9679;</TD>
    <TD STYLE="text-align: justify">sales of our common stock by us or our stockholders;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&#9679;</TD>
    <TD STYLE="text-align: justify">declines in the market prices of stocks generally or of companies that are perceived to be similar to us; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&#9679;</TD>
    <TD STYLE="text-align: justify">general economic, industry and market conditions.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, companies trading in the stock
market in general, and The Nasdaq Capital Market in particular, have experienced extreme price and volume fluctuations that have
often been unrelated or disproportionate to the operating performance of these companies. These broad market and industry factors
may seriously harm the market price of our common stock, regardless of our operating performance. In the past, following periods
of volatility in the market, securities class-action litigation has often been instituted against companies. Such litigation, if
instituted against us, could result in substantial costs and diversion of management&rsquo;s attention and resources, which could
materially and adversely affect our business, financial condition, results of operations and growth prospects. There can be no
guarantee that our stock price will remain at current prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our common stock may become the target
of a &ldquo;short squeeze.&rdquo;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the past several weeks prior to the filing
of this Quarterly Report on Form 10-Q, securities of certain companies have increasingly experienced significant and extreme volatility
in stock price due to short sellers of shares of common stock, known as a &ldquo;short squeeze.&rdquo; These short squeezes have
caused extreme volatility in those companies and in the market and have led to the price per share of those companies to trade
at a significantly inflated rate that is disconnected from the underlying value of the company. Many investors who have purchased
shares in those companies at an inflated rate face the risk of losing a significant portion of their original investment as the
price per share has declined steadily as interest in those stocks have abated. There can be no assurance that we will not, in the
future be, a target of a short squeeze, and you may lose a significant portion or all of your investment if you purchase our shares
at a rate that is significantly disconnected from our underlying value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to the information set forth in
this Form 10-Q, you should carefully review and consider the risk factors discussed in &ldquo;Risk Factors&rdquo; in Part I, Item
1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2020 filed with the SEC on December 28, 2020. These
risks could materially and adversely affect our business, financial condition and results of operations. The risks described in
herein and in our Form 10-K are not the only risks we face. Our operations could also be affected by additional factors that are
not presently known to us or by factors that we currently consider immaterial to our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><A NAME="a_009"></A>Item 2. Unregistered
Sales of Equity Securities and Use of Proceeds.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the period covered by this Quarterly
Report on Form 10-Q, we have not sold any equity securities that were not registered under the Securities Act of 1933 that were
not previously reported in a Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 34; Value: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><A NAME="a_010"></A>Item 3. Defaults
Upon Senior Securities.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><A NAME="a_011"></A>Item 4. Mine
Safety Disclosures</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><A NAME="a_012"></A>Item 5. Other
Information.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 35; Value: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><A NAME="a_013"></A>Item 6. Exhibits.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 12%; border: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit
</B><BR> <B>Number </B></FONT></TD>
<TD STYLE="width: 88%; border-top: windowtext 1pt solid; border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><BR><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(3)
</B></FONT></TD>
<TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Articles
of Incorporation and Bylaws </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.1</FONT></TD>
<TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000113707005000007/ex31.htm">Articles of Incorporation (incorporated by reference to Exhibit 3.1 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 filed on May 9, 2019)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.2</FONT></TD>
<TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000108503707002199/exhibit3_1.htm">Bylaws (incorporated by reference to our Current Report on Form 8-K filed on September 28, 2007)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.3</FONT></TD>
<TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000108503707000198/form8kexh99_1.htm">Articles of Merger filed with the Secretary of State of Nevada on January 10, 2007 and which is effective January 25, 2007 (incorporated by reference to our Current Report on Form 8-K filed on January 25, 2007)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(31)
</B></FONT></TD>
<TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Rule
13a-14(a)/15(d)-14(a)Certifications</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">31.1*</FONT></TD>
<TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="e2736_ex31-1.htm">Certification of Christopher Missling, PhD.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">31.2*</FONT></TD>
<TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="e2736_ex31-2.htm">Certification of Sandra Boenisch</A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(32)
</B></FONT></TD>
<TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Section
1350 Certifications</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">32.1*</FONT></TD>
<TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="e2736_ex32-1.htm">Certification of Christopher Missling, PhD and Sandra Boenisch.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(101)</B></FONT></TD>
<TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>XBRL</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.INS*</FONT></TD>
<TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL
INSTANCE DOCUMENT</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.SCH*</FONT></TD>
<TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL
TAXONOMY EXTENSION SCHEMA</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.CAL*</FONT></TD>
<TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL
TAXONOMY EXTENSION CALCULATION LINKBASE</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.DEF*</FONT></TD>
<TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL
TAXONOMY EXTENSION DEFINITION LINKBASE</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.LAB*</FONT></TD>
<TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL
TAXONOMY EXTENSION LABEL LINKBASE</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.PRE*</FONT></TD>
<TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL
TAXONOMY EXTENSION PRESENTATION LINKBASE</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">* Filed herewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 36; Value: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><A NAME="a_014"></A>SIGNATURES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>ANAVEX LIFE SCIENCES CORP. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="border-bottom: Black 1pt solid; padding: 0pt; font: 10pt/115% Calibri, Helvetica, Sans-Serif; width: 45%; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/Christopher
Missling, PhD</FONT></TD>
    <TD STYLE="padding: 0pt; width: 55%; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0pt; font: 10pt/115% Calibri, Helvetica, Sans-Serif; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
Missling, PhD</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0pt; font: 10pt/115% Calibri, Helvetica, Sans-Serif; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
Executive Officer</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0pt; font: 10pt/115% Calibri, Helvetica, Sans-Serif; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
Executive Officer)</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0pt; font: 10pt/115% Calibri, Helvetica, Sans-Serif; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
May <FONT>13, </FONT>2021</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font: 12pt/115% Calibri, Helvetica, Sans-Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0pt; font: 10pt/115% Calibri, Helvetica, Sans-Serif; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-bottom: Black 1pt solid; padding: 0pt; font: 12pt/115% Calibri, Helvetica, Sans-Serif; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Sandra Boenisch&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0pt; font: 10pt/115% Calibri, Helvetica, Sans-Serif; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandra
Boenisch, CPA, CGA</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0pt; font: 10pt/115% Calibri, Helvetica, Sans-Serif; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
Financial Officer</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0pt; font: 10pt/115% Calibri, Helvetica, Sans-Serif; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
Financial and Accounting Officer)</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0pt; font: 10pt/115% Calibri, Helvetica, Sans-Serif; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
May <FONT>13, </FONT>2021</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">37</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>2
<FILENAME>e2736_ex31-1.htm
<DESCRIPTION>EX-31
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Exhibit 31.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Christopher Missling, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1. I have reviewed this Quarterly Report on
Form 10-Q for the three months ended March 31, 2021 of Anavex Life Sciences Corp. (the &ldquo;registrant&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2. Based on my knowledge, this report does
not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3. Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results
of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">4. The registrant&rsquo;s other certifying
officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules
13a&ndash;15(e) and 15d&ndash;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&ndash;15(f)
and 15d&ndash;15(f)) for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(a) designed such disclosure controls
and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(b) designed such internal control
over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(c) evaluated the effectiveness
of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(d) disclosed in this report any
change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent
fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control
over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5. The registrant&rsquo;s other certifying
officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(a) all significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(b) any fraud, whether or not material,
that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial
reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font: 10pt/115% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: May<FONT> 13, </FONT>2021</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font: 12pt/115% Calibri, Helvetica, Sans-Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt/115% Calibri, Helvetica, Sans-Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/Christopher Missling, PhD</FONT></TD>
<TD STYLE="font: 10pt/115% Calibri, Helvetica, Sans-Serif; width: 55%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Christopher Missling, PhD</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font: 10pt/115% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer, President and Secretary</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font: 11pt/115% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Executive Officer)</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>3
<FILENAME>e2736_ex31-2.htm
<DESCRIPTION>EX-31
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Exhibit 31.2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, Sandra Boenisch, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1. I have reviewed this Quarterly Report on
Form 10-Q for the three months ended March 31, 2021 of Anavex Life Sciences Corp. (the &ldquo;registrant&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2. Based on my knowledge, this report does
not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3. Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results
of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">4. The registrant&rsquo;s other certifying
officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules
13a&ndash;15(e) and 15d&ndash;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&ndash;15(f)
and 15d&ndash;15(f)) for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(a) designed such disclosure controls
and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(b) designed such internal control
over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(c) evaluated the effectiveness
of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(d) disclosed in this report any
change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent
fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control
over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5. The registrant&rsquo;s other certifying
officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(a) all significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(b) any fraud, whether or not material,
that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial
reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font: 10pt/115% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:
May<FONT> 13, </FONT>2021</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font: 12pt/115% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt/115% Calibri, Helvetica, Sans-Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/Sandra Boenisch</FONT></TD>
<TD STYLE="font: 10pt/115% Calibri, Helvetica, Sans-Serif; width: 55%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font: 10pt/115% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sandra Boenisch,
CPA, CGA</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font: 10pt/115% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Principal Financial
Officer, Treasurer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font: 10pt/115% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Financial
and Accounting Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify; text-indent: 20pt"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify; text-indent: 20pt">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>4
<FILENAME>e2736_ex32-1.htm
<DESCRIPTION>EX-32
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;Exhibit 32.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CERTIFICATION PURSUANT TO<BR>
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO<BR>
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Quarterly Report of
Anavex Life Sciences Corp. (the &ldquo;Company&rdquo;) on Form 10-Q for the three months ended March 31, 2021 as filed with the
Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), the undersigned, in the capacities and on the
date indicated below, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that to the best of our knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(1) the Report fully complies with
the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(2) the information contained in
the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 55%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: May 13,
2021</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/<FONT STYLE="text-decoration: none">s/Christopher
Missling, PhD </FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher Missling, PhD</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Chief Executive Officer,
President, Secretary</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer) &nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">/s/Sandra
Boenisch</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandra Boenisch, CPA, CGA</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">Principal Financial
Officer, Treasurer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and Accounting
Officer)</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The foregoing certification is being furnished
solely to accompany the Report pursuant to 18 U.S.C. &sect; 1350, and is not being filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before
or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement
required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed
form within the electronic version of this written statement required by Section 906, has been provided to the Company and will
be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>e2736_10-qimg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 e2736_10-qimg001.jpg
M_]C_X  02D9)1@ ! @$"^@+Z  #_X0S[17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  ,   $Q
M  (    4    <@$R  (    4    AH=I  0    !    G    ,@   $L
M 0   2P    !061O8F4@4&AO=&]S:&]P(#<N,  R,#(Q.C U.C$P(#$X.C V
M.C(P      .@ 0 #     ?__  "@ @ $     0   G2@ P $     0   4
M        !@$#  ,    !  8   $:  4    !   !%@$;  4    !   !'@$H
M  ,    !  (   (!  0    !   !)@("  0    !   +S0        !(
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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M)9SH,=X\#]Q2WCP/W%2224QWCP/W%+>/ _<5)))3'>/ _<4X,^/S$)TDE/\
M_]/U5)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?J
MI)?*J22GZJ27RJDDI__9_^T1ME!H;W1O<VAO<" S+C  .$))300E       0
M                     #A"24T#[0      $ +Z     @ " OH    "  (X
M0DE-!"8       X             /X   #A"24T$#0      !    '@X0DE-
M!!D       0    >.$))30/S       )           ! #A"24T$"@
M 0  .$))32<0       *  $          CA"24T#]0      2  O9F8  0!L
M9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M 0 U     0 M    !@       3A"24T#^       <   ________________
M_____________P/H     /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H   X0DE-!         (  3A"24T$ @      !      X0DE-! @
M     !     !   "0    D      .$))300>       $     #A"24T$&@
M   #20    8              4    )T    "@!5 &X = !I '0 ; !E &0
M+0 Q     0                         !              )T   !0
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !0
M  !29VAT;&]N9P   G0    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
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M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))3001
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M,:[ +W$AK0W.,D]OH>Y:GW;'5G&?LR?]^Y?WG)=#(/MQ_P#JMVF_7'+:V#A
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M(_Q\W_?N=C8?6,['9E877?5HLDLM96US3!VG\[\UX<U2/1/K.>.NN'_6&_\
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MI)?*J22GZJ27RJDDI^JDE\JI)*?_V0 X0DE-!"$      %4    ! 0    \
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M P,# P,# P,# P,# P,# P,# P,# P/_P  1" %  G0# 1$  A$! Q$!_]T
M! !/_\0!H@    8" P$             !P@&!00) PH" 0 + 0  !@,! 0$
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M;W6^U,IO/=4]138/$-CTJY*2CGKZDRY3)T6'H(8*2F1YII*G(Y"*,6%AJN2
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MXO._^AWU]_\ 7OW[KW7O[^=H?\^+SO\ Z'?7W_U[]^Z]U[^_G:'_ #XO._\
MH=]??_7OW[KW7O[^=H?\^+SO_H=]??\ U[]^Z]U[^_G:'_/B\[_Z'?7W_P!>
M_?NO=<7WSV=(CQOT5G61U9'7^_?7XNK JPN,V#R#[]U[H&LEUIA<MAJ#;]?\
M1DEPV+PF'VW04$>]MC4T-+@L$,VN/Q<?VVXX7^T*;DKEG4D_=K5.)_(#Q[KW
M36G4.*I\EALMC_C'N;$5FV:N6MVM_".W,!C:3:LM7E*W,9.+;6/I=WQT&%HL
MO7Y"9ZJG@C2GE#VT <>_=>Z%+$U>]L+N3=.[*'HG=O\ &=Y?P89QZGM':-91
M.,!22T.,6@QE5N6;'XE8Z>=@XI8XO,QU2:FL??NO=*G^_G:'_/B\[_Z'?7W_
M ->_?NO=>_OYVA_SXO._^AWU]_\ 7OW[KW7O[^=H?\^+SO\ Z'?7W_U[]^Z]
MU[^_G:'_ #XO._\ H=]??_7OW[KW7O[^=H?\^+SO_H=]??\ U[]^Z]U[^_G:
M'_/B\[_Z'?7W_P!>_?NO=>_OYVA_SXO._P#H=]??_7OW[KW7O[^=H?\ /B\[
M_P"AWU]_]>_?NO=>_OYVA_SXO._^AWU]_P#7OW[KW35G=P;[W-A,QMS/?'W,
M9/!Y_&5^&S&.J-][!\%?B\G2RT5?13>/.H_AJJ69D:Q!LQY]^Z]T&N?Z]Q6Z
M*A*G/_$:#).F0QF2\<V\-@+2O/AL;C,3BX9:*'/QT<V.H:##4B)2,AI08$;Q
MZA?W[KW3?@>LH-L;CPF[,#\;MW8W/;<H:##82NB[BPDIQ^V\711T./VG#!4[
MQGISM>CAB!CH64PJW( ]^Z]T(.SY=Y;&I\S2X#HG>"PY[<67W3D?XGVKM3.2
MOF<[4FKR<T-1F-SUM13T\U0Q*0(PAA6RQJJ!5'NO=*[^_G:'_/B\[_Z'?7W_
M ->_?NO=>_OYVA_SXO._^AWU]_\ 7OW[KW7O[^=H?\^+SO\ Z'?7W_U[]^Z]
MU[^_G:'_ #XO._\ H=]??_7OW[KW7O[^=H?\^+SO_H=]??\ U[]^Z]U[^_G:
M'_/B\[_Z'?7W_P!>_?NO=>_OYVA_SXO._P#H=]??_7OW[KW7O[^=H?\ /B\[
M_P"AWU]_]>_?NO=>_OYVA_SXO._^AWU]_P#7OW[KW3'N/+;RW?B9,%N;XZY'
M-X::LQ5?/C,AO;KV>BJ*K"96BS>,>H@;-^.=*7*8Z&;0X9',8#!E)!]U[H+]
MR=6[?W?,]1N;XA19F62?<M3,:W>VQW2>IW=]S_'JBHC7<BQU$]5]Y+XW<,U+
MK/@,9M;W7NI^W-DUFU-VUV^<'\>]ZTVZ\M%6P9K,S]R8.OJLY#61PP1QY@U^
M[ZE:_P#AT%/''2,X+TRH-!!%_?NO=++9D^[]@X7^ [9^/^XZ2@>OR.5J#4]D
M;+R59693+U<E=D\A6UV0W%4U=55UM7,SNSN;D\6''OW7NE7_ '\[0_Y\7G?_
M $.^OO\ Z]^_=>Z]_?SM#_GQ>=_]#OK[_P"O?OW7NO?W\[0_Y\7G?_0[Z^_^
MO?OW7NEQM3-;CS5-52[CV;6;-GAG2.GI:S,X/-/61,FIJA)<'5U<,*H_ITN0
MQ^H%O?NO=*OW[KW7O?NO=>]^Z]U__]'?X]^Z]U[W[KW1;OEGOK=O7/2&XMT[
M(RPP>XZ?*[3H*/)_9460-+'EMSXK&U96ER$%322%Z6I=?4AM>XL;$8[_ 'I^
M>.:O;SV6YBYFY+W067,27-E%'.8TE\,7%W#"[!) R$Z':FI2!QXTZEWV-Y9V
M+F[W(V?9>9+(W.T-#<R/'K:/68K>21060A@-2BM"/V=(E>E/E.RJW^SAU/J
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M -YAU7_HE=D?_5OOW^LW]YK_ -FUE_\ '>V[_K9U[_7%]E?_  @2?]S>\_Z
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M@^O?]!#WR$_Y\=TU_P E;W_^RKW[_@-.1O\ IKMV_P!YM_\ H#KW_!H\]_\
M3(;3_O5Q_P!!]>_Z"'OD)_SX[IK_ )*WO_\ 95[]_P !IR-_TUV[?[S;_P#0
M'7O^#1Y[_P"F0VG_ 'JX_P"@^O?]!#WR$_Y\=TU_R5O?_P"RKW[_ (#3D;_I
MKMV_WFW_ .@.O?\ !H\]_P#3(;3_ +U<?]!]>_Z"'OD)_P ^.Z:_Y*WO_P#9
M5[]_P&G(W_37;M_O-O\ ] =>_P"#1Y[_ .F0VG_>KC_H/KW_ $$/?(3_ )\=
MTU_R5O?_ .RKW[_@-.1O^FNW;_>;?_H#KW_!H\]_],AM/^]7'_0?7O\ H(>^
M0G_/CNFO^2M[_P#V5>_?\!IR-_TUV[?[S;_] =>_X-'GO_ID-I_WJX_Z#Z]_
MT$/?(3_GQW37_)6]_P#[*O?O^ TY&_Z:[=O]YM_^@.O?\&CSW_TR&T_[U<?]
M!]>_Z"'OD)_SX[IK_DK>_P#]E7OW_ :<C?\ 37;M_O-O_P! =>_X-'GO_ID-
MI_WJX_Z#Z]_T$/?(3_GQW37_ "5O?_[*O?O^ TY&_P"FNW;_ 'FW_P"@.O?\
M&CSW_P!,AM/^]7'_ $'U[_H(>^0G_/CNFO\ DK>__P!E7OW_  &G(W_37;M_
MO-O_ - =>_X-'GO_ *9#:?\ >KC_ *#Z]_T$/?(3_GQW37_)6]__ +*O?O\
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MZR?]DO?C:/=>TEV^]BCLN<8 6DMPQ*21U_M;<MW,HP'0U9#DU4@]6I^X#ZR
MZ][]U[KWOW7NO>_=>Z__TM_CW[KW7O?NO=%"^<__ &3GN7_PY-@?^]M@O>)O
MWVO_ !'OF/\ Z6.U_P#=QMNIY^[7_P!/:V;_ )Y+W_M$FZ-U%_FX_P#@B?\
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M!'=?_/I>QO\ T#-P?_4'OW]8N7/^FDV[_LJ@_P"MG7OZM\R_],UN7_9+<?\
M6OKW^@CNO_GTO8W_ *!FX/\ Z@]^_K%RY_TTFW?]E4'_ %LZ]_5OF7_IFMR_
M[);C_K7U[_01W7_SZ7L;_P! S<'_ -0>_?UBY<_Z:3;O^RJ#_K9U[^K?,O\
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M]0>_?UBY<_Z:3;O^RJ#_ *V=>_JWS+_TS6Y?]DMQ_P!:^O?Z".Z_^?2]C?\
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M;W7@<UF]P;/W,_7^:P9V[D]SXF+";BGJ<+M[#8[&[D;(4$"E'J[S13#67?\
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M1R_(O*5,F=0+B*B7JWHE9-EL,DM:9, L'6$4-<[4@-&1E5R*^ Z@/.!*&O\
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M[KW10OG/_P!DY[E_\.38'_O;8+WB;]]K_P 1[YC_ .ECM?\ W<;;J>?NU_\
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MID^=?5#[MP^VY_AG_,@R>XJB/&YK'0Y?XK;EKJ&2*;'KGZ:2HSK^/$4DTU&
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M!F+-'XRA1X/=K3*$88U4&H(ZLOWH/>+5").2MEC#H7!=IU4*LO@L6)GQH?#
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M^NH3C?XKC\_54V^6_A=9AH\O3O5*%E6-9.&9E90)+?[IGMO<R7\,?,&_B>W
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M3,>(RM'EH=J89>F,TTNTJRKGC?$UM5E6[@\FYX\/ K(\+PT@JBVHM':Q2O\
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MT';CI!>Q<_;A#''<\EWYD6S^F+_27.IE$PF#MV4,G:%)_$!4]V>G7?L_RI[
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MD ^E>LV_NB^[>W^T'(',W+7.'+U^EQ=[J;A5;;+N5M'@0QAE=+:0"I1@5)'
M'SKU:Q%\B_B_<F7=._ZFI.DS9K/?%OY*[KR4MEMX:>#<>R:^C@C0_P"[7$LA
M/ "CZXQ1?=3Y]@32]]82 \?]VNWN?V2WA7\^/IUDO-]YSD2X='2'=8](P%VO
M<(Q^9BL@WY?MZ<(/D=\4HZF*:?>/;$R*T$=1#2?&/Y"81*NC2I6KFH9EQ/7,
M,4M%43("860Q@BX )]^_X%#G(S13?[K258'.Z[>E0"#2D=X!GTX=;_X*'E!4
M>.NY%2"1_NJW)Z,13562R)J!CCT)NY?FC\5,["S4F<[,Q65^[AK(LL/C'\@:
MV2&2.5&FTQ3=7I9JB$-&6!! <D<^Q1O'W<N;]TC8BWVU)CFO[TVWC_V5]$>V
M_>'Y-V]U'C[H\%*%?W7N8!!_ZA*]!C3?*7H.FAF4=E[_ %J'DADAG@^&O=JI
M%XX*P.DJGKH/5)+72QS^IKH8]*\,2 M#]U+W!",?K]I0DX!O=I8CY%C<DFO'
MY<.A'/\ >A]N'9-6U[RX"D&EGNP!)([@/I<4 *XXUKUP7Y2]%QM/(G:>^DDE
ML%:/X7=X1!8FDJ?+%*D?7\8J%DIJCQ7)!4 GDL?;4/W4O<RW>5H=YVI=?I>[
M4O"O'3=9XXKPZW+]Y_VRECC3]R;QC^*SW5O3A6SQPKCB>I]-\K.@5K:6?(=E
M=A5U+"^N6D3X?][*]1HIVCB!J)>NG\;Q3D,K:6(5=/%[^W;?[KGNG%<QS-OF
MVZ5/_*?M9\CY&ZI^WJDOWF?;-H7B@VC=$=OQ&PW6@SQH+/S'IU'K_E1T+721
M2CLK?H*4M''/]Q\.N])S-6P!ON:Q"W7UXDJV(/C.K1I N1:SUU]U[W0N#5=_
MVX?]1NT?]M/3MM]YSV\MUTO:[DV32FW[P* ^7^XOEU@A^4/0,,T$_P#I(WXW
MAN7C3X;=X*TSND/E9)AUV'IS)4(\C:+:C(0?;5M]U3W%@;6V][>6_P">W9_^
MVGIZ;[S_ +<3*$^AW,)\['>#3CY?29XTSZ#IG[E^4GQPS_QX[EV=@ZGL?='8
MFYNH>RML8"IC^,O>N#ERN?W#M'-XK$T=/YNN4H,8M34UL<.IYDB4$L[ 7/N4
M/;CV YBY:YSY2WS=1MKBTW*VEDF.X[8-,<<R.3HCNLZ5!. 6/H3U%GN1[[<N
M<R\G\W;)MDFZ%KK;+B**+]V[G1I)(715U/:@#4Q&6( KDTZTZ8_CG\@ B ](
M=M@A%!'^CG=_U  /_+G]]8#S?RB23_6O;./_ "EP?];.N4 Y/YPH/^0ENG_9
M)/\ ]:^N?^RZ?(#_ )\AVW_Z+G=__P!9_>OZW<I?]-7MG_97;_\ 6SKW]3^;
M_P#IDMT_[))_^M?7O]ET^0'_ #Y#MO\ ]%SN_P#^L_OW];N4O^FKVS_LKM_^
MMG7OZG\W_P#3);I_V23_ /6OKW^RZ?(#_GR';?\ Z+G=_P#]9_?OZW<I?]-7
MMG_97;_];.O?U/YO_P"F2W3_ +))_P#K7U[_ &73Y ?\^0[;_P#1<[O_ /K/
M[]_6[E+_ *:O;/\ LKM_^MG7OZG\W_\ 3);I_P!DD_\ UKZ]_LNGR _Y\AVW
M_P"BYW?_ /6?W[^MW*7_ $U>V?\ 97;_ /6SKW]3^;_^F2W3_LDG_P"M?7O]
MET^0'_/D.V__ $7.[_\ ZS^_?UNY2_Z:O;/^RNW_ .MG7OZG\W_],ENG_9)/
M_P!:^C 8:?Y@83;U!M*FZ%WK+MC$;?HL'AL1+U'N]!BJJDASD,FY:7(TV,@R
M[Y^O_O/DFF:6>2G+5LFB)!IL%K@>WMS=RW[\W60O9)2[N+V#N!*'PRI<KH7P
MXP* -V"K'/0LMS[BVUI%8)R=>FRCB"(ILI^T@./$#! VMO$D))8KWFBC%'RO
MW5\T\E2TU'6=$;NE@EPJ[?W4#TUNMI-^XQ-IS[-5=T5$F,EJ%JOX77UDK3T+
M4<LE76SRN27L$L5G[;PN\D?-MF'$FN+_ !Z#]!O%$OZ8UTIJ50 ^L!451PZ4
MRWGN7-&D<G)]X5,?AR_XC/\ KKX1A_5.BM=+.24*$L[,>/32U5\MZL54>7^/
MO8.4IJW8.WNOJJ"'8O:^WI*B@V[6R9%<S/7[8J,/D)\YFZZ5I<D[RM!6LWKB
MM8>WPO($>@V_.-@CK=23@FYLY &D73H"R:E"(!2, :D\CTG+>X4FL7')E^Z-
M:QP$"VO(ZK&=6LM'H8N[9D).E_,=(O>NT?E1O>'"PU/1?96 _NYBJG;.#DVM
MUQO["R4.R9(J5*+8[M#2M]]MS$R0RRP)/Y)C)5SF1Y X"F.W;AR+MK7#)S;M
MTOC.)'\2[MG#35-9LMVR-4!BM!15H!3)=N6W<^[FMLK\H;C%X*&-/"M+E*0F
ME(<+W1K0E0U35FJ37$O<.V/DYF<1A,'B?CMV!LO%XC:XV=54.U^O>R$HL]@F
M=*BJBR=)EHLI!!5Y/(&:JJZBD%/-4U%0[.Q C5&[2]Y)M[BYN9^=+"XGDF\4
M-)=6M4?@"I5E)"K155M055%!DDN7=ASS<06UM!R3?VT$<'@E8K6ZHZ<2&#JP
M!9JLS+I+,Q)/ !XI:;Y7T4^_*^D^/N_Z7+;]B-%4Y"#K[L^.GPF'2@I,7CL-
MBMO!_P"[-51;?Q]#$F,>OHZN>@=1)&XD 8,/)R'(NUQ/SC8&"U-0INK2KOJ+
M,[25\0%V8F0(ZAQ@BE:J$BY_C?=)8^3+];BZ%"PM;NB)I"JBQT\,B-5 C+HS
M(<@USUU2)\R(ZO:$V4Z?[8W#0[23< .#RNPNPX\+N.HW-_'X\ED-PT.+IL?'
M-DA1[CG@AG@\$D4032;@D^D;VZ:._6'F;;(I)_#[UNK77&(]&E49F:BUC5BK
M5!-:_+2)[D"3;VGY7W.6.W$G8UK=:)#)KU-(JJM6I(RAETD"GGU.1OE3!14E
M)0?&;<F.EP!G785;2=6]EB?KNGJ=M4^U)8MM132RTE5/_"X"ZU&22NG6KEDG
MU:V%FC_41I)'DYXM766GC WEI2<B0R?J$$$#4::8RBZ0%I09= Y^6...+D6[
M1HJ^ 19W=8 8Q$1&"""=(KJD#MK):M>I.$RGS%P]/0M4=#;XW!FZ*@K=OG<^
M=ZLW[-F*O964RL&9R^R*I*&GH,8<+E*V$B25*=*U(9'C295;W6YB]N[AI0O-
MUE%;,PD\-+RV""95*),*LS:U!P"Q0D E21U>UE]QK=(B_)U]-<JIC\1[.Y+F
M%F#O"=*JNAB,D*' ) 85Z2^=VQ\BL_MW<>VZCXM;LI:3/1[,HZ*IHNONUEJM
ML8GK_&28G:F)PJSSSTL]/0TE54F22LCJ9ZB6JD=W)":5MM?<G6MW:7B<^VC/
M$9B0;JSI(T[:I6>A!!8A:!"H4* !QJBNK#G.ZM+RS;D"\6.40@%;6\K&L"E(
MD2M00H+5+ABQ8DGA0'/]ET^0'_/D.V__ $7.[_\ ZS^Q!_6[E+_IJ]L_[*[?
M_K9T'?ZG\W_],ENG_9)/_P!:^O?[+I\@/^?(=M_^BYW?_P#6?W[^MW*7_35[
M9_V5V_\ ULZ]_4_F_P#Z9+=/^R2?_K7U[_9=/D!_SY#MO_T7.[__ *S^_?UN
MY2_Z:O;/^RNW_P"MG7OZG\W_ /3);I_V23_]:^G[;/Q3^1>Z<S2X:CZ8[.H?
M,M145F4R?7V\Z?$X;&4-/)69/,9:JCP4S4V-QM%"\LKA68A=*AG95);NWN)R
M+LMC-N-_S=MPMT'X;F%F)\E55<DD^7\^C/:?;GGS>[^';MOY/W(W#_Q6TRJ!
MYLS,@  \_/TZM<ZIVAL?IKIR&# 9/>&>V]2YY*#/[MGV%V<:&JWIE<>^0DHZ
M+'OM-GQM/)14C/%%''IT)JD8R,2<>-T]VN3M]O9-SN.9]OBCKH5?$6H49 -,
ML?5N%<"@H.LC-I]H^<MAL8MKM^5]PDDR[,8VH6."1^%17@M:^9J:GK)GZ;)5
M>?P.TZ7;N^)]R;MH\3D=M8>+K?L5JK,4.X*<UF%JJ5O[J> 19"F]:>1T('Z@
MIX]K;7W$Y"62*-N<=N#L 1^LM,\*G@/S((\Z=(;OVXY_:.61>3-R**37]%JX
MXT%*G[0"#Y5Z+CF*3+97%;AS>-VOO^MQ.V9*"#/U\'6'9C08J7*U,M%CDJK[
M0#WJZN!XTT!AJ7FWL36/NC[;A'=N>=L"J16LRCC@4'$_D#3SZ#E[[6>Y)=4'
M(NYEGK2D+'ADU/ ?F17RZ _=.SM[.NW"G7W9[C>L J-IZ.J>S6_CT+Y.;#(]
M!;:)+!LK3O -6DZU_I8D36GNS[81^!KY_P!J&OA^NOK3/\.?XJ>O#/04N_:3
MW2<S:/;[=CX?Q?H-Z5Q_%C^&OIQQT"^4ZM[4FR^Y*&+J?MV2LV3#D*O=M.G4
M79S2;?IL9D(,7D)\A;:5DCI,C4QQ.5+69A^.?8C@]X/:D>.A]Q-H#1@EO\83
MR-#0\&SY+J)XBHST&I_9SW89H7'MQO!22@7_ !=\U!(J.*X'%](' T..G.BV
M1OW'X7$[BK>M^U*7!YFLR&/Q64FZE[/6EKZW$+1G)T].W]T2[247WT6NX ]8
ML3S9/-[P^U/AI+_KB;3H:H'ZZUJ...(XC) !\J]*(/9OW9UO#_K<[OXBBI_Q
M=@*&M,_">!P"2/.G0Q8WKKL>GW'6;/GZR[5BW1B:*MR63PC]4=E"NHJ#&XML
MW754R_W3\0BIL2IG:S$Z/H">/:.7W9]K_&D@_P!<':?$ )/^,)2@%3W5TG'D
M"2> %<=+8?:/W3\*.?\ UO-W\(D ?XN]:DZ1VTU#/F0!Y\,]+#$8S.+MY]UM
MM'L-=MPY>' 2YANK>S12)F9Z.3(0XXD[0\OW#T4+2"RZ=(Y-[#V62>[7M>8F
MF'/^U>'JI_;K6M*_#\7#SI3RK7HTB]H_=)9EA/M]NOB::_V#4I6GQ?#7Y5KY
MTIT,.(V_N<;BV_M([,[#&Y-T4>(R.WL.>L>QQ59:ASM**[$55*3M00"*OI#Y
M$UNI"_JL01[1/[I>VK2QQ#GO:]; $?KI3(J*G@/L)!'G3I;'[5^Y@C>4\A;K
MX:$@_P"+O6HP:+34?M4$'RKU9M\#/AON#O[);?[BW96;^ZXZJV%OZER&-H)<
M#EME;F[BR^TIJ>OI#@\GDIL7NK;/7F(W-"(JZK2BIZG-R4TE-2SI1^::HQ?]
M\_?';MQL+CDSDN[2XMYETW5R &C9#0^% 3QK^.2F/A0UJ1E-[$>Q>Y;;?6W.
M?.UH]O<0G5:VQ)617!(\6<#A3\$=<UU.*  [&_O#OK,GKWOW7NO>_=>Z][]U
M[K__U]_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW10?G!\
MKZ?X8]$UW=M5LF7L"&BW-M[;AV]#GTVV[G/25,8J_P")OB,X%%-]M^C[<ZRW
MU4<^Y)]J?;M_=#FV+E6/=ELF:WEE\4QF4?I '3I#H<UXZL>AZC/W9]QD]K>4
M)>:Y-H:]5;B*+PA((B?%)&K44<=M.&G/J.J=*3_A0D:^C.1H/AMNROQXKJ?&
M&NH>RJFLH_XG6$BDQPJ*;JR6)J^J*VCA!,CFP )('O)1_N;>%)X,ON=:K+I+
M:6M2#I'%J&Y!TCS/ =8SQ_?/\6/QHO:^Z>+4%U+= C4>"U%N1J/D.)ZFT_\
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M $$8X'_O%3)?^C@@_P#M:>_?\!9=?^%%A_[(W_[:.O?\&U:_^$YF_P"RQ/\
MK1U[_H(QP/\ WBIDO_1P0?\ VM/?O^ LNO\ PHL/_9&__;1U[_@VK7_PG,W_
M &6)_P!:.O?]!&.!_P"\5,E_Z."#_P"UI[]_P%EU_P"%%A_[(W_[:.O?\&U:
M_P#A.9O^RQ/^M'7O^@C' _\ >*F2_P#1P0?_ &M/?O\ @++K_P *+#_V1O\
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M62":J?X4;S6FIMOXK=E1.W9<HB@VMG*R''X7<<KGJ^R83*UU3'#!4G]J21U
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MOP-1GAD9ST@_^@C' _\ >*F2_P#1P0?_ &M/9I_P%EU_X46'_LC?_MHZ*_\
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M/ <D]F]>V'Y-JG)'C_8#WDO]TT$^[UJ ,_NZZ_XX.L8_O<$#V>NB3C]XVO\
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MV?R^[8<S*&7#56(W'M'==?A91#215+0K3&21UB"#=MR#<Q(K3;L7N#;> U$
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M% (#L-1UMQ>I."QZ27_.U[N$UY')=31;/>2QRW,$;@!G72'\(D$QJ=(T+P3
MR%'37G.V-J9+?V,W#%UU!6;6PF1P&0P^*S$='_>6BH-I8>+&[7V4,S0R?PZ3
M96.>@I?+$],U751I(9)3)(3[>MN7MRAVN:T;<V6]D1U=DKX9:5RTDV@]WC-J
M:A#:5) "T'3-SS'MLVZP78VM&LHG1D5Z>(%B0+'#K4Z3"NE:@KJ8 DM4]<Y^
MZJ:3KE]J5>T8=U[BRV[O[Y[CR>]Z/$UV$GS3T^YH*NJIXL'3X7<.7>L;<ADB
M7*5E1'CFB/VXM*X]Z7EB<;M]<EXT%HD'@QK"65PE8R 2Y>-*>'0F-%,@/?\
M".MMS3;G:#8R6:SW<EQXTC3!"A>D@)&@)(U?$J!([".G9\1Z$VI^4>$S1ACW
M'L7,U&+HJ6OQIVOC*C:]/M;=N'K,=M9$H=\XZJP<\M7EH<QMSSIFJ22'*PQ+
M3JDA> -[)DY%O;;4;/<$$[,K>(PD,D3AI,PL' "E)*&%@8B=9(HU.CI^?+*Y
M*"\V]S JLOA*8A%*A6+$RE"2X>.HF0B4#0 :K7IEZ[^2V.V*FWLFO6M-#N#:
M9W+08>AVM7-@=F5.$WG4;7EW!-E,;5C+94[FBBVXPIJJ*H\32S))(@\"JRC=
MN2;K<S=P_O5C:S^&SM(NN8/$)- 5AI7PR9.Y2M: @'N)";:.>+7;!:3?NI!=
MP>(J")M$)28Q^(64ZF\0"/M8-2I!([0"U5G>&U(=H;DVGA-H[J\%?UU#UEA9
ML_7[8K9UP\>43.KE\MEJ7!PY^DR--EY)7%'CZF*@JH5ACJ$81MK41\K;DU_9
MWUS>0ZENS<.$60#7IT:%4N4*E*#6ZEU.HJ1448DYKVQ=OO+"VLYM+68MD+M$
MQT:M>MF""0,').B-@C#2'!H:E=\4G^H;_;'V--#_ ,)Z!/B)_$.O>*3_ %#?
M[8^_:'_A/7O$3^(=>\4G^H;_ &Q]^T/_  GKWB)_$.O>*3_4-_MC[]H?^$]>
M\1/XAU>G_)G^#'=/9/;6V?D]_>+='4_5'7N8:6BW#B)6Q^9[.R%,YAR.SL*L
M\;P5.TJA0U/FJJ2.2!HV:EB#3F22EQ*^\Y[K<L;/R]?^WJV<&X<Q7:#6CC4E
MF.*RL0:BX\XE!!4'6_:0KY=_=>]IN:-YYCV_W%:]N-NY=LW.AT.E[P\&B6HH
M;;RF8@AB-"=P+)N->^;G72SKWOW7NO>_=>Z][]U[K__1W^/?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%W^5O<6Q_C]T+OON3L7:%1OK:6Q
M(<-7Y+;5)18BOK*YLCN#%8"D>DI\[)#C/+356620M(ZE45M/-@1G[>\L[KSC
MS?M'+&R[DMIN-XSJLK,ZJNF-I#J,8+4(0C .2*XZ!/N)S/M/)G)^\<T;WMC7
MFVV:HS1*J,S:I%C&D2$+4%P<D8!IU26/YYOPI97=?B7OEDCTF5UVKU0R1:VT
MIY'&6*QZVX6Y%SP/>4?_  *7N@" ?<2TJ?\ AMW_ - =8K?\%G[6T)'MO>4'
M_"K3_H/KP_GF_"EBRK\2]\LR?K5=J]4LR< C6HRQ*W!_/O?_  */N@*$^XEG
M3_FM=_\ 0'7O^"S]K3@>V]Y7_FC:?]!]=_\ #Y7PL^O^RD;\ YY.T^J@/3?5
MR<K;TVY_I[U_P*7N?_X46S_YS77_ $!UO_@L_:[_ ,)M>_\ .&T_Z#ZX?\/G
M_":VK_93=[Z22 W]U^I])*FS6;^+Z38\'_'WO_@4?='A_KAVE?\ FK=_] =:
M_P""T]K/_"<7G_.*T_Z#Z\/YY_PG)L/B;O<M?3I&U^IRVHVLND9>]S?@?GW[
M_@4?=#_PHEI3_FK=_P#0'7O^"T]K:T_UN+RO_-*T_P"@^NO^'T?A+8M_LI^]
MM(;26_NQU-I#<C2S?Q>P:ZG@\\>]_P# H>Z/_A0[2O\ S5N_^@.O?\%I[6?^
M$XNZ?\TK3_H/KQ_GH?"4<'XG;V!(5@#MCJ<>EQ=&YR_Z7'T/T/X]Z_X%#W1_
M\*':?\Y;O_H#KW_!:>UG_A.+O_G%:?\ 0?7)?YYWPH:Y7XF;X8*+L5VMU0P4
M?ZIB,N0%X^IX]^_X%'W0''W$M/\ G+=_] =>'WM/:T\/;B\_YPVG_0?2MV9_
M./\ C%V/DJK#=>?!GN#?67H,;49FOQFT.NNN-PU]#AZ22&*KRU92XNOJ9J7&
M4LM3&LD[A8D:10S"X]ENZ?=JYYV.W6[WOW8VNSM&<*'FN;B)2Q!(4,Z@%B 2
M!6I /IT:;3]YCD??[E[/8O:'=;V[5"Y2"UMI7" @%BJ,Q"@D FE*D#SZ6^ _
MFB=4;LAJJC:G\M[Y';HIZ&7P5T^V^G-DYV&BF]5HJR3%U%4E*YTFP<K>W'LA
M;V4W!,M[^\N@?]+"3H1'WHM!Q^[SS+_W+4_S=*$?S%-KF]OY6'RW;3;5I^/6
M!-K_ $O:,VO?C^OO2^RU^P#+[_<N%?4;C)UH^]5DHJ?N]<R@?]*V/_-UT?YB
MVU@+G^5C\MP..?\ 9>L#;U?3_=?Y]Z_UE[[-??\ Y;_[F+_Y^JCWLL"*C[OG
M,A'_ $KH^NQ_,5VN0"/Y6'RW(-[$?'K D$@A2!:,W(8V/^/O7^LQ>_\ LP'+
M?_<Q?_/UO_7KL?\ V7OF3_N6Q_YNO-_,4VN@N_\ *P^6ZBX6[?'K J+G@"YC
M N3]/>_]9>^)H/?_ )<K_P!+%_\ /U[_ %Z['_V7OF3_ +ET?^;H/M]_S<.@
M>K8L9-V=_+][XZZAS3U46&EWSU1L3:T>6EHEA>MCQCYJIHUKGI$J(S*(]10.
MM[7'LXVG[NO-V_M.NQ>\6T7K1 %Q!=SRE U=);0&TUH:5XT-.B;=_O'<H<OB
M!M_]F-XL5E)"&XLX(0Y6FH+XA752HK2M*BO'H.O^'T/A-_WB=O;_ -!CJ;_Z
M\>SK_@4?='_PH=I_SEN_^@.B3_@M/:S_ ,)Q=_\ .*S_ .@^O?\ #Z'PF_[Q
M.WM_Z#'4W_UX]^_X%'W1_P#"AVG_ #EN_P#H#KW_  6GM9_X3B[_ .<5G_T'
MU[_A]#X3?]XG;V_]!CJ;_P"O'OW_  */NC_X4.T_YRW?_0'7O^"T]K/_  G%
MW_SBL_\ H/KW_#Z'PF_[Q.WM_P"@QU-_]>/?O^!1]T?_  H=I_SEN_\ H#KW
M_!:>UG_A.+O_ )Q6?_0?7O\ A]#X3?\ >)V]O_08ZF_^O'OW_ H^Z/\ X4.T
M_P"<MW_T!U[_ (+3VL_\)Q=_\XK/_H/KW_#Z'PF_[Q.WM_Z#'4W_ ->/?O\
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MWV%35;QGVU68V.IJ_P#+*!G2M>S33 VDY.W][I;RWTP!:^%&'J85=I^Q9/B
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MM,6"E@-6FH)IPJ.L0OO?<Y<H\T6/(:<M<S6-^\,UT9!;S1RZ R0Z2^@G36A
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M?>H_Z:&^_P"YN?\ K?U[_7A^ZA_TS=A_W*!_UHZ]_L^/\CZU_P#1'U=;^O\
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MOW^M#]ZC_IHK[_N;G_K?U[_7A^ZC_P!,W8?]R<?]:.O?[/A_(_\ ^?0]7_\
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MGA.)!'(P1R3"+?PRC"A3]0SF,!OCU:BRCHUFEY4EN(UVV[VR"R\53&9(U+H
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M<^+CVW(B[7K<?F0(,^U.Y,<JJH%WNMQ[D;VH@YXN>=]KA]NKI8>;"DOA,QC
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M^"1]Z?\ IMY?^<%K_P!:.O?\#3[)?],-%_SGNO\ K?U[_AHC^7C_ -X[8_\
M]#WM+_[-_?O^"1]Z?^FWE_YP6O\ UHZ]_P #3[)?],-%_P Y[K_K?U[_ (:(
M_EX_]X[8_P#]#WM+_P"S?W[_ ()'WI_Z;>7_ )P6O_6CKW_ T^R7_3#1?\Y[
MK_K?U[_AHC^7C_WCMC__ $/>TO\ [-_?O^"1]Z?^FWE_YP6O_6CKW_ T^R7_
M $PT7_.>Z_ZW]>_X:(_EX_\ >.V/_P#0][2_^S?W[_@D?>G_ *;>7_G!:_\
M6CKW_ T^R7_3#1?\Y[K_ *W]>_X:(_EX_P#>.V/_ /0][2_^S?W[_@D?>K_I
MMY?^<%K_ -:.O?\  T^R7_3#1?\ .>Z_ZW]>_P"&B/Y>/_>.V/\ _0][2_\
MLW]^_P""1]Z?^FWE_P"<%K_UHZ]_P-/LE_TPT7_.>Z_ZW]>_X:(_EX_]X[8_
M_P!#WM+_ .S?W[_@D?>K_IMY?^<%K_UHZ]_P-/LE_P!,-%_SGNO^M_7O^&B/
MY>/_ 'CMC_\ T/>TO_LW]^_X)'WI_P"FWE_YP6O_ %HZ]_P-/LE_TPT7_.>Z
M_P"M_7O^&B/Y>/\ WCMC_P#T/>TO_LW]^_X)'WI_Z;>7_G!:_P#6CKW_  -/
MLE_TPT7_ #GNO^M_7O\ AHC^7C_WCMC_ /T/>TO_ +-_?O\ @D?>G_IMY?\
MG!:_]:.O?\#3[)?],-%_SGNO^M_7O^&B/Y>/_>.V/_\ 0][2_P#LW]^_X)'W
MI_Z;>7_G!:_]:.O?\#3[)?\ 3#1?\Y[K_K?U[_AHC^7C_P!X[8__ -#WM+_[
M-_?O^"1]Z?\ IMY?^<%K_P!:.O?\#3[)?],-%_SGNO\ K?T=+IOI+JOX_;&H
M.M^G-EXG8NS,=455;#B,7]U,T]?72"2LR.1R.0J*S*9;(U!"JT]5/-+XT1 P
M1$58LYEYGW_G#=[C?>9=TDN]UE #2/3@HHJJJ@*BCR50%&32I/4K<L\K\O\
M)VT6^P\L[7%9[3$25C2O%C5F9F)9V)XLS%C@5H!T*?LAZ/\ KWOW7NO>_=>Z
M][]U[K__UM_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW54
MW\ZK_MWCV_\ ]K[J_P#]^/MKWD#]V#_I\W+7_-*Z_P"T:3K'K[TO_3EN9?\
MFM:_]I,76G;T[VGM;;6)'7NZ>O=@YC&;J[%V'F,MV!N2@^ZSFU\#ALS1/EZ*
MD8PRQG%55"LGF4@CQR2@AM7OI3S!LE[>3_O:RW6ZCF@M)D6"-J)([H=!.1W
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MR0_]L?6'?]<_N=?^$[W'_G'-_P!MO7O]F#_D(?\ >+W:GZM/^;W-<M_J0/\
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MC^G6I\J CY]9G_FZ] QY/:N/?JOY!BGW%2XRHR>8_@'5AQFR),A52T]31;K
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M[_7@^[U_[+\O^]0?]!=>_P!G^_E6?]ZW,?\ ^?3$?]>/?O\ 6C^\%_X7UO\
M>9_^@>O?Z\'W>O\ V7Y?]Z@_Z"Z]_L_W\JS_ +UN8_\ \^F(_P"O'OW^M']X
M+_POK?[S/_T#U[_7@^[U_P"R_+_O4'_077O]G^_E6?\ >MS'_P#GTQ'_ %X]
M^_UH_O!?^%];_>9_^@>O?Z\'W>O_ &7Y?]Z@_P"@NO?[/]_*L_[UN8__ ,^F
M(_Z\>_?ZT?W@O_"^M_O,_P#T#U[_ %X/N]?^R_+_ +U!_P!!=>_V?[^59_WK
M<Q__ )],1_UX]^_UH_O!?^%];_>9_P#H'KW^O!]WK_V7Y?\ >H/^@NO?[/\
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M_<^ IVVOD,9UOD4KZ>#)=?Y//]FR;YW)14]32'RU&V<AC5IJ=$5EFBJJ*.4
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MQ8O]^+^T=>^WJ/\ CA-_U*?_ *-]^\&7_?3?L/7O%B_WXO[1U[[>H_XX3?\
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M_'[M7O4./NPO_97??YNO?\$W[)GA[2/_ -DEA_T%UVW\XK^7&I ?X*5*$DJ
M_5O12791J91JK1Z@.2/J![\/NU^]1K3W87_LKOO\W7O^":]DQQ]I'_[)+#_H
M+KH_SB_Y<0^OP5G' ;GJ[HD$J20& -<+J2/J./?O^!J]ZO\ PK"_]E5]_P!
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M.NFGSKCJ0?\ A0!T@F?P./F^.G>4> KZ+%3YW<8S/4;G;M95TOER=!_!AO\
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M?'#ZZ?P^O]:^VV^ZM[IJB-3;2Q)J/J144X$DI3/E0GAFG5U^]?[4L[+7<P@
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M?M+?PGKVM/XQ^WKWCD_XYO\ \DM_Q3W[2W\)Z]K3^,?MZ]XY/^.;_P#)+?\
M%/?M+?PGKVM/XQ^WKWCD_P".;_\ )+?\4]^TM_">O:T_C'[>O>.3_CF__)+?
M\4]^TM_">O:T_C'[>O>.3_CF_P#R2W_%/?M+?PGKVM/XQ^WHT/Q1Z>[7[&[,
MP^9Z[K<EM"EVC74]?FNP(X)/L\' 3>3'Q*X6GRV2RM.&C6A8LDD;%I0(P3["
MG.&[;7M>TS0[G )C.I5(3Q<^M?PA30ZN(/#/0NY-VC==UW>&;:YS"L#!GF'!
M!Z>C,PQIX$9..M@&KI*H 1M%,\HC%[Q:9)"%!,GB4>D./5P+ ?3CWCI&"0:#
MSZR2=@.+?GTDJVGG*LPB<J#8N%)4$WL"WZ03;@?GVOC4T&//I$["O'I*UM-4
M:@/#+J=;HNAM3@\ H+7<$CBU[^UJ*V,=()&6ASY])*LIY_7^U)Z!Z_2?1]1Z
M_P#4<\<VY]KHU;3PZ0R,OKTDJRGG N8G 8>@E2 ]C8Z#]&L>.+\^UL:MVX\^
MD,K+Z]).MII_6OADU(&+KH.I OZBZVNH7\WM;VNC1OX3T7R.M?B&3_DZ25=!
M-8MXVTG4 UO22.2H;])8#\?7VMC5L&F*](G=:TU9Z2M;35&HKX9->F^C0VNV
MD-?1;5;3S]/IS[7Q(W#2:]%TKII8ZA2O21K()>6\;%0;%@/2"5X!;]()_ ]K
MHT:E:8Z0R,NLC5GI)UD$U[>)[LOI&DW<$<%!]7!_%KW]KHT?M&DUZ02NG'4*
M#_-TDZN&7G]MO2/587T<@>O_ %//'-N?:U$;/:>/2"1UU?$,_P";I)5L,MB?
M&P#:M)(X:QL=)^C6/]/:^-&JO:<](G=>_NX=)2M@FU./$]U5BPTG4H Y+"UU
M _-_I[6QH]*:37HOE=,G4*=)*NBD"ZM#:2;!K>DD6N WT)'M=$C5!TFF>D4C
MID:A6G22KH9=3KXWU6OITG5;ZWTVO:W/^M[7Q1O4#0:]%LLB::ZQ3J/3Q265
MM#:18%K'2"0; GZ GW=D;CIQU173M&H5Z?*>*7T#QO=A=1I-V!'!46NP/XM[
M::-ZTTFI'3JNG'4*"O3Y3Q2Z;Z&LMM1L;+P!ZO\ 4\_U]L,C5/:>'2E72@[A
MT]P0R^@Z&LWZ21PW%O3_ *KG^GMED?\ A/#I\.E?B'3Y!#-<CQO=02PTFZ@6
MN6'U4#\W^GMDH^1I-1TZKIVG4*'IY@AEMJT-I)(#6])( ) ;Z$@'Z>V61J5T
MXZ>5UU4KGI\@@FU:?%)J^NC2=5OK?3;5;3S_ *WMID?(TFO3J2)QU"E>GN"&
M70&T-I!L6MZ03R 6_2"0/I[89&R=..E 9>T5ST^4\$WH'B>[6TKI.IP3P47Z
ML#^+7O[:9'J!I-3T\KIH)U"@Z>J:";3?QO9;:C;A/5;UGZ+<\<VY]LLC9[3T
MZKK1>X<.GNG@F&DF-[,PTFW#^JWH/]KGCB_/MED;^$]/!UJ>X8Z>Z>GGNP\4
MFI;%UTG4@'U+K]4 _-[6]M%'K\)\^G5=*$ZA0]/<,$UE;QMI) #6])('(#?I
M)'Y'M@JU*TQGI1K6H&H5Z?8*:HN%\,FNU]&AM=M.J^BVJVGGZ?3GVV4>E-)K
MT[K2E=0IT\TT$VD-XWT@V+6](8K<*6_2&('T^OMG2U:Z<=.HZ\-0KT^T]-/=
M%\,FIP"BZ#J<$>DHMKL&_%KW]LE6U?">E*NE3W#HS?Q'Z0[5[C[OV9N_IBMV
M_MW*]'[TIVWAVSD6^_DZRQ^XL!,^=VM0X"FJJ-]W[DWYM>9:8X>HE&.I(:FG
MR5>I,-!#4XP?>.YNY1M-A/*][9PWO,LG=$M>ZTJ/[9F7*L1A8ZC7Q<%1G*'[
MMO)_.%WOXYIL;V:QY9C&F5J56\H?[!5;#*#EY*53@AU$TVB_>!W6?/7O?NO=
M>]^Z]U[W[KW7_]7?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]TEMY[&V7V-M^KVGV!M+;>]]K9"2FEKMN;MPF-W#@ZR6BJ(ZNCDJL5EJ:K
MH9WI:N%)8RR$I(H86(!]K]LW7<]EO(]QV?<9[6_0$+)"[1R*&!!HZ$,*@D&A
MR#0]%^Z;3M>]V<FW;SMT%WM[D%HYD62-BI!4E'!4T(!%1@BHZ!+_ &3#X@_]
MXM?'G_T3?7O_ -CWL4_ZYON/_P!-]O/_ &67'_6SH+?ZV/MO_P!,#LW_ &1V
M_P#UKZ]_LF'Q!_[Q:^//_HF^O?\ ['O?O]<WW'_Z;[>?^RRX_P"MG7O];'VW
M_P"F!V;_ +([?_K7U[_9,/B#_P!XM?'G_P!$WU[_ /8][]_KF^X__3?;S_V6
M7'_6SKW^MC[;_P#3 [-_V1V__6OKW^R8?$'_ +Q:^//_ *)OKW_['O?O]<WW
M'_Z;[>?^RRX_ZV=>_P!;'VW_ .F!V;_LCM_^M?7O]DP^(/\ WBU\>?\ T3?7
MO_V/>_?ZYON/_P!-]O/_ &67'_6SKW^MC[;_ /3 [-_V1V__ %KZ]_LF'Q!_
M[Q:^//\ Z)OKW_['O?O]<WW'_P"F^WG_ +++C_K9U[_6Q]M_^F!V;_LCM_\
MK7U[_9,/B#_WBU\>?_1-]>__ &/>_?ZYON/_ --]O/\ V67'_6SKW^MC[;_]
M,#LW_9';_P#6OKW^R8?$'_O%KX\_^B;Z]_\ L>]^_P!<WW'_ .F^WG_LLN/^
MMG7O];'VW_Z8'9O^R.W_ .M?7O\ 9,/B#_WBU\>?_1-]>_\ V/>_?ZYON/\
M]-]O/_99<?\ 6SKW^MC[;_\ 3 [-_P!D=O\ ]:^O?[)A\0?^\6OCS_Z)OKW_
M .Q[W[_7-]Q_^F^WG_LLN/\ K9U[_6Q]M_\ I@=F_P"R.W_ZU]>_V3#X@_\
M>+7QY_\ 1-]>_P#V/>_?ZYON/_TWV\_]EEQ_ULZ]_K8^V_\ TP.S?]D=O_UK
MZ]_LF'Q!_P"\6OCS_P"B;Z]_^Q[W[_7-]Q_^F^WG_LLN/^MG7O\ 6Q]M_P#I
M@=F_[([?_K7U[_9,/B#_ -XM?'G_ -$WU[_]CWOW^N;[C_\ 3?;S_P!EEQ_U
MLZ]_K8^V_P#TP.S?]D=O_P!:^O?[)A\0?^\6OCS_ .B;Z]_^Q[W[_7-]Q_\
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MA_\ HW>UO_LS]^Z]U[_0GLG_ )7.P_\ T;O:W_V9^_=>Z]_H3V3_ ,KG8?\
MZ-WM;_[,_?NO=>_T)[)_Y7.P_P#T;O:W_P!F?OW7NO?Z$]D_\KG8?_HW>UO_
M +,_?NO=>_T)[)_Y7.P__1N]K?\ V9^_=>Z]_H3V3_RN=A_^C=[6_P#LS]^Z
M]U[_ $)[)_Y7.P__ $;O:W_V9^_=>Z]_H3V3_P KG8?_ *-WM;_[,_?NO=>_
MT)[)_P"5SL/_ -&[VM_]F?OW7NO?Z$]D_P#*YV'_ .C=[6_^S/W[KW7O]">R
M?^5SL/\ ]&[VM_\ 9G[]U[KW^A/9/_*YV'_Z-WM;_P"S/W[KW7O]">R?^5SL
M/_T;O:W_ -F?OW7NO?Z$]D_\KG8?_HW>UO\ [,_?NO=>_P!">R?^5SL/_P!&
M[VM_]F?OW7NO?Z$]D_\ *YV'_P"C=[6_^S/W[KW7O]">R?\ E<[#_P#1N]K?
M_9G[]U[KW^A/9/\ RN=A_P#HW>UO_LS]^Z]U[_0GLG_E<[#_ /1N]K?_ &9^
M_=>Z]_H3V3_RN=A_^C=[6_\ LS]^Z]U[_0GLG_E<[#_]&[VM_P#9G[]U[I9[
M7VAB-H4]538>;/315DZU$QSVZ=S;IF61(Q$!3U&YLMEJBDB*CE(F1"W)%^??
MNO=*CW[KW7O?NO=>]^Z]U__7W^/?NO=>]^Z]U4W_ #L_^W?'8W_B0^B?_?R[
M)]R_[%_]/&VW_GFN_P#M&EZAGW\_Z=GNO_/3:?\ :3%U:]3_ / >#_EC%_T(
MON(F^)OMZF1/@3[!UF]UZMU[W[KW57_<?\U3I3IW=GR=VA6;([$WAD_BYD>B
MJ/<T.S*?!9>LWM!V]O7:&S-VU'7V+&6CR.;J.D*G?>*DW%2M'%4,]9'3TBSS
MDH/=>ZAO_->Z3K]Q=<[5V=M#=N^\OVS5?)VBV VVLKM&HQN=J/C]F=W[?V6J
M9";-Q(J?)+,['R--LQD603SP&.J\#6!]U[IMK?YK?7N8[+ZLZ[ZLZUR6_*?M
MYML4FS]ZYGL'8W7NU,KG]P[#ZO[&J=G8NHSU74UF5WEA-N]S[<$U!'$'-56R
M0Z@]/(/?NO= [O+^=-38JKZ,'7_PE^3_ &KBNU_D_'\3MX93;.*QK_Z(^T]M
MKCL?W)BMQTE F::NFZDWAD'PD\FNDQ^6K,;D'HJQX*3RR>Z]T<#J#Y];4[D7
MO7;>#VACL3V_TWV/DNK,3U9E^W.K15=F[TI]JXW=U'MS:NYZ+/5>%&X(L=E(
MXLK2?NG$U(9'>4#5[]U[J#T5\^9>XMX]([.ROQ[[%V .\/\ 9A!M_>=7N?KW
M='7Z-\?MT5&V*\8_.[>W#-D]Q0;T:@GK\54TV/%%)C!#.9O\HB4^Z]U8=[]U
M[KWOW7N@G[Z_YD9W/_XB?L7_ -X_,>S?E_\ Y+VR?\]D/_5Q>B;F/_E7M]_Y
MXI_^K3=%3_E4_P#;O+XI_P#B-$_]WV;]C3WC_P"GH<Z_\]K?\=7H#>R?_3J>
M1O\ GA7_ (\W5@GN-.I2Z][]U[KWOW7NM7__ (4?[NW#L&J^#^]MI9!L3N;:
MVZ^WLW@LDL,%2:')44'64E-4"GJHYJ>;0W]EU(/O*W[L5M#>?UZM;A-4$D-L
MK#A4$S5&,]8A?>KNI[(^W]Y:R:;B.:Y930&A @H:''6O5@OF1EGJ]FYO?,-;
MNC=%-OKM/?N^<\XR5'/DLKO+$TE%@X<70X7<N#PSTAGI0M;Y:45,,2@T\ROS
M[R;EY9C"W45H1' 8HHXUP:!"2U2RLU<]M#0GXAUBS#S7*6M)KP&2Y$TTDC9%
M3( %H%=5ICNJ*@?"0>G[/_*W9&X:M=S-+V-AZ^DQN^%JNNL;34+[$WODNP=@
MXC;$L&Y\A-N(5<F-V974\E/!-5TN1K:_&4=(6>.I,KAF'EZZA7P*0,I9*2$G
MQ$$<A;M&FE7%"0"JJS-@K0=/S\S6<[>.3.KA9*Q #PY#+&J4<ZZTC-0"0S,B
MID-4]/&[?FCMG<.<I=QXZDW]M[.ONKNBMW+EL150XT[MP>Z^M#L3K*OR=)C\
MO3C^\^$CCIH<F6=XWCH8:B-GG+#VW;\L3PQ- [0O#X< 4$5T,DOB2@$@]K9*
M_P"F*D =.77-MO/,L\:SI-XLY=@::U>+PXB0&'>N _R4,*FO2(I_E!@\?28C
M*4>?[6ES=7!T+C\MM:6H2GVSLO\ T25.&DW/N+:.7AW$U7D\QO>/%3@(U)0O
M;+5JU4LQ?4ZH[#*[2QM#;^$#.0_%G\;5I5P5H E1YM\":0*=)%YCAC2*1)KD
MS$6P*&@2/P=.MT;55FDTFF%IK?436I46#^76"Q!V%N#^*;TDW5L+L3M#>5,*
M[#SY6:O3=N6W1D=JEL_4[\2B2'$1YBF6II)L3.Q\1$=2$ 4LR\N2R?5Q>'%]
M/-#$F&I30%#]OAUS0T(<<<KTIBYIAC-C/XDOU,$\KBJUKK+%.[Q*=M14%"<8
M;IV3YE==[8VT^ ZXV-GL'0X1-XY+9N!KYI:;&P[FWW6]<;HSM9F,GMG<&%S3
M4,.ZMMUT%/'%*+XFEH(I P,R!O\ JS>SSB:^NT=FT!V&25C$B*%#*RUT,I-1
M\9<CR/5_ZV6%O;^#863HB:S&IP-<AB=BQ1E:@=& H?@" UR.FS;7RYVIC<[A
M]\9NI[ R&7J<7UQBLYUW38W&4O7.V\GLK.T>=S6]]I)3;BI@<GN2KQ[RQTT5
M'024\V6KM52RZ-=Y^7+AXI;6)85C#2%9*DR,'4JJ/53A0:$DL"$3M]&[?FBV
MCEANYFG:0K$&B 41*T;!FD2C#+D5 "J07?N]9+_+;JFMH<O29/96[I9NR8MG
M9?L&JI:NFCAVKN/K#;^U:3KK&;2HZVMR%=NS"8?<&W*BH6KR5=3UT=/DY5<U
M$BEWK_5W<%>-H[J,"#6(P1\:RLYD+D !&*L!15*U4?".%OZS[:R2+):REK@1
MM*01V/"J"(("27560FKL&HYKJ(J0DQG:W7&&[)[JS^)WKVQ@\)VG325V-W/M
M[;./Q6]<#EJCM#![_J,8*&#?4-.U-]GB6IEJQ76:5PS0:+@F3[?>RV.UPR6M
MN\MN:%68E&'A-'6OA\:FM-/#SZ*X]RL(MPW>>*\NDAN14.J 2*QF66E!)2E%
MIJU<>(IT.=3\U=F#<.U-\XG"YG%Y/;V![3Q;['_N]'+AYIM]U/8LU+35&=7>
M2XBMP4M)O&.FJX5P5/.HDJ&65U"QDI7E>Z\&XM))59'>(^)J[OTQ'4Z=%0U4
MJ#XA' 4''HY/-UH)[:\BA=9(TF'AZ>W]0RT!;Q-)6C@,/#!RQ!(H.H,_ROZC
M&S<GUMMG%;RVAL[%[2S^R.OQ5X*'<-1C,)5[OVMNNDJ,S'AM\;/J9\WE*W'Y
M&IJITJGCAJ:A!XYHQ877E[<?J4OIY(I+EI%DDHQ6K!'4A=2.-(!4 4J0#D'J
MC<R[7]))M]M%+%:K$T<55#$*71P6TR(2Q(8DUH"1@CKT_P T-IU%=LK)QX[?
M6*S>U>P^KJW(9_#S4V/JMR]9=>]=9#;--@\O3TF5IS59[%9O+5$5,SR-#4XI
M:=)"KP*#X<L7"K=(7B:*2&4!34A99) Q921A2H!.*AZD<>O-S;;,UG($F6:*
M>$EE(!>**(H%8!A5E9B!FA32#E1TB]L_)KKF@V)_=7=>W=[[JRV].O*;JWLG
M<%1E(%GH]M8Y]Y9/'5F(^[GKJC=-9'NK=--E##52T(%3B*8^0V(]J9]CO7N_
MJ+::*..*;Q8EIQ8Z 0:4TC0A2H#8=L=)+?F';TLC;75O-++- (96)&%&L@K4
MDN=;AZ$KE%STEL/WKA=G],X7 80K7;FK.NIMC5F*\V=H(</F*#N#<F^*G<E9
M48/-8"M1LQM[<-(M&\<TZ-44+)/&41;J)-IEN=SEFE%(!/X@/::J85CTC4K#
MM937 PU0>DL6\PVNTPP0]UP8/#*]P"L)WD+DJRGN5ETT)%5(88Z5^U?E-AJ5
M86W'N[N6EEQ6,^/51228.J7)U69R74&*S5-NO;]9-E-TT<%!A]Y5>2C#5+)5
MK+&K-/3.;+[37'+\C5$-O;$,UQ74* "8J4840U9 .&*'@PZ66W,L*T-Q<W8*
MK;$:34L8%8.IJXHLA/&AKYJ>B\]W[MP>[\YL^KP;44G\,ZWVMB<M)CA+]C%E
MS)E,Q-AZ1YHH))8-JT>8@Q ;3I_R"RDH%/LZVJWEMHKE9:]T[D5XTPNH_P"G
M*E_]MT0[Q=0W4UHT-#IMT5J<-66TBO\  &"?[7&.@8]F?13U[W[KW7O?NO=>
M]^Z]U[W[KW1VNHOE'LKK39VQ-D3[#W!-!L[<>,[-;=.)SB09P]L8S=!K8<MC
M\9/,F'BQ:;.(Q:3L16BP/Z1;V%MRV"[OKJ[NA=I65#%H*]OA%*4)XUU]]/AZ
M%^U\QV>W6ME:&R<B*03:U;N\8/6H![=/A]E?B_+I7K\RNOY:*C-?U)DJG*;J
MV)2]<=NM39Y,9C*_ Y++[_SN_*_9M'1/&J5.[<]O9,H**M HZ:OHHROI5"J8
M\LW@=]&XJ(XYC)#5:D,!&L8<GR14T:ADJQZ5#FNQ*+KVQC)+"(IZ-0%2TC2&
M,#S=I->ENT,H^73'C_EEM22DEQN6VSGJ2'/]95&'WUD(<=M_=3;F[:K,QL!:
M_L"? YC(XF@GI*_:W6U#&8Y)_-#D:BHG6X>Q=?EVX#!XYT)2<-&*LFF$"2D>
MH FH>5C@4*@#IE.9K8J8Y+9P'MRLAHKZYBT592K%004B49-0Y8CCTWS_ #/W
MAM"BZZ/2F7W=LO</6^U,GU[!GLW_  +-KO#:>;QV(EKLIN3&5,5=2P;MH\WC
MS344L?E6#!T]#3>2]*?)=>6+:Y:]_>D<<L,\@DTKJ70ZDT"D4.@J:L,5<NU.
M[#;<VW5JEA^Z)98I[>(Q:FTMK1@M68&HUAA12*TC"+7MR'^Z>\MKY;J[9FQ1
MM:IWAFL'6[ES>1S>]HI,2E%GMSX/;^-J\C0R[0W+!6;HRM#6X3R4==D1$(*7
M1 :9[%@L@VF>._NKOZ@1Q,%4*F:JK,0#K4A 0V56M34ZND5SO-M+MMI9_3&6
M9&=BTG;1G502-#@N05JK/2@H-)Z<X.]]K5,6^L)DI^RJ79M?T[A>J-D[:H:C
M'9&FD.*K*#.U.X-[I5YN@BGK,INB&MJW-.)7C_BDN@J8U#4.TW"FTE00&Y6Y
M:5V((.05"I13@)I&:5T"O'IQ=ZMF%[%(;@6C6BPQH"",$,6DJPR7U,:5IK-.
M Z7G7/RQV3LO%X2^P,[@ZW&[8W!U_)MC965:/8]/M[=6\J'=^0WMC'W)F,KG
MO](6*EIF2D69G@,RPR^>)8A%[1WO+UW=22_XXC*TBR:W'ZFI$*!#I 7PS7NI
MFE10UKTML.9K.TBAK8NCK&\6B,_IZ7D#F0:V9O%6E%KBM#J%*=(/?/=^R]U]
M<[MV/#5=HN9HNH:+9T>8_@E3BITZJVK/MF7<.Z53.R/2;BW5'7/Y?M8JC[>G
MI*:'RR@$JKM-JNK>]MKLK!CQB]-0/ZKAM*=N52F*D5)8T'2*]WFTNK"[LP;C
M/@".NDK^BA34_=AGKG2#0*HJ?(N.TMI[FWWN;!;.V9@\IN7=>Y<I18;;^ PE
M'/D,MELK7SI3T5#04=,CSSU,\[A551>_LYO+RUVZUN+^^N4ALX4+N[&BHJY+
M$^5/V^0ST165C=[G=VVW6%J\]].X2.-!J9V; 4#SK^P#)QU]%[^6IT-W[\<?
MB?L'K/Y%]BR;\WQCH?N:'%OX*Q.L]NU%-2C&=;0[C1Y*C<\>W?&_^4.S14[2
MFEIF:E@@9N:GN9O_ "]S+S?N>[<L[7]+MSG[/&<$ZIRG",R<= _TQ[F;KJ/[
M6<N\R<K<E[7L_-.[&ZW.,5]?!0TTP"3C((QC6?\ 2KV*O1^?8 ZD3KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[K_T-_CW[KW7O?NO=5-_P [/_MWQV-_XD/H
MG_W\NR?<O^Q?_3QMM_YYKO\ [1I>H9]_/^G9[K_STVG_ &DQ=6O4_P#P'@_Y
M8Q?]"+[B)OB;[>ID3X$^P=9O=>K=>]^Z]T3-OY??Q%.[<-O^'IW"T6_</O\
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M,]IO^F*MO]ZF_P"MG7O^&AOY<'_>+&S?_0A[!_\ LO\ ?O\ 7I]T?^FQN?\
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M*[Y"?]>_?O\ 7F]T/^FRN_\ C'_0'7O]8_VH_P"F(L_^JG_0?7O^&]?Y8O\
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M[/\ _L4]^Z]U[_3/MK_GG.U?_1.]G_\ V*>_=>Z]_IGVU_SSG:O_ *)WL_\
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M_P"QOW[_ %\-N_\ ",<G?]D3?];>O?ZQ>Y?^%LYS_P"RY?\ K5U[_AM?=O\
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M?]DT'_6OKW[_ .8/^F@O_P#LIG_ZV=>_TU]P?\_1[ _]"[.__5WOW]7^7_\
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MZ]_IK[@_Y^CV!_Z%V=_^KO?OZO\ +_\ TS]A_P!DT'_6OKW[_P"8/^F@O_\
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MYG_WBQ_[;>O?ZW.P_P#A8^5O][OO^V+KW^R:]>?]YS?$;_SY]Y__ &B_?O\
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M7_3+\V_]EME_UJZZ&[?Y4C6MUE\SC=M MVETZ;M_J1;KOEO\/K[]^[OO ?\
M32<I_P#9'>_];>M?O+[O/_3,<V_]EME_UJZR?WG_ )57_/K?FG_Z,[J#_P"U
MU[U]![__ /33<I?]D=[_ -;NK?O#[O?_ $RW-W_9;9?]:NO?WG_E5?\ /K?F
MG_Z,[J#_ .UU[]]![_\ _33<I?\ 9'>_];NO?O#[O?\ TRW-W_9;9?\ 6KKW
M]Y_Y57_/K?FG_P"C.Z@_^UU[]]![_P#_ $TW*7_9'>_];NO?O#[O?_3+<W?]
MEME_UJZLO_E8=@_RP<7\D:2FV/L[M;:/:^7QQQO6>XN_MS;,W)A8LW4NT-3B
M]JS;<P6WZ/";OS%+)XJ:>JCE>9==/3RQ2S>.H@3[PVS>^T_)/B[ONNVW?+44
MFJZCVZ*:)@HIH><2LS20H<D*=*&CNI #+/WW=-Z]A(.>/!V?:=SM.9IH]%K)
MN4T$REC77' T2JL<SC +#4XJB,"2K;3OO /KH+U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7__U]_CW[KW7O?NO=%K^6_QOQORPZ,W-TEE
M=V9/9%/N');6RT>Y<1CZ7*5N.K-J;FQ>YJ,K05DU/#41SU&+6-QY$8*Q(8$#
MV./;KG:X]O.;=NYJM]NCNW@653$[,JNLL;1,-2Y!HQ(-#GRZ ON/R/;^XO*.
MX\J7&XR6BSM$PEC569&BD653I;!%4 ()&#QZ*V/A5\O  /\ AS#N/@6YZIV&
M3_L2<F23[D;_ %U_;3_P@&T?]EEY_GZC;_6D]S?_ &83>?\ LCL_\W7?^R5_
M+S_O9AW%_P"BHV%_]<_?O]=?VT_\(!M'_99>?Y^O?ZTGN=_[,)O/_9'9_P";
MKW^R5_+S_O9AW%_Z*C87_P!<_?O]=?VT_P#" ;1_V67G^?KW^M)[G?\ LPF\
M_P#9'9_YNO?[)7\O/^]F'<7_ **C87_US]^_UU_;3_P@&T?]EEY_GZ]_K2>Y
MW_LPF\_]D=G_ )NO?[)7\O/^]F'<7_HJ-A?_ %S]^_UU_;3_ ,(!M'_99>?Y
M^O?ZTGN=_P"S";S_ -D=G_FZ]_LE?R\_[V8=Q?\ HJ-A?_7/W[_77]M/_" ;
M1_V67G^?KW^M)[G?^S";S_V1V?\ FZ]_LE?R\_[V8=Q?^BHV%_\ 7/W[_77]
MM/\ P@&T?]EEY_GZ]_K2>YW_ +,)O/\ V1V?^;KW^R5_+S_O9AW%_P"BHV%_
M]<_?O]=?VT_\(!M'_99>?Y^O?ZTGN=_[,)O/_9'9_P";KW^R5_+S_O9AW%_Z
M*C87_P!<_?O]=?VT_P#" ;1_V67G^?KW^M)[G?\ LPF\_P#9'9_YNO?[)7\O
M/^]F'<7_ **C87_US]^_UU_;3_P@&T?]EEY_GZ]_K2>YW_LPF\_]D=G_ )NO
M?[)7\O/^]F'<7_HJ-A?_ %S]^_UU_;3_ ,(!M'_99>?Y^O?ZTGN=_P"S";S_
M -D=G_FZ;\M\%OE9G,7DL)EOYD_<%;BLQCZS%9.C?JK8J)5X_(4\E)6TSO'E
M5D59Z:9E)4A@#P0?;UO[O>W-K/!=6_L)M"7$;JRL+N[J&4@J<DC! .1TS<>S
MGN1=6\]K<?> WA[>1&1E-G9T*L"&!H*Y!(QT=_X[=,X_X\])=<=*XO.5FY:'
MKS;T>"@SV0I8:&KREJJIK):J6CIY)H:77-5,%0.^E  68W8Q)SOS5<<[\V;]
MS9=VJ07%_<&4QH252M!I!;)H ,GB?(<.I>Y&Y4MN1N4=@Y2M+MY[>PMUB61P
M ST))8A<"I)P. Q4\>AH]A;H5]>]^Z]U[W[KW6NS_P *(59^GOCNJ*6;_2)N
M]M*@LVD;=QP+6%S8%AS_ (^\U/N7*S<Q\\Z03_B$/_5[K"3[[+*O+?(FI@/]
MV$W_ %9'6OOTIO'J+#[ 7;78E%01YD[IW]N3'9QMN2Y+)XFKBZ[H\7M;'UTR
MT4QJ]M;FR$]92M"&<TE<M/5:5",QS*YCVCF2XW7ZS:1*;?P((V37I5@9RTC
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M\?\ I,6YO_MS>_?ZSFZ_]-ERY_V7I_T#U[_7LVC_ *8?F?\ [E[_ /077O\
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MW[_6<W7_ *;+ES_LO3_H'KW^O9M'_3#\S_\ <O?_ *"Z]_LSW97_ #H]\?\
MI,6YO_MS>_?ZSFZ_]-ERY_V7I_T#U[_7LVC_ *8?F?\ [E[_ /070I=5=F=E
M]OQ;A;;^[=O82IVO7TV.S&-W;TOG<1D:>IJX99H5--'V_5LATPL&5]#J0+K8
M@D)<W<D[KR9+MR;C=6D\5U$9(I+>3Q8V4'2:-0>?F*@^M00!CR9SYL_/,6Z/
MM=I>036<PBECN8O"D5F74*K4\1ZT(].'0M?P7O/_ )^%UI_Z*W<7_P!M3V#^
MAKU[^"]Y_P#/PNM/_16[B_\ MJ>_=>Z]_!>\_P#GX76G_HK=Q?\ VU/?NO=
M[W!MPU..PZ]X9WX^[EQB5=3)@X-[?'G+;SIJ6M\4:54]#2U>_<NM%,T+HKR!
M4U @7/T]BWE.'G.:XNQR;=7<5SH'B>!.8"5K@,0Z:A6I J:<:=!#FZXY)M[>
MR;G6WLY+8N?"^H@$P#4[M(*/I-.)H*C'0!_W1^-__.L^&_\ Z1O4?_9![''T
M'OE_T==Z_P"R]O\ K?T!?WG[#_\ 1MV3_L@3_K1U[^Z/QO\ ^=9\-_\ TC>H
M_P#L@]^^@]\O^CKO7_9>W_6_KW[S]A_^C;LG_9 G_6CKW]T?C?\ \ZSX;_\
MI&]1_P#9![]]![Y?]'7>O^R]O^M_7OWG[#_]&W9/^R!/^M'7O[H_&_\ YUGP
MW_\ 2-ZC_P"R#W[Z#WR_Z.N]?]E[?];^O?O/V'_Z-NR?]D"?]:.O?W1^-_\
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M/?OH/?+_ *.N]?\ 9>W_ %OZ]^\_8?\ Z-NR?]D"?]:.O?W1^-__ #K/AO\
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M%_\ ;4]^Z]U[^"]Y_P#/PNM/_16[B_\ MJ>_=>Z]_!>\_P#GX76G_HK=Q?\
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MS"NWQI,Y5C$\NLE*$40@B@S4]$B/4W3/%^_L?_0?\8VWA^?^JOW./]:^=_\
MPG$O_97#_FZ@W^JW(WG[E1?]D<W^?KK_ $2]+DV_T_8ZX/\ S[;>%P?K_P K
MG!_/O?\ 6OGC_P )Q+3_ )ZX?\W6OZK<C</]<J*O_/)-_GZZ_P!$_2PX'R Q
MPM^/]'&[^/\ &WWGO?\ 6KG@_P#@MY?^RJ'_ #=>_JOR(/\ P9</_9)-_GZ[
M_P!$W2]A_P 9_P =9OT_\8WWAR2/Q_EG/'O7]:N>,_\ ,.)<?\O</^;KW]5N
M1<?\Q+A_[))O\_7?^B;ID?\ -?\ '_3_ )]OO"]C_P!5G]?>OZU<[_\ A.)?
M^RN'_-UO^J_(W_A2XO\ LDF_S]=#J?I<_3O_ !QM];=;[OXM_P!5GXO[W_6K
MG@?^"XE_[*X?\W6OZK<BGA[EQ?\ 9)-_T%UX=3],<V^0&.XY;_C&^[^/\3_E
MG'OW]:N=\?\ ,-Y?^RN'_-U[^J_(N?\ F)</_9)-_GZ[_P!$_3!M_P Y 8_D
M7'_&-]X<C^H_RSD>]?UJYW_\)O+_ -E</^;K?]5^1O\ PI<7_9)-_GZZ/5'3
M M?Y 8X7^E^M]W\_ZW^6>]_UIYW_ /";R_\ 97#_ )NM?U8Y%_\ "EP_]DDW
M^?KO_1/TS_S_ /Q__HM]X?\ U9[U_6KG?_PG$O\ V5P_YNM_U7Y&_P#"EQ?]
MDDW^?KW^BCIBP/\ LP&/L> ?]&^[[$_T!^\][_K5SOP_UMY:_P#/7#_FZ]_5
M?D;C_KEQ?]DDW^?KW^B?IG_G_P#C_P#T6^\/S]/^4OWK^M7._P#X3B7_ +*X
M?\W7OZK\C?\ A2XO^R2;_/UW_HFZ9/T[_H/Z_P#,MMX?GZ?\I?OW]:N=O_"<
M2_\ 97#_ )NO?U7Y&/\ X,J+_LCF_P _7O\ 1-TU_P _^H/_ $6V\/\ ZK]^
M_K7SM_X3B7_LKA_S=;_JMR/_ .%*B_[(YO\ /U[_ $3=-?\ /_J#_P!%MO#_
M .J_?OZU\[?^$XE_[*X?\W7OZK<C_P#A2HO^R.;_ #]>_P!$W37_ #_Z@_\
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MXU#5N9H%2E44>5K&JY3+41Z9I#*^ICJ-_=>Z4?OW7NO>_=>Z][]U[HJW0?\
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MDEFQ$<\=34)3K(*<L(W\@!]G5_MEY?6&V6FU)=6D?U3EC,\A>-/"D <Z92Y
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M#"XGK#LW?^[]OYG:>(WW5[?;)XV@&$QF?HNU:K$81,=D*:J7&8T9*5IZB0+
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,U[W[KW7O?NO=?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>e2736_10-qimg002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 e2736_10-qimg002.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" && B8# 2(  A$! Q$!_\0
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M>2+VK]HGQA^TSI?[/'[)7Q__ &8_^"O_ .TY\0_ _P =OVNOV4OV9Y?%M_\
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MOB1J/QC\0?$;Q'K6G?$A+D^)Q=B:._\ [4FNX #YC^+'[8GQ0_8__96^!/\
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M .'A7[??_1\7[8'_ (DO\:/_ )M:/^'A7[??_1\7[8'_ (DO\:/_ )M: /\
M<XHK_#'_ .'A7[??_1\7[8'_ (DO\:/_ )M:/^'A7[??_1\7[8'_ (DO\:/_
M )M: /\ <XHK_#'_ .'A7[??_1\7[8'_ (DO\:/_ )M:/^'A7[??_1\7[8'_
M (DO\:/_ )M: /\ <XHK_#'_ .'A7[??_1\7[8'_ (DO\:/_ )M:/^'A7[??
M_1\7[8'_ (DO\:/_ )M: /\ <XHK_#'_ .'A7[??_1\7[8'_ (DO\:/_ )M:
M/^'A7[??_1\7[8'_ (DO\:/_ )M: /\ <XHK_#'_ .'A7[??_1\7[8'_ (DO
M\:/_ )M:/^'A7[??_1\7[8'_ (DO\:/_ )M: /\ <XHK_#'_ .'A7[??_1\7
M[8'_ (DO\:/_ )M:/^'A7[??_1\7[8'_ (DO\:/_ )M: /\ <XHK_#'_ .'A
M7[??_1\7[8'_ (DO\:/_ )M:/^'A7[??_1\7[8'_ (DO\:/_ )M: /\ <XHK
M_#'_ .'A7[??_1\7[8'_ (DO\:/_ )M:/^'A7[??_1\7[8'_ (DO\:/_ )M:
M /\ <XHK_#'_ .'A7[??_1\7[8'_ (DO\:/_ )M:/^'A7[??_1\7[8'_ (DO
M\:/_ )M: /\ <XHK_#'_ .'A7[??_1\7[8'_ (DO\:/_ )M:/^'A7[??_1\7
M[8'_ (DO\:/_ )M: /\ <XHK_#'_ .'A7[??_1\7[8'_ (DO\:/_ )M:/^'A
M7[??_1\7[8'_ (DO\:/_ )M: /\ <XHK_#'_ .'A7[??_1\7[8'_ (DO\:/_
M )M:/^'A7[??_1\7[8'_ (DO\:/_ )M: /\ <XHK_#'_ .'A7[??_1\7[8'_
M (DO\:/_ )M:/^'A7[??_1\7[8'_ (DO\:/_ )M: /\ <XHK_#'_ .'A7[??
M_1\7[8'_ (DO\:/_ )M:/^'A7[??_1\7[8'_ (DO\:/_ )M: /\ <XHK_#'_
M .'A7[??_1\7[8'_ (DO\:/_ )M:/^'A7[??_1\7[8'_ (DO\:/_ )M: /\
M<XHK_#'_ .'A7[??_1\7[8'_ (DO\:/_ )M:/^'A7[??_1\7[8'_ (DO\:/_
M )M: /\ <XHK_#'_ .'A7[??_1\7[8'_ (DO\:/_ )M:/^'A7[??_1\7[8'_
M (DO\:/_ )M: /\ <XHK_#'_ .'A7[??_1\7[8'_ (DO\:/_ )M:/^'A7[??
M_1\7[8'_ (DO\:/_ )M: /\ <XHK_#'_ .'A7[??_1\7[8'_ (DO\:/_ )M:
M/^'A7[??_1\7[8'_ (DO\:/_ )M: /\ <XHK_#'_ .'A7[??_1\7[8'_ (DO
M\:/_ )M:/^'A7[??_1\7[8'_ (DO\:/_ )M: /\ <XHK_#'_ .'A7[??_1\7
M[8'_ (DO\:/_ )M:/^'A7[??_1\7[8'_ (DO\:/_ )M: /\ <XHK_#'_ .'A
M7[??_1\7[8'_ (DO\:/_ )M:/^'A7[??_1\7[8'_ (DO\:/_ )M: /\ <XHK
M_#'_ .'A7[??_1\7[8'_ (DO\:/_ )M:/^'A7[??_1\7[8'_ (DO\:/_ )M:
M /\ <XHK_#'_ .'A7[??_1\7[8'_ (DO\:/_ )M:/^'A7[??_1\7[8'_ (DO
M\:/_ )M: /\ <XHK_#'_ .'A7[??_1\7[8'_ (DO\:/_ )M:/^'A7[??_1\7
M[8'_ (DO\:/_ )M: /\ <XHK_#'_ .'A7[??_1\7[8'_ (DO\:/_ )M:/^'A
M7[??_1\7[8'_ (DO\:/_ )M: /\ <XHK_#('_!0G]OP]/VX?VP/_ !)?XT?_
M #:TG_#PK]OO_H^+]L#_ ,27^-'_ ,VM '^YQ17^&0/^"A'[?AY'[</[8'_B
M2_QG_P#FUI?^'A'[?O\ T?#^V!_XDQ\9_P#YMJKDE:_*[6O>W3^G_5F!_N;4
M5_AD'_@H3^WX.O[</[8'_B2_QH_^;6D_X>%?M]_]'Q?M@?\ B2_QH_\ FUJ0
M/]SBBO\ #('_  4)_;\/3]N']L#_ ,27^,__ ,VM!_X*$_M^#K^W#^V!_P")
M+_&?_P";6G9I)M.SV=M /]S>BO\ +\_X-B?VQ?VN/B?^WI\7?#WQ+_:D_:*^
M(V@6O[(GCS6;70O'WQJ^)'C/1;;6+7XR_ 2QM=6M]*\2>)-3L(-4MK+4]2L[
M?4(K=+R&TU"_MHIEAO+A)"D!_.'_ ,% ?^3\OVVO^SN?VD?_ %<GC.OD:OKG
M_@H#_P GY?MM?]G<_M(_^KD\9U\C4 %%%% !1110 4444 %%%% !1110 444
M4 %%%%"W70!P0GV^O%.\IO5?S'^-24N"<<'DX'N:]*AA:<H*53F2Z:\JE>UF
MFTUM?9.W4F3MHM7VWMZV(O+]#^G\\GIZU*EK(_3!SS@<X'X9Q4\,#2.%"DG(
M)7N1Z >I]#[>M?3/P>_9S\;?%=G;1=.G2V10!.8-ZRY (:/++O&6&X@_3IQ^
ME>'GA;FOB#F3P64X3$UU&/-.5-3;IVE%-2Y82LTG=:WZ<K/%SSB#+.'L!5S'
M-\9A\!A:2O.MB)JG"*T5[R>K;:2BDY.ZLF?,1LI!G_ZY[>W3\0,_A4+0.IQP
M?I_7&?KFOT<UO]A#XH:39S3&QN)&1"Z 6R;6VH"RDK(2,DX&1SCH2 #\5^-/
M OB#PA?S:?K6G7%C<QL5_?0X20*2"T<FW!&!T)#+_%CBON./_H[\2\%8"./J
M8'%5:4'-5FE-RCR-?9<4W[KNVERQ:Y7=GA<,^(7"W%E6I2R3/,NS"I27O4L/
M77M.EFHS46TU=W5].G;S7RSW//?C/]:-GO\ I_\ 7JT8B&*DY;G(Y!&.^".?
M3_$XJ+'7IQ[_ (?UZ]*_!99:H-KEN];KF?-'EM=-)ZO76R>MTC[7G?9+Y^F_
MROT^6C(&7'<'^?XBFT]P<D]C_A3*\FI'EDURN*6FM]?/4M.ZO_2\@HHHK,84
M444 %+@^A_(TJ DC Z$9Z="<=ZU;73Y[V9(+>*:>5W")%$C2.SD$JJH@+OSC
M  ))Z#I7=E^78O,\13PN"H5:]>K)0ITZ5.=24Y-I*,8P3DY-M623;;2ZDRG"
M"<IM125[O1+57;;T22W9DX). "3Z8.?RIPCD/1'..N%;C]*^CO#O[+WQR\1Q
M6UW8_#;Q3]CNP'AO)]%O;>"1'&5=7EM]Q4@$Y"D]>@S7U%X)_P""?/Q:UR"*
M6]TV[M(VD5)$CM)E9'QN*DRP9W 8YV@=>>,C]]X/^C-XC<5-RJY5CLIH)0?M
M,9@U%N,TGS<KKQ:C!.\Y;)6NS\^S[Q5X X<C.69\49-2=-RC*$<?0J5(RBVG
M&=.C*K.+NI*TDGH]+)GYG%' R48#U*D#^5)@CJ"/PK]+_BG_ ,$_?B?X*TD:
MIIVDW^HA<%K0VTC32]R8"EM& PPQPP8'CD9X^0_$/P+^)_ARPDU36_!6OZ;8
MQ#<UQ<Z=.D2* "69C& 1S@MC:.G7J^+/HR^(O"U:I!Y9C,QHTZ"KRQ6$PJE1
M5-J4G)R5=K2*YFOBM>27*FUIP]XG<#\48:GB<FXCRG%PJUOJ\81QM*%5UK1O
M"-*K[.<VW)64%)OI<\+P?2BM*XM_)8JPY7=CC 8#@YY]1CD?ASQ19>"0.?TP
M/R^O?FOP3'99B<OK5*&(@Z=2E)QJ0G%PG&<?BC*,E>,D_LO6W<^^4HR5XM-/
M9IW3]/O(Z***\X84444 %%%%"W70!RJ3ST'4=_TJ7:HZ#\\'^G'TR?YTW>OH
M1^ _QJ55+8QT/?(''4GGVYKT\)0IU%./QRN[*+UUT6VNMO0F3:M97[[C0N>J
M@D_E^9]A6O8Z=]H95$#2,Q551!DLS9 P-I/)X  R3TS56"(LP4+N'/'7.,YZ
M=?;'IUK]4_\ @F_^QKXE_:.\?1Z@-!FO/#NF- TMQ) '@,BRH7*[N#M5ST&<
M9.. :_:_"'P[P_%^=N&/J87"Y/EN&J8_.,;F%6CAL)@L#0C>M7KXG%6P\(J]
MHJ<ES32C'WI)GPOB%QUDGASPEF_%V?XNEA<ORK#RK5'4J*'/+14Z,.9WE4JR
MM"$$I-ZNTE%H_.RY^''B&WL/M[Z#>K:8W>:UK(#C 89PNX#G!QRO(/85Y[=V
MA@9D,11B<8P?E]L8SD$8(SGKGO7]TT?_  33T/6K$>%YO#^G1F.V">8\4493
M,:@G>RC9R3@Y(& %'-?SJ?\ !2G]@76_V8_%']K65DTFA7K>9<RP!%A@+%E1
MSM7  (^8@$%<MN(&:_:_$/P?\,,[RW%4O"_C#AW.>(<JR[^U,=DN6X[#3QN(
MP,;S>*P]&E2ISJ4J<(R]KR.HH)2<O=CS'\Q^"WTT/#[Q7XKCP<J\,NSG&<]3
M+*=2M&4<5"*C*,>:<:256HG%0@N9RE:-KGXXD8X-%69X'21AMVA1QT (&>1V
MZY&!T((/-5\'\CC\:_A[$8:MA:M2C5A*,J<YTY<T9+WJ;Y9[I/1_@T?VNFFD
MUJFKI]TQ****YQA1110 4444 %*!D@>I _.DIRJ6/&>.21V'K_GZ]J:5VDMV
MTDGU;=DOFP$(Q@\_7&,'T^HQ3T&XD8Y ST!.>!@YYQSV(_/&'K'G@!FXS@9.
M/RQQD]3ZUI6MA)<2J(U)>3 15PS,6*@ +UR>,+WR .3BO9R[)<QS/$4,+A,+
M+$5:U2%.%.FFYRE)JR2:UT\]5HMK.)5(1CS2DDEWT[7W[7U*"QL>@./I]>PQ
M_2IV@( .QL$<@JW;&1VQP>_UYS7T?X*_9S\?>)[>+4DT2\@T^781(\$@D='S
MA@H3:BD<C>P/(R 2!7H_C3]E7Q9HWA]M9LM*OG6WA$DZR(Y$B*KL[ B/ < <
M L%YZBOZ8R?Z-W&6*R*KF=? RP]:%+VU/!5J<U6G3C351M>ZN67)[RA)7M&6
MBY7;X/%^(W"6"S&EEU7/,OCB*U94$EB:32JM_!)J34-FFWM=7M<^()%R.!TR
M<X R,GJ< C'/7'.:C5>N0/;H?7-=-J.B7]C--!<VLT,B%U,3J%?Y6(;<'QD#
MU4D'J2>",%H6C&2, MM^\#SZ<'''&2..E?SSGG#6:91CJV&QV7U\'4I5)4OW
MU*I2A*<6VO9^TC%2O!<UDVU'6UE<^YI5Z56E3J4YQG&<4XN,DTUIJG%R35FG
MIT\M2%A\IP/3I]1Z5"<]\_C5D@CK44A^[SSCCZ$G@]^N1CMR,"OGJ^'=.-Y2
MBFMHMI/7I:]^G;I:W;5-->?4_IC_ .#5#_E(9\9/^S,OB'_ZN_\ 9VHH_P"#
M5#_E(9\9/^S,OB'_ .KO_9VHKD&?BC_P4!_Y/R_;:_[.Y_:1_P#5R>,Z^1J^
MN?\ @H#_ ,GY?MM?]G<_M(_^KD\9U\C4 %%%% !1110 4444 %%%% !1110
M4444 %%% &2!ZG%-*[26[:7W@6*UM-L;C4)H;2W1I)IY$ABC0%G>5WPBH ,J
MSEPF!CC))P<5E@8*^^#_ %_E7LOP0LM,OOB/X0MM5E\JQEURR^TRLRJ$02C)
M)(  R!C.1QD@\5^L>&_#.&XHXHR+(L=*,</C<;AZ-63DDHP=6FW9M--M7T33
M:TO;F3\C.<=_9N6YAF*A*I]2PF)Q/LXIMS^KT9U.1**;;DXI)+5W2ZG[W_\
M!/'_ ((8ZS^T3X;TSXA_%W6-4T/2M3N4&B^&]#M%GU/5XD <L9)" L1RJLP8
M*-^T@8.[]T=(_P""9WA?]G2W:P\'Q7@DT^S#OIVNVBVNHM% J?O$96:-@%A1
M2 Z\EBH(QC[O_8Q\8^&/A;\,_AQJ_AZ>QU72]-\,VV ]]:[(KB4L;D32/+L@
M;*I@L4 &2Q)P:[?X_?M)>!?&&H7&H76J:9#>264NF1:?IUY:W<\LLBNF,VTL
MJ@(,AG8CYOE8<BOYBS'Z7'T\^&?I\YCX/>"'@QB*'T<^'.(EPU7S6CX7XW'5
M*N%P$JD,PSG'\4K"WAB,9.C*O'%*M&FJ?LZD8R@VS_#+Q3\:*_BEX:<4<69Q
MXQ\0T_$W"<<XK*<D\&<ORW#TN'*7!]/,8X.ACJ\HX:>,>.=.DZLZM?'2=DK0
MBMOS<M?AZ^N*UA-H%M)(9#;EO+#!P %+$$EBI7('4]>G?S+XM?\ !)SX3?&O
M3+C_ (2 P:#JES!YG^AP2,T9F!;<[JC>64+ KPI"K@$BOO/P)X-U?41;:LLD
M5MI,DS2HUQNBN'56&UHQMRZY/+DA 0<!LG'T'<ZI::(LUS?:A:65NT2KYES(
MB%UCB"R/&CE7D.%R A;+$C Y-?U%]+?Z9WCQPLJ7"/T>/]7^+N-)YI4PV8\,
M8O+)<2RI.=6?UFGC<#6JJ5&3K1F[<]H0AI*7,I/^3<C\4\_X8XHP-3)N*<RX
M9I4/:SK8[)?:5ZT:]-.5&DX57*-64Z_+&>DFE)*7NMH_@<_X*&?\$V_$'[&F
MLVT]IJK^(/"VJ,\UI?B,[HDRORB8^4S%00KI(=PZ@\8/Y-W$*Q%E4@X)R<8Z
M<\8S@$>O/H3SC^XC_@J7X3\%_'3P-<-+K"0P:+9RBVG>2" 2,(B7=?,W N[#
M)"?,I W-G!/\47C73+71_$&JZ;9S+<0V-]=6L,ZMO65()I$1P0 &PHPQ *DC
M/U_8/$#@;-JOA+X=^)G$?#V4\+<8<1<.8"OQ;D>7X>>"PN&XB;J0QOU+ U*E
M2KAZ52K",XTY.2A>UW&5W_N?]#GQGS_Q:\.,-+C#%5L?Q7E<ZF'S#&U\%]3J
M8G#JHXX2M65)?5_;S@FIQIJ-VG*VIPYQ@YQ[$GH>>GY<_48J"I"K<YZYY&1U
M'3VX!QU/OSTCP1U&*_D>M.=23E)-)-I::+OK;OTZ7^;_ +&225ET"BBBL1A1
M110!<M(C(X &2Q "X]^I/8#'\OP_HK_X(Q?L-0_$3X@V'Q7^)/@M=:\&V, N
MK$:E;EK+SXHQ-#(4D@>&59&\LD%]QCXVX)!_G9TYS',K@# =>3VSQ_G!Y]#C
MG^V[_@E/^WC^S?H/[+_A3P5XMU_3O"?B?PM \=_;W,*+_:+A%7S<PQ*6DC:-
M@%97W"0?-BOVWAG&<:\->#'BMQAX0<"9IXD^,F7Y)5RG@KAC**U.AF5"MQ%0
MQF4UN(L!>,J]7%9$J]+&T?J_[R%2E&<5HS^-/IO<3<<Y%X2/+N"L'F,O]:<V
MP_#^?9OE6%Q^-Q^0Y)BJ%6IB<?A\-E<)XZI4J3H_5DJ49).O'G7+8_IB\._L
MR?#&Y^&VG7<ND6]A//HU_J%LW]AZ3'X>TFVTY08[*Y9K-&C:Z5]MJI):5PY*
MJV&/YH?%S0/AKX2U* P:18V]Y/&\DMKI]K$D+JEQ)'',-B[465(U8B,+CDX.
MZO!?&'_!771?$6LCX;_#+3/$/C2W6XCMOM#R36^E1#C+"QB7+JORN TI!V\H
MJKN/U7\/O!^F?$/1+?QIXWL&U'6-28-]FF9XK>T000%8BJR*XC5"J(BE5VIS
ME]QK^*OH6> WTR/HD5.+_'CZ:_BKQY7X+XLQ$L)D_AIA..\5Q;GDLXQ./GCJ
MM+'\^88C!93B*%&?L,7AY>RKTZG(JE*G)^]_E-])/._#;"X/PL_U,\(<W\+*
M&0\+TLMXJS7%8NE@\Y\0LYE1HI9IB<B]M7GEU!U*=?$QK8^K/'36(M.$&H,V
M/@O\.O 7Q"M=)E/AS1[JXNM0%I%)J=I#,EN2#AU@D0HSD$8#?*,9!)S5/_@H
M[^S!X?\ #WP)\8:%:>!M,\2:C=>&3>:4-/T#3Q=I=)+Y<D5L;.U1B(U9F8#(
M&S;UQCUK1[*S\*7UKIOAK29K"-66[ENH69+>Q>)=V]"SDDG) 565G8O@8//I
MGC'XG7GB+PW;)XKG$\.@Q2SMJ\\_EM#:1+OD8L4>0J$# 1("7.%!YQ7X+X\>
M-7TI^"?IP^!_C%X<YQXA\<^#F+X@P>+P7@I@.)LPCC\?2JSC#$9;F. PF(QF
M&J_7?;P]ZOAI07L+IQYX0?Q?A3Q=X01\.^/HY_A\PP'BY@,\X>XH\.>)<5C,
M76R]X#+,TH5\7PW4I8&;KX6MF'L*N'CB*%"I)^TBY1NXV_S!_P!H/X,^-/A=
MXIO8_$_A?4_#=O?W5U<Z=%?6-Q9H4:1F$,9GBB5B@*,%4DLN/EQ7S6Z$$KWP
M>OT/UK^DO_@NQ^TS\'/BEKGA'X>?#V*#4-<\*-=-X@UV*UAA,S^8OEPYBBWL
M8QB/+,&?RRS$Y&?YMIV.YB#ST.1Z\<?G^>>*_P!8/&.EA<75R#B;$9#CN$LZ
MXKX<R[B#/^#\QQ.$Q69<+YOCY8E8K*<?5PC=*6(PZI4[QCR2BOB49-G^]'T>
MN.>)/$3PJX8XLXJX=J<,9MF5&LI9;5J5*CGA:55TL+C8>VITZT:>,HQCB*:J
MQ4Y0G&32O9U.V?K^F/\ &BC_ #_G\J*_ 7Y>7Y:_B?N 4444 %%%% $B[2,$
M#(!)) ]:OP1,SJJ@D-MP><C<2!@ =<<C.0?0]*ST&6Q['] 6_F*^P/V)_A+I
MWQN_:/\ A5\.-6"KIVO>*=*M]1,CA8VLTN8A,C$@@K(2FY2V64, &W!3]SX>
MY%#B/B?+<IJUGA<-BZ[6+Q?)*HL-AJ-*5;$57"*;:C3A*5H+GLGRV9X?$V>X
M+ACA[.^(\RDX8#(\KQN:XJ48\TO88&A/$U8PBM95)4Z<U!+>5E=)W7Z*?\$[
M?^".WQ,_:[L]/\<^);B;PIX!NY46Q<6KW&JZT"V&6P@CD#22.I+*$".J?.65
MN%_LD_9[_8@T']B[X3V/A+P[X:NM-LC(L5SK-Y"$OM5NF&W9(Z3W MTB4A?+
M!#$_ZP CYONW]E3X$Z)\,?AE%9>#;:"SM=,\$W6A>&=(L"L,EK-%92V"-%/*
M4>&[NIF\Z2YD=7P<B0( #\^?!OP!\4_A#\/OC%I?QD\2V]U-XR\06=SX.\*W
M.M0ZWJ>FR0WPDGU2Y:":X%@BV"26R),\=Q-YNYT=5)3_ !<^DY^U#XZ\6N/>
M+? OZ/\ 5R;@GP2R#C3A3A*ID>'PE:KXE>+3I9K3RK.,=B\RIXBG5HX+ZS2K
MYE_9M# K"*A6I4JDY5,/&5/^,>+? '%_2(^B'XO_ $F?'/QMP_AU_JUEF)XG
M\)/ ^K4RO"91G> K8/$XC(*V-KK$5<=GF?5\.J59X935'"5,12C*DTFG\:_$
M?]I#3?#'Q-LO#&E3":_1TL)8\*6>3YXIE*-NWL6"\$8/'/((Z7]HK]EKP?\
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MU^SM^S)\.O@9XN\;_M5>.O@A\*?CSXX_X*7?";X_:;=Z+\/YOB%*Q^*/P?\
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M(\0)X5MO!GC*_P#B7\'8+CPS?>(K_P",\]IKFCWZ#_@C[\;=3^(NG?!CP?\
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M?X4_8DTSP;-%;>-D\0V?B2R,9O-*U>VO;#4+&Y"KYL-W;ZA'!<12B13N1X0
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MF;44ADCNHF7RE\W:  I7)",V3\PX/8\5_DY]'?B_-LX\6N.N(O"K"XK/./\
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MPBS*>%P]>I1KUZ4)>[6AAJE+$*C4BXJ/LY\OLFI<T5*HI6E\,OS[Q-SJ7#_
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M^"W%NMG\=I$&D1Z<[S71>1<F689VG>1\S#&UCG(!('0 #\&[EOOJ>HSQW_\
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M8\8)&X8=@0  >2,DD\@#MN'XR?\ !,?]LSPW^T#\+-!\'SW!C\0:18"%(IR
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M_#D%%%%>06%%%% &C:9* #KO./QP*Z"VBD! *Y7Y3R,#( !(XR/?G ^IK%L
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M;4EI\24MO-ZJ_6S0K+LON_KLON)_-/\ ?'_?)I-X.<D'/'W>WY>YJ&BDIO\
ME@_6/HOT0G%=K>:23_(DR.Q0?@V1[_=Q[TS<3G))SZ\_SI**;J2>RC%=5%<J
M?F[/5KH]U\V5;^OZ] HHHK-NX!1110 4444 /61T^ZQ ZX!(_E]!5D7UVJ[%
MNKA5P<*)Y0F3UPH8CO\ 0^U4Z*Z*6+Q-%-4J]:FFK6A5J05O2,DNG:^_<3C%
M[Q3]4F3>?,3DSR9]3)(3^?/^?>G)<W"'*7,J-_>6693^8(^M5Z*M8[&QDYQQ
M>*4GO)8BLGY7?/=V\VQ<L6K.,6NS2M]Q9:ZN).9+F9SZM+*Q/;JQ)Z'''88Y
MSQ;L]8U/3G\W3]2U"RE''F6=[=6KMDC^.WDB;CT/7OGC&713_M#'<ZJ+%XE5
M%M45>LIK;::FI+9:)I;=E9.G3DN64(2B]XRA&47ZQ::?HU8U[S7-7U DWVJZ
ME>G& ;N^O+D]L?--,[<$#@<  8Z8K-,LASF5VSP06<@C'O\ E^/6HJ*53'8V
MM_%Q>*J_]?,16J7]>>I((TX024(0BELH0C!+T44DODD@S_G\O\****Y'J6%%
M%% !1110!('(_C/Y=?IS[#KCMZ4HD=?NRN!G/#.,D=#QW'X_EQ45%;1Q%:#O
M"I.+M:\9SC+_ ,"C)/\ 'JQ67])?/IUZDYGE(QY\GTWOC\1@?AZ5)'=W,>=M
MU<*" "$GF3(&>#M/(YX!!JI16OU_&IIK%XE6[5ZR7X3_ *L'+%[QBUV<4U]S
M5BR;F8G<;B;/J9)&/YGGG)ZYIIFD.<S.<]F9_KV/7I_^JH**4L;BY*SQ6(:>
M_P"_JN_76\W?777J+EBMHQ7I%+\D2^;+C'G/CTWR8_*D,C=-['/JS''IC(&/
MZBHZ*AXG$25G6JM;J]2;L^ZO)M/H-12Z+[E^B78=O?\ OM_WT::22<DDGU/)
MHHK.4YR5G*35[V<I-7M:]FWKY^?884445 !1110 4 XY%%%&P#]Q_O=>OH.O
M;'?V]SS3Q(?[^3[@M@=L=/Y#Z=<PT5?M)VM=V>ZN[.UK72:3M;2^WW TGNDR
M;?SDD'_@)[=._P#D<4\RH0!M48SV/4C&>F?R/3@8ZU6HI<W]V/W?+^O^""LK
MV5K]M/RM]ST\B;?@YW#/^Z?3'K_^OKUIK,6_C_1A_C4=%/G?1)-;22M)>2=]
M/^'[L7*KWLON7^5^E]Q2<G/^'] *2BBI;;W&?T;_ /!L/>7=E^WO\7);.YFM
M96_9"\?1M)!(T;M&?C-\ 6*%E()4LBL1TRH/:BJW_!LA_P GY_%O_LT7Q[_Z
MN7X!T4@/Q\_;M_Y/@_;)_P"SJ_VAO_5N^+Z^5*^K/V[!G]N']L@9 S^U9^T,
M,GH,_%WQ?R?85B^.?V-OVN_A?\.[3XO_ !,_99_:.^'7PEO[?1+NP^*/COX'
M?$_PC\.[VT\3K;/X:NK7QOX@\+:?X8N+;Q"EY:2:)/%JCQ:K'<V[6#W FBW@
M'S;1110 445TG@[P;XN^(?BOP[X%\ ^%O$?C?QMXNUBP\/>%/!_A#0]4\3>*
M?$VOZK<1VFEZ'X>\/:):WVKZUK&I7<L5K8:9IMG<WMY<R1P6\$DCJI .;HKT
MBR^#GQ;U+XIR? S3OA=\1-0^-<7B^^^'S_!^Q\$^);SXHCQ[I>HW&D:EX)_X
M5_;Z9)XL_P"$NL-5L[O3;WPV-).LVM_;7%I/91SPRHF18?#WQWJOACQ?XUTO
MP9XLU+P;\/KKP_8>/?%NG^&]:O/#/@C4/%EUJ%EX5L/%^O6UC+I7AJ]\37ND
M:M9>'[76[NQFUF\TK4K;34N9K*X2, XZBN\M/A;\2[_5?AWH5E\/?'%UKGQ>
MATVX^$NBVWA+7[C5OBE#K7BS5/ >C2?#G3HM/>\\;QZQXXT/7/!NER>&H=3C
MU#Q7HNJ^';5I=8TZ\LX7>(/A7\3/">F7^M>*OA]XW\,Z/I?CK7OA?J>K>(?"
M7B'1=,T[XE^%+>TN_%/P[OM0U+3;:TL_'?AFUU#3[GQ!X0N9HO$.C6]_9SZC
MIUO%<Q.X!P-%?2_PX_8N_;#^,<1G^$'[*/[2GQ7A3P[X>\7R2_#7X%?%+QU%
M%X3\7WGB+3_"?B=Y?#'A74XQX>\47WA'Q79^'=;#'2];NO#/B"WTR[NIM%U*
M.VX_XB?LY?M _"!O%$?Q;^!OQA^%DO@CQ!X9\)>-(OB/\,?&_@=_"'BKQMX<
MO?&/@OPSXH'B;0],_P"$?\0^,/".F:GXI\+:+J_V/4?$'AS3;_6])M[O3K2>
MXC /&**]Z\(?LK?M.?$+6KCPWX!_9T^.WCCQ%:^!= ^*-SH/@_X0?$/Q-K5M
M\,_%>FV>M>%_B)<:5HOAR]OX/ GB31M1T_6- \72VZ>']9TN_L[_ $W4+JVN
M89'\Y\!?#CX@_%7QAI/P\^%_@;QC\2/'^OS7=OH'@?P%X8USQAXPUV>PL;O4
M[^'1_#/AZPU'6]2EL=,L+_4KR.SL9GMK"RN[N94@MYI$ .+HKZ;U+]BG]L;1
MO''A7X8ZS^R=^TOI'Q+\=VVLWO@;X=ZG\!_BI8^.?&=EX;MEO/$=YX4\)7/A
M2+7_ !%:^'[-TN];N-'T^]ATJV=)[YX(W5F^=];T36?#6LZOX<\1Z1J>@>(=
M U._T37="UNPNM*UG1-9TJZEL=4TC5]+OHH+[3=3TV^@GL[^PO((;JSNH9;>
MXBCFC=% ,RBBB@ HHKTWP/\ !7XP_$SP[XZ\7_#CX5?$CQ_X3^%NCIXA^*'B
MCP5X$\5^*_#OPU\/2K=/%K_C_6] TC4-,\'Z++'87\D>IZ_=6%FZ6%XPEQ;R
M%0#S*B@\$]_<=** "BBN]N?A9\2K3P-!\3[CX?\ C:'X;W4^G6T'C^7PIK\?
M@J6YU?4?%>D:1;IXJ?3UT)I]6U7P'XYTW2XEORVHW_@OQ;9V8FN/#FKQV@!P
M5%%% !1110 4444 %%%% !170>*?"?BGP/KM[X7\:>&]>\(^)=-%JVH^'O$^
MCZCH&NZ>+ZSM]0LOMVD:M;6>H6?VS3[NUO[7[3;1?:+*ZMKN'?;W$4C\_0 4
M4H&2 .I_$GV [D]AW-=YJWPK^)FA>#M,^(>M?#SQQI/@'6FT==(\;ZEX3UZQ
M\(ZFWB&3Q=%X?2P\27.GQ:-=2:])X \=KHT4-Z\NJ#P9XI:Q2== U4V@!P5%
M%% !1110 4444 %%%% !170^%/"7BCQWX@TSPGX*\.:]XN\5:U/]ET7PSX7T
M;4O$'B#6;O8TIM-)T72+6\U+4+D0QRSF"TMI9!!#+)M*QFNN\-_!+XQ^,O ?
MC3XI^#OA/\2_%OPO^&[VD?Q#^)'AGP%XKU[P%X"DU!0VGIXT\7Z7I-UX>\+/
M?@@V::YJ-BUR"#"'4@D \PHHHH **W/#7ACQ'XRUW3O#'A+0=9\3^(]7F:WT
MK0?#^F7NLZSJ4Z123O#8Z9IT%Q>74B00RS.L,+F.&*29]L4;NLOBGPGXH\#Z
M[J'A?QGX=UWPEXFTB6.#5?#GB?1]2T#7M,FFMX;N*+4-'U:VL]0LI);2XM[F
M-+JVA>2WN(9D5HI$<@'/4444 %%%% !1110 4444 %%%>U>+/V;/VA_ 7B_P
M5\/?'7P'^,W@KX@?$JWT:Z^''@3Q;\+?'7ASQE\0+;Q'>C3O#UQX(\,ZOH-I
MK/BN#7M0(L-&FT*SOXM3O&6ULGFG(CH \5HKL_B!\.?'_P )_%VM_#[XI>"/
M%_PV\?\ AFY@L_$G@7Q_X9USP;XQ\/W5S9V^HV]OK?AGQ'8Z;K6E33V%W:7T
M$5_9022V=W;7**T,\;MQE !117?:A\+/B5I/@C2_B7J?@#QII_PZULZ4ND>/
M;WPKKUKX+U.37=2^(6C:'%8>*9]/30KN;6]8^$GQ5TK1XK>_DEU/4/AIX^M;
M))I?"&OK8 ' T444 %%%% ']%W_!LA_R?G\6_P#LT7Q[_P"KE^ =%'_!LA_R
M?G\6_P#LT7Q[_P"KE^ =% 'X^?MV_P#)\'[9/_9U?[0W_JW?%]?TI^._AY\=
M?A%_P4<^(/[8?Q6CUCP9_P $\-3_ &&_"&C_ !:\7>+_ !GHNC?"?X]> M>_
MX)>>!_AS<?!'PWH&K>(;>#XN^+?B)\2Y]&\ >%_"'AG1?$NL:!X].G^+GT_2
M%\#7VNZ#_-;^W82/VX/VR"#@C]JS]H8@CJ"/B[XO(-?*@)!SQD<]!ZYZ8Q_]
M;CIQ0!_3+J/[.'[/MK\(=2DU_P#9K^ J?L;Z5^R!^PW\0?V=?VL3XRN_AEXL
M^/7[:GC[4_V9W^//PAUO]HR_\97-I?ZUXH\4^*?VH_AM\6_A-K>GC0?V5/ /
MPY_X67#X9\#R?#._\7>+_I[Q-^QW^R1J'[1O@;4_'/P.T#X5:K>> /VZ?^%$
M_LR:Q^ROX;\!?'7QG\4?A5+\'M5^"GA?4?@;HW[; ^ /[;'PH\,>#O'/CV]_
M9>^-?ACXH_"#5OVTOB+\.?%?A+Q_I_QDCTO0?!/B3^/T,0<C&>1T'\0P>W<?
MS..IH#L.F,'J,+@X! R,8.,\9'!YZ\T ?L;^V1\'OV6O#?\ P4$_9@^''B3P
M]XJ_9W^%?C/3OV:Y?VP-/U?PK\/_ (4ZW\/=0\8>-WL/BUXOC^!_P_\ CG^T
MW;_LZZO<_"?^PO'NM?!7Q#\0YM;\$>--1U^6R^'WPY\)ZCX8^'V@_L1^S]X'
M\.? 3X_^'OB5\3?V5_V;?V5OB[X3_:,_:9^&O[)N@^&M.@ET'XS_ +'UO^Q'
M^UKKWB'QX+?6_%/B:'XR^"_AQXY\+?L]Z5\*/VLX]4GU[XPO\8OB!I5U\2?B
MBVF6Z^!/XZ220!G@9P.@R0 3QW( R>IP,TN]LD_+R,$;5QCZ8P#[@9SSG- '
M[&_\$UM;^'OP;T;]K3]O+XI?$GQ%\!;WPKX:3]G']GKQG\(?AI9>/?&'@K]H
MG]K73_&MIK/B_P"'OPYG^(WPCTN73OAO^S9X/^/-C%J,?CO1A\.?%OCGX4Z_
M8F^U2WT;1M5_6SQE\8_@=^SG\-?V_?VI_ FCZ%\8?V+_ /@I+\6O^"<OQ;^(
M7P7N-,T3P;J?CCX.?'#1?^"COA3]KKX6Z;X5@U_Q8/@Y\0_@[^TSX+\6>)/@
MX=$\5>(G^#7BOPE\"_%L6N>)-#73SXA_D'WMZ@\$<JIX;)/4'NQ/L>1@@$'F
M-G/RY+;B=B9R>ISMSSW'3KQR: /ZW/%OP?\ @%^S)XX_9?\ COK_ .TI;^*O
M@1^Q!_P2.U'4O@7^T'\)O"'A_P <>*?$GQF_:T_;6_;QTC]BGQ+H7PC\2_$'
MP+<:?\6OAKX<^+/_  TWXJ^'VI^,=,O/AMXN^ ?B7PYK&H7LNDPPZQD^/OAU
M\-?V\+K7/A5\(?BW9ZSX6_X*F_#+X4?M/?"OXC_%RU\._!J#PO\ \%./V%M4
MN/A1^VGJ_P 4/"MO\0_'FC?#<_'+X >*OC_^TGJ]G-XPU*+Q-XA^*?P8TK3M
M2O)M/LK2R_DY+L222,G<3\JCEB"2,#@D@<C!QP" 32;V)))!R03\JX)!R#C&
M..G3H2.A((!_5=\-O%WAS]N+X5_\%([GX3_LR?M&?M,_"?PS^U[_ ,$X/ /[
M.7P5_9]^-5I\!_BIX0_9?_9R_9M_;M^!GP3\5:_K6L_"3XTF]T72/AYIO@NU
M^(.B6_@W36U/XG_$)/%5YX@M;]KFTUKQ?]E70_"_[&GQN_:Y^+?[<WP)^+_P
MP_X)ZW&F_"KX/_&3]A+XW>,[?XQ_&C]I?QUXLM_#7C_X*^!M \20Z9\"XM1\
M4?!O4-#D_:FU'XL:9HW@+_A"OAKX?/P6GU4_\+YL]*\:?S<LS,26.2><X /Z
M#].E =E.5.T[67(P"58%6!QU#*Q5LYRI*G(XH _J6\ ?LC?MT?$OX^_M5_%3
MXL?%#XN_M2_L_P#@_P#:%^!G[5<G_#) M=%\8?M\_$C6/"FN^,/V2-6^#&I^
M&(+)/@3\,M/^%OB.]?6?%LLD.A?L;>&-5N?AYX-^'&J_&/2O#/PQN/R4^-FC
M:5\8/CEXA\9Q?$SXF^!?^"C_ ,=_VP?B#I_QA_9SB^ NB_"+X,?!OXA?%'XN
M^.].\0:9X/\ CS9_M#^*/%DT6C>)-5T729?"NH?!3PO!HUCJ^N:7-XEO8O"<
M%[XG_-0N2<X3.2>(T R>3P% QZ#&%Z* * [+G:<;@0<=P<@@^QSTZ=..!0!_
M0!\7O$/QI_: _;2_:._9Q_9@UKQI\6/V>/V3_AM=_LL^&?V</!_Q4N/#GQ7_
M &LOV4_@I\>_ S_%#3OAC=6?AOQ/K/COXA_M _%W0[S]KWXN:/H&E:[K\]O=
M>*M9TS1]6\'_  \L=#TKQG_@JROB/Q#\?OVL/'.B_#_P9X@\*ZCXH_8BN/B7
MXREU*T\?>//V5/BGK_[+VI3C]C!_BQI.NV]E\0=4\ 7VD^-?A5\8?B'JOAS5
M_&'Q-\>_L\6/BKQQK'A_QS<>*]/US\9=[8QGC(.W VY (!QC&0"0#C(R<4!V
M!!! (Z$ #')/IZDX].,=!@ ;1110 5_2+_P3(M/&/B'X8?\ !+7Q1\)M7GTW
MP-^RO_P57^,GQK_;NU2V\4V.D>'?A/\ !O6?"W[%US8_&/X[6\^LVL6E_!O6
MO@K\-OVAO 6G>(/$MI_PC6J7&C?$OX;6C7.M^/UT+Q/_ #=4NXX SD*<@$ X
M[GJ.A/4=#Z4 ?II^QM-\(-$\#_\ !1_XV:I\'_A;\3]2^#7P#\$>,_V?_#OQ
MFTV\\0>&O#/BSQ9^VK^S=\-H-;?PG%K^E6GC'5-&^&OCGQ<L/AO7WUWPW>,)
M+GQ+H6OZ%9ZEIEY^Q?BSX-_\$^O&WQY^)GPZ\;_ ?]FKX)?!/X&?\% O^"<F
MA:/J?A7Q1XG\%PZ_X _:F^ _[1GC_P"-OP_^*?Q=U;XAW_B)?@OXJ^+7@KX;
M:3=>)KGQ#I__  SMX.N+D>$/$7A#1X]4%[_*"&8-N!^;.<]\GO['WZUW'PT^
M)/C/X0_$+P5\4_A[K)\/>.OAYXETCQ?X1UH:=I&K1Z;K^@WT6HZ9<7&CZ[8:
MGH6LV0NH4%]HVN:9J6C:K://8:KI][87-Q:R@'ZV_P#!2;X-:IX'_9 _8D^)
MWQ0_95^"W[+?[1?Q&^/G[=WA+XG:1\'M-A\+/XI\%_#'0OV-KOX3S^,?AYIO
MBWQ)H'P^U+0K?XA>,++PYIFCZ9X3_P"$M\%W?A_XI:EIWB+4?']QX^\7_IW\
M!-._9@E^&?QS_9(_:7\0:!9>!OV:_&O_  2=_9S\#:%XIU18?@U?_M>GX2_\
M%'_B7XQ\+?M+^)M$\2^&?%^@_LK:-^W)\<_BW:?&SQO\-+U_%6F^"H+&WTZ^
MT.SU:\\4Z-_-;^T#^U;\8/VE8? NF?$2Y\":1X3^&-IXAM?A[\./A)\)/A7\
M"_A;X.D\8:G#K7C+5]%^''P<\'^"/!Z>)?&&J6MA-XF\4W.D7/B/6+31?#FC
M7>J2:#X8\,Z5HOSD)''\6>6;D \L &)R#G<  V?O 8;(H _J(^#?[*'A^;P'
MX:\+:_\ LB?LX^+O#=I^QM_P5"\;_ML?%+6XM(L_BI\"/^"@?P.\-?MO:OX*
M^%VFGP_\1K(?#2\^&/AGX:_ '5/AO\#O"_AFX\!?$'P+XD\5?&%_"_B(Z4/%
MGPG_ )=*^PO"7[=?[1'@?X+Q? KPUK'P\T[PK:> _B#\*M*\7_\ "C?@E=?&
M_P /_"KXL7_B?4OB9\+_  W^T'=_#^;XV:!X!\<W7C;QK%K_ (=TOQW;6LND
M>-_''ARV%MX=\;>+=*UKX]H **** "BBB@ KT'X5?$_Q;\%_B%X6^*/@-_#T
M/C/P7J)UCPU>>*/!G@[X@:1IVL+:W-M9ZJ_A/Q]H7B;PGJ&H:3+<C4]$N=4T
M2]?1M<M-.US3?LVJZ;8W<'GU% 'ZX?\ !2:XLO'G_!7KXG7'B+4(/%MGXQ^,
M7P2;Q/J.HZC'J,7B'^WO!OPQ'B.?5-3\]UNGU&6ZO_[3NI+@R-++<//+YH=Z
M_7?3/"W[%NJ?M*?#;X:#]BG]CJ'P;XJ_X+L_%#_@FI?F*P\9RW5G^Q%/XO\
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M?>(=$^)&E:?X8_81^.?Q-\,Z#\/=.\6Z?JOA'Q7X[^)^D?%^R^-7C/P=H?\
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M.GZ+<QR7#^&M O=0N])L_P @J]Z^/G[2?Q4_:1U?PAJ/Q)O/"5MIOP[\(?\
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M_#>G^.X+*X\/^+_%_A%%C\(>+/$>@ZI\>ECGC! X!**"1DXR.?RR<#"@X H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6?\ ^B5?!?\ \/[X$_\ DBO]9*B@#_)M_P"(2#_@L_\ ]$J^"_\ X?WP)_\
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MK_62HH _R;?^(2#_ (+/_P#1*O@O_P"']\"?_)%'_$)!_P %G_\ HE7P7_\
M#^^!/_DBO]9*B@#_ ";?^(2#_@L__P!$J^"__A_? G_R11_Q"0?\%G_^B5?!
M?_P_O@3_ .2*_P!9*B@#_)M_XA(/^"S_ /T2KX+_ /A_? G_ ,D4?\0D'_!9
M_P#Z)5\%_P#P_O@3_P"2*_UDJ* /\FW_ (A(/^"S_P#T2KX+_P#A_? G_P D
M4?\ $)!_P6?_ .B5?!?_ ,/[X$_^2*_UDJ* /\FW_B$@_P""S_\ T2KX+_\
MA_? G_R11_Q"0?\ !9__ *)5\%__  _O@3_Y(K_62HH _P FW_B$@_X+/_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWPWT?Q>?A%\2_@W^SW<^';;3/"/PMN/C;^S-XV^).D?%#QY^TEX#_P"$9\4
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M^WF7^V1O&CQGS/[-M=V#?2Y7&_&. > .1\V[C&M]@UG_ *#Q_P#!9:?_ !5
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MS.99(XP#W>BHX5D2*-)I?.E5%$DNQ8_,<#YG\M253<>=H) Z9/6I* "BBB@
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M\0>-_"L>B>&SXPT?QUX/U;X=?#:]\/Z+:>(P#]!J*** .0\;?\@K3?\ L;_
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M3/@ \5GW'Q3^&-YJNA&T^)'@&Y*W%\"(/&/AV9B7L)D50L>HLQ)<@# /8=6
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M^L=,T#6K_4[VSTVPM=,O9;J_U"Z@LK*UA%O(&FNKNYDBM[>%<C?+-*D:CEF
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M.F_^5=)H"*MK>;55?^)UKH^50O UB]P. ,XR<9Z9XXK<K8S,3[7KW_0&LO\
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MDKPW\6_$G@2/2;#4)I_ALGC'0_CO#\7O$5O(WA_PG-=ZW>>.+_2(?$VE2ZH
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M/^PUKW_IXO:VJQ="_P"/6\_[#6O?^GB]K:H **** "L3Q)_R -7_ .O"X_\
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M2FL/#^CV(N1>Z]?ZA)<1V/\ PCEHUI>)<^(8;B71();2ZBDOUDMYD3L_A_\
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M-@".H-W;@C\/,I/[5TO_ *"5A_X&6_\ \<J3^S[#_GRM/_ :'OU_@H^P6/\
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M-*R11I$K.6*QHB A5 $M% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]I+W@!/\6-7C\/>"-0\0S*9(?#]_H&NRQ@D>9'H^O:;J+QDC)PZVQ4D D Y
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M_P"PUKW_ *>+VMJ@ HHHH *Q/$G_ " -7_Z\+C_T6:VZQ/$G_( U?_KPN/\
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M *#7B[_PK-=_^3?Y\^M'_"'6?_0:\7?^%9KO_P FU^<O_!-OX]?'[XEP^+_
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M8/B+XPTO4O'GQLUKP5KOA+PD ?M!_P (=9_]!KQ=_P"%9KO_ ,FT?\(=9_\
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MAJOB#1[""RLO[&\-1>+O'%WX4TG0=2\<>++S6/JM7;<XV,1G(." >PP2JYX
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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G 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>avxl-20210331.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Created by Electro Filings, LLC- http://www.electrofilings.com -->
    <!-- Field: Doc-Info; Name: Source; Value: avxl.xfr; Date: 2021%2D05%2D13T17:07:21Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:avxl="http://anavex.com/20210331">
    <link:schemaRef xlink:href="avxl-20210331.xsd" xlink:type="simple" />
    <xbrli:context id="From2020-10-01to2021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-11">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-012017-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-03-31_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-03-31_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-06</xbrli:startDate>
        <xbrli:endDate>2019-06-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-03-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-03-31_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_PurchaseWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_PurchaseWarrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_StockOptionPlan2015Member_custom_OptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:OptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_StockOptionPlan2015Member_custom_OptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:OptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-03-31_custom_StockOptionPlan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_StockOptionPlan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_StockOptionPlan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-03-31_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-01to2021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-01to2021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-01to2021-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-01to2021-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-01to2021-03-31_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-01to2021-03-31_custom_ParkinsonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avxl:ParkinsonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2021-05-11" unitRef="Shares" decimals="INF">70038920</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-03-31" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-09-30" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2021-03-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2020-09-30" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-03-31" unitRef="Shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-09-30" unitRef="Shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2021-03-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2020-09-30" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-03-31" unitRef="Shares" decimals="INF">70030620</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-09-30" unitRef="Shares" decimals="INF">62045198</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-03-31" unitRef="Shares" decimals="INF">70030620</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-09-30" unitRef="Shares" decimals="INF">62045198</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">75810296</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">27236569</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">20289699</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">24791746</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">62047</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">186851752</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-159677230</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">70032</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">251427781</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-175687517</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">52652</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">153633807</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-133396760</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">58666</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">171958462</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-147225382</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">66964</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">57082</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">213766108</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">165891753</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-167532295</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-139988685</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">46300777</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">25960150</us-gaap:StockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2020-10-01to2021-03-31" unitRef="USD" decimals="0">3704401</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2019-10-012020-03-31" unitRef="USD" decimals="0">3072176</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">2233745</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">1720142</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2020-10-01to2021-03-31" unitRef="USD" decimals="0">14646360</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2019-10-012020-03-31" unitRef="USD" decimals="0">12401715</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">6720841</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">6053047</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses contextRef="From2020-10-01to2021-03-31" unitRef="USD" decimals="0">18350761</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2019-10-012020-03-31" unitRef="USD" decimals="0">15473891</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">8954586</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">7773189</us-gaap:OperatingExpenses>
    <avxl:NonOperatingIncomeFromGrant contextRef="From2020-10-01to2021-03-31" unitRef="USD" decimals="0">10820</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant contextRef="From2019-10-012020-03-31" unitRef="USD" decimals="0">149888</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant contextRef="From2016-10-012017-09-30" unitRef="USD" decimals="0">597886</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">10820</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">74944</avxl:NonOperatingIncomeFromGrant>
    <avxl:ResearchAndDevelopmentIncentiveIncome contextRef="From2020-10-01to2021-03-31" unitRef="USD" decimals="0">2230195</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome contextRef="From2019-10-012020-03-31" unitRef="USD" decimals="0">1660543</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">960879</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">717328</avxl:ResearchAndDevelopmentIncentiveIncome>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2020-10-01to2021-03-31" unitRef="USD" decimals="0">7657</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2019-10-012020-03-31" unitRef="USD" decimals="0">116900</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">9216</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">70180</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2020-10-01to2021-03-31" unitRef="USD" decimals="0">178071</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2019-10-012020-03-31" unitRef="USD" decimals="0">-272848</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">-154563</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">-325960</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2020-10-01to2021-03-31" unitRef="USD" decimals="0">2426743</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2019-10-012020-03-31" unitRef="USD" decimals="0">1654483</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">826352</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">536492</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2020-10-01to2021-03-31" unitRef="USD" decimals="0">-15924018</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2019-10-012020-03-31" unitRef="USD" decimals="0">-13819408</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">-8128234</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">-7236697</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="From2020-10-01to2021-03-31" unitRef="USD" decimals="0">86269</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="From2019-10-012020-03-31" unitRef="USD" decimals="0">9214</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">26988</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="From2020-10-01to2021-03-31" unitRef="USD" decimals="0">-16010287</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2019-10-012020-03-31" unitRef="USD" decimals="0">-13828622</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">-8155222</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">-7236697</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2020-10-01to2021-03-31" unitRef="USDPShares" decimals="INF">-0.24</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2019-10-012020-03-31" unitRef="USDPShares" decimals="INF">-0.24</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2021-01-01to2021-03-31" unitRef="USDPShares" decimals="INF">-0.12</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2020-01-01to2020-03-31" unitRef="USDPShares" decimals="INF">-0.12</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2020-10-01to2021-03-31" unitRef="Shares" decimals="INF">66421380</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2019-10-012020-03-31" unitRef="Shares" decimals="INF">56544037</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2021-01-01to2021-03-31" unitRef="Shares" decimals="INF">68594867</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2020-01-01to2020-03-31" unitRef="Shares" decimals="INF">58353954</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:ShareBasedCompensation contextRef="From2020-10-01to2021-03-31" unitRef="USD" decimals="0">2785470</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2019-10-012020-03-31" unitRef="USD" decimals="0">2965177</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2020-10-012021-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2020-10-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">2785470</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2020-10-012021-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2019-10-012020-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2019-10-012020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">2965177</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2019-10-012020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">1846156</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">1700753</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1846156</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1700753</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2020-10-01to2021-03-31" unitRef="USD" decimals="0">61934439</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2019-10-012020-03-31" unitRef="USD" decimals="0">15365492</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SharesOutstanding contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">62045198</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">70030620</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">52650521</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">58664946</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">66962957</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">57080356</us-gaap:SharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2020-10-01to2021-03-31" unitRef="USD" decimals="0">24111198</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2019-10-012020-03-31" unitRef="USD" decimals="0">15365492</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2020-10-012021-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">4008</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2020-10-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">24107190</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2020-10-012021-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2019-10-012020-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">5965</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2019-10-012020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">15359527</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2019-10-012020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">6649796</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">4367540</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">662</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1571</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">6649134</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">4365969</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2020-10-012021-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">4007996</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2019-10-012020-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">5964584</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">324383</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2020-10-012021-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">4086209</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2019-10-012020-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">6014425</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2020-10-012021-03-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" unitRef="Shares" decimals="INF">3552313</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">661708</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1570424</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2 contextRef="From2020-10-01to2021-03-31" unitRef="USD" xsi:nil="true" />
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2 contextRef="From2019-10-012020-03-31" unitRef="USD" xsi:nil="true" />
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2 contextRef="From2020-10-012021-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">78</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2 contextRef="From2020-10-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-78</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2 contextRef="From2020-10-012021-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2 contextRef="From2019-10-012020-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">49</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2 contextRef="From2019-10-012020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-49</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2 contextRef="From2019-10-012020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2 contextRef="From2021-01-01to2021-03-31" unitRef="USD" xsi:nil="true" />
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2 contextRef="From2020-01-01to2020-03-31" unitRef="USD" xsi:nil="true" />
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2 contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">22</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2 contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">13</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2 contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-22</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2 contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-13</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2 contextRef="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2 contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2 contextRef="From2020-10-012021-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">78213</avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2>
    <avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2 contextRef="From2019-10-012020-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">49841</avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2>
    <avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2 contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">21571</avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2>
    <avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2 contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">14166</avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2020-10-01to2021-03-31" unitRef="USD" decimals="0">36688544</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2020-10-012021-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">3552</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2020-10-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">36684992</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2020-10-012021-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">28169987</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">2037</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">28167950</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2020-10-012021-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">3552313</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">2037484</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2020-10-01to2021-03-31" unitRef="Shares" decimals="INF">11505199</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-10-012020-09-30" unitRef="Shares" decimals="INF">10576266</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2020-10-01to2021-03-31">&lt;p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zB6lChZMEpAj" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Recent&#13;Accounting Pronouncements Not Yet Adopted&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on its results&#13;of operations, financial position or cash flow.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="From2020-10-01to2021-03-31" unitRef="USD" decimals="0">2230195</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="From2019-10-012020-03-31" unitRef="USD" decimals="0">1660543</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="From2020-10-012021-03-31_currency_AUD" unitRef="USD" decimals="0">2980095</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="From2019-10-012020-03-31_currency_AUD" unitRef="USD" decimals="0">2548000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">960879</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">717328</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="From2021-01-01to2021-03-31_currency_AUD" unitRef="USD" decimals="0">1244133</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="From2020-01-01to2020-03-31_currency_AUD" unitRef="USD" decimals="0">1203000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="From2021-01-01to2021-03-31_custom_ParkinsonMember" unitRef="USD" decimals="0">497931</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <avxl:ValueOfSharesObligatedToPurchase contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" unitRef="USD" decimals="0">50000000</avxl:ValueOfSharesObligatedToPurchase>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" unitRef="USD" decimals="0">50000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <avxl:NumberOfSharesObligatedToPurchaseProrataBasic contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">162191</avxl:NumberOfSharesObligatedToPurchaseProrataBasic>
    <avxl:StockIssuedDuringPeriodSharesNewIssues4 contextRef="From2020-10-012021-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">4007996</avxl:StockIssuedDuringPeriodSharesNewIssues4>
    <avxl:StockIssuedDuringPeriodSharesNewIssues4 contextRef="From2019-10-012020-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">5964584</avxl:StockIssuedDuringPeriodSharesNewIssues4>
    <avxl:StockIssuedDuringPeriodValueNewIssues3 contextRef="From2020-10-012021-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" unitRef="USD" decimals="0">24111198</avxl:StockIssuedDuringPeriodValueNewIssues3>
    <avxl:StockIssuedDuringPeriodValueNewIssues3 contextRef="From2019-10-012020-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" unitRef="USD" decimals="0">15365492</avxl:StockIssuedDuringPeriodValueNewIssues3>
    <avxl:StockIssuedDuringPeriodSharesNewIssues3 contextRef="From2020-10-012021-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">78213</avxl:StockIssuedDuringPeriodSharesNewIssues3>
    <avxl:StockIssuedDuringPeriodSharesNewIssues3 contextRef="From2019-10-012020-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">49841</avxl:StockIssuedDuringPeriodSharesNewIssues3>
    <avxl:StockIssuedDuringPeriodValueNewIssues4 contextRef="From2020-10-012021-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" unitRef="USD" decimals="0">0</avxl:StockIssuedDuringPeriodValueNewIssues4>
    <avxl:StockIssuedDuringPeriodValueNewIssues4 contextRef="From2019-10-012020-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" unitRef="USD" decimals="0">24111198</avxl:StockIssuedDuringPeriodValueNewIssues4>
    <avxl:PercentageOfGrossProceedsFromSales contextRef="From2020-10-012021-03-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" unitRef="Pure" decimals="INF">0.030</avxl:PercentageOfGrossProceedsFromSales>
    <avxl:GrossProceedsFromSaleOfCommonStock contextRef="From2020-10-012021-03-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" unitRef="USD" decimals="0">37823241</avxl:GrossProceedsFromSaleOfCommonStock>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="From2020-10-012021-03-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" unitRef="USD" decimals="0">36688544</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:LeaseAndRentalExpense contextRef="From2020-10-01to2021-03-31" unitRef="USD" decimals="0">60861</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2019-10-012020-03-31" unitRef="USD" decimals="0">110915</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">29903</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">98290</us-gaap:LeaseAndRentalExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2019-09-30_custom_PurchaseWarrantsMember" unitRef="Shares" decimals="INF">350000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2020-09-30_custom_PurchaseWarrantsMember" unitRef="Shares" decimals="INF">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2021-03-31_custom_PurchaseWarrantsMember" unitRef="Shares" decimals="INF">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-09-30_custom_PurchaseWarrantsMember" unitRef="USDPShares" decimals="INF">4.19</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-09-30_custom_PurchaseWarrantsMember" unitRef="USDPShares" decimals="INF">3.88</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2021-03-31_custom_PurchaseWarrantsMember" unitRef="USDPShares" decimals="INF">3.88</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod contextRef="From2019-10-012020-09-30_custom_PurchaseWarrantsMember" unitRef="Shares" decimals="INF">150000</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod contextRef="From2020-10-012021-03-31_custom_PurchaseWarrantsMember" unitRef="Shares" decimals="INF">0</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice contextRef="From2019-10-012020-09-30_custom_PurchaseWarrantsMember" unitRef="USDPShares" decimals="INF">3.17</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice contextRef="From2020-10-012021-03-31_custom_PurchaseWarrantsMember" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2021-03-31" unitRef="Shares" decimals="INF">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2021-03-31_custom_PurchaseWarrants1Member" unitRef="Shares" decimals="INF">350000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2021-03-31_custom_PurchaseWarrants2Member" unitRef="Shares" decimals="INF">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="AsOf2021-03-31_custom_PurchaseWarrants1Member" unitRef="USDPShares" decimals="INF">4.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="AsOf2021-03-31_custom_PurchaseWarrants2Member" unitRef="USDPShares" decimals="INF">3.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2021-03-31_custom_PurchaseWarrants1Member">2021-06-30</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2021-03-31_custom_PurchaseWarrants2Member">2024-05-06</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2021-03-31_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">6050553</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2021-03-31_custom_StockOptionPlan2015Member_custom_OptionsMember" unitRef="Shares" decimals="INF">146371</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member_custom_OptionsMember" unitRef="Shares" decimals="INF">146371</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2021-03-31_custom_StockOptionPlan2019Member" unitRef="Shares" decimals="INF">1856665</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2020-09-30_custom_StockOptionPlan2019Member" unitRef="Shares" decimals="INF">3161665</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="From2020-10-012021-03-31_custom_StockOptionPlan2019Member" unitRef="Shares" decimals="INF">6000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2020-10-012021-03-31_custom_StockOptionPlan2019Member">The exercise price will be determined by the board of directors at the time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair market value of the Company&#8217;s shares of common stock on the grant date</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2020-10-012021-03-31_custom_StockOptionPlan2019Member">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2021-03-31_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">11005199</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-09-30_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">8462933</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">10076266</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2021-03-31_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">3.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-09-30_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">3.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">3.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2021-03-31_custom_StockOptionPlan2015Member" unitRef="USD" decimals="0">122805858</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2019-09-30_custom_StockOptionPlan2015Member" unitRef="USD" decimals="0">4115032</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member" unitRef="USD" decimals="0">14982581</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">1695000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2020-10-012021-03-31_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">1305000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">2.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2020-10-012021-03-31_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">5.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">2.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2020-10-012021-03-31_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">4.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">68332</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2020-10-012021-03-31_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">29167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">3.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2020-10-012021-03-31_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">1.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">13335</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2020-10-012021-03-31_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">346900</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">3.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2020-10-012021-03-31_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">2.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2021-03-31_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">7513533</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2021-03-31_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">3.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2021-03-31_custom_StockOptionPlan2015Member" unitRef="USD" decimals="0">84890710</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2020-10-01to2021-03-31" unitRef="USD" decimals="0">2785470</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2019-10-012020-03-31" unitRef="USD" decimals="0">2965177</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2020-10-012021-03-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">1216780</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2019-10-012020-03-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">1291410</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2020-10-012021-03-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">1568690</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2019-10-012020-03-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">1673767</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">1846156</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">1700753</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2021-01-01to2021-03-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">793957</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2020-01-01to2020-03-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">810309</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2021-01-01to2021-03-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">1052199</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2020-01-01to2020-03-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">890444</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2020-10-01to2021-03-31" unitRef="Pure" decimals="INF">0.0064</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2019-10-012020-03-31" unitRef="Pure" decimals="INF">0.0168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-10-01to2021-03-31">P5Y7M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-10-012020-03-31">P5Y5M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2020-10-01to2021-03-31" unitRef="Pure" decimals="INF">0.9626</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2019-10-012020-03-31" unitRef="Pure" decimals="INF">0.9761</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2020-10-01to2021-03-31" unitRef="Pure" decimals="INF">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2019-10-012020-03-31" unitRef="Pure" decimals="INF">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <dei:DocumentType contextRef="From2020-10-01to2021-03-31">10-Q</dei:DocumentType>
    <dei:AmendmentFlag contextRef="From2020-10-01to2021-03-31">false</dei:AmendmentFlag>
    <dei:DocumentPeriodEndDate contextRef="From2020-10-01to2021-03-31">2021-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="From2020-10-01to2021-03-31">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2020-10-01to2021-03-31">2021</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2020-10-01to2021-03-31">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:EntityFileNumber contextRef="From2020-10-01to2021-03-31">001-37606</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2020-10-01to2021-03-31">ANAVEX LIFE SCIENCES CORP.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2020-10-01to2021-03-31">0001314052</dei:EntityCentralIndexKey>
    <dei:EntityIncorporationStateCountryCode contextRef="From2020-10-01to2021-03-31">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityCurrentReportingStatus contextRef="From2020-10-01to2021-03-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2020-10-01to2021-03-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2020-10-01to2021-03-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2020-10-01to2021-03-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2020-10-01to2021-03-31">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2020-10-01to2021-03-31">false</dei:EntityShellCompany>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">7763942</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">7305628</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredIncomeCurrent contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">487111</us-gaap:DeferredIncomeCurrent>
    <us-gaap:DeferredIncomeCurrent contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">0</us-gaap:DeferredIncomeCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">3618779</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">3316574</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">3658052</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">3989054</us-gaap:AccountsPayableCurrent>
    <us-gaap:Assets contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">83574238</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">34542197</us-gaap:Assets>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">386809</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">443839</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:IncomeTaxesReceivable contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">7328090</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">4849340</us-gaap:IncomeTaxesReceivable>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">75859339</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">29249018</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">22185630</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">26563071</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">83574238</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">34542197</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">-175687517</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">-159677230</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">251427781</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">186851752</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:CommonStockValue contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">70032</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">62047</us-gaap:CommonStockValue>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2020-10-01to2021-03-31" unitRef="USD" decimals="0">61798544</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2019-10-012020-03-31" unitRef="USD" decimals="0">15365492</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2020-10-01to2021-03-31" unitRef="USD" decimals="0">998802</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2019-10-012020-03-31" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsOfFinancingCosts contextRef="From2020-10-01to2021-03-31" unitRef="USD" decimals="0">1134697</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts contextRef="From2019-10-012020-03-31" unitRef="USD" decimals="0">0</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2020-10-01to2021-03-31" unitRef="USD" decimals="0">-15188223</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2019-10-012020-03-31" unitRef="USD" decimals="0">-10988051</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2020-10-01to2021-03-31" unitRef="USD" decimals="0">302205</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2019-10-012020-03-31" unitRef="USD" decimals="0">1062755</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2020-10-01to2021-03-31" unitRef="USD" decimals="0">-331002</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2019-10-012020-03-31" unitRef="USD" decimals="0">126402</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2020-10-01to2021-03-31" unitRef="USD" decimals="0">-57030</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2019-10-012020-03-31" unitRef="USD" decimals="0">-195439</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="From2020-10-01to2021-03-31" unitRef="USD" decimals="0">2478750</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="From2019-10-012020-03-31" unitRef="USD" decimals="0">1509202</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2020-10-01to2021-03-31" unitRef="USD" decimals="0">998802</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2020-10-012021-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">347</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2020-10-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">998455</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2020-10-012021-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">998802</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">347</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">998455</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2020-10-01to2021-03-31">&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;  &lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; width: 53px"&gt;&lt;font style="font-size: 10pt"&gt;Note 1&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 3px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;u&gt;Business Description and Basis of Presentation&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;Business&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;Anavex Life Sciences Corp. (&amp;#8220;Anavex&amp;#8221;&#13;or the &amp;#8220;Company&amp;#8221;) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics&#13;by applying precision medicine to central nervous system (&amp;#8220;CNS&amp;#8221;) diseases with high unmet need. Anavex analyzes genomic data&#13;from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment&#13;of neurodegenerative and neurodevelopmental diseases. The Company&amp;#8217;s lead compound ANAVEX&lt;sup&gt;&amp;#174;&lt;/sup&gt;2-73 is being developed&#13;to treat Alzheimer&amp;#8217;s disease, Parkinson&amp;#8217;s disease and potentially other central nervous system diseases, including rare diseases,&#13;such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein&#13;2 (&amp;#8220;MECP2&amp;#8221;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;Basis of Presentation&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;These unaudited interim condensed consolidated&#13;financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;)&#13;and accounting principles generally accepted in the United States of America (&amp;#8220;U.S. GAAP&amp;#8221;) for interim reporting. Accordingly,&#13;certain information and note disclosures normally included in the annual financial statements in accordance with U.S. GAAP have been condensed&#13;or omitted pursuant to such rules and regulations. In the opinion of management, the disclosures are adequate to make the information&#13;presented not misleading.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;These accompanying unaudited interim condensed&#13;consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management&#13;are necessary for fair presentation of the information contained herein. The consolidated balance sheet as of September 30, 2020 was derived&#13;from the audited annual financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited interim&#13;condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes&#13;thereto included in the Company&amp;#8217;s annual report on Form 10-K for the year ended September 30, 2020 filed with the SEC on December&#13;28, 2020. The Company follows the same accounting policies in the preparation of interim reports.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;Operating results for the six months ended&#13;March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending September 30, 2021.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;Liquidity&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;All of the Company&amp;#8217;s potential drug&#13;compounds are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful&#13;or, if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial&#13;revenues. To date, we have not generated any revenues from our operations. The Company expects the business to continue to experience&#13;negative cash flows for the foreseeable future and cannot predict when, if ever, our business might become profitable.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;The Company believes that its existing cash&#13;and cash equivalents, along with existing financial commitments from third parties, will be sufficient to meet its cash commitments for&#13;up to three years after the date that these interim condensed consolidated financial statements are issued. The process of drug development&#13;can be costly, and the timing and outcomes of clinical trials is uncertain.&amp;#160;The assumptions upon which the Company has based its&#13;estimates are routinely evaluated and may be subject to change.&amp;#160;The actual amount of the Company&amp;#8217;s expenditures will vary depending&#13;upon a number of factors including but not limited to the design, timing and duration of future clinical trials, the progress of the Company&amp;#8217;s&#13;research and development programs and the level of financial resources available. The Company has the ability to adjust its operating&#13;plan spending levels based on the timing of future clinical trials.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;Other than our rights related to the Sales&#13;Agreement (as defined below in Note 4), there can be no assurance that additional financing will be available to us when needed or, if&#13;available, that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional financing on&#13;a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and development activities.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;In December 2019, a novel strain of coronavirus,&#13;COVID-19, was reported to have surfaced in Wuhan, China. In March 2020, the World Health Organization declared COVID-19 to be a global&#13;pandemic as a result of the rapid spread of the virus beyond its point of origin.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;The global outbreak of COVID-19 continues&#13;to rapidly evolve as of the date these interim condensed consolidated financial statements are issued. As such, it is uncertain as to&#13;the full magnitude that the outbreak will have on the Company&amp;#8217;s financial condition and future results of operations. Management&#13;is actively monitoring the global situation on its business, including on its clinical trials and operations and financial condition.&#13;The effects of COVID-19 did not have a material impact on the Company&amp;#8217;s result of operations or financial condition for the period&#13;ended March 31, 2021. However, given the daily evolution of the COVID-19 situation, and the global responses to curb its spread, the Company&#13;is not able to estimate the effects COVID-19 may have on its future results of operations or financial condition.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;Use of Estimates&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; color: gray"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;The preparation of financial statements in&#13;accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities&#13;at the date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly&#13;evaluates estimates and assumptions related to accounting for research and development costs, valuation and recoverability of deferred&#13;tax assets, asset impairment, stock-based compensation, and loss contingencies. The Company bases its estimates and assumptions on current&#13;facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which&#13;form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are&#13;not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&amp;#8217;s&#13;estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will&#13;be affected.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;Principles of Consolidation&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;These consolidated financial statements include&#13;the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited., a company incorporated under&#13;the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex Canada Ltd., a company incorporated&#13;under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have been eliminated.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;Fair Value Measurements&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; color: gray"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;The fair value hierarchy under GAAP is based&#13;on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair&#13;value which are the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;Level 1 - &amp;#9;&amp;#160;quoted&#13;prices (unadjusted) in active markets for identical assets or liabilities;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;Level 2 - &amp;#160;&amp;#160;observable&#13;inputs other than Level 1, quoted prices for similar assets or liabilities in active &amp;#9;&amp;#9;markets, quoted prices for identical or similar&#13;assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value&#13;drivers are observable; and&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;Level 3 - &amp;#9;&amp;#160;assets&#13;and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant to the fair&#13;value of the assets or liabilities.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;The book value of cash and cash equivalents&#13;and accounts payable and accrued liabilities approximate their fair values due to the short-term maturity of those instruments.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;At March 31, 2021 and September 30, 2020,&#13;the Company did not have any Level 3 assets or liabilities.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;Basic and Diluted Loss per Share&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; color: gray"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;Basic income/(loss) per common share is computed&#13;by dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the&#13;period. Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of&#13;(1) the weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options&#13;and warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the&#13;diluted net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation&#13;of diluted net loss per share because their effect would be anti-dilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;As of March 31, 2021, loss per share excludes&#13;11,505,199 (September 30, 2020 &amp;#8211; 10,576,266) potentially dilutive common shares related to outstanding options and warrants, as&#13;their effect was anti-dilutive.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="From2020-10-01to2021-03-31">&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;  &lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; width: 53px"&gt;&lt;font style="font-size: 10pt"&gt;Note 2&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 3px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;u&gt;Recent Accounting Pronouncements&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;i&gt;Recent Accounting Pronouncements Not&#13;Yet Adopted&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;The Company does not expect the adoption&#13;of recently issued accounting pronouncements to have a significant impact on its results of operations, financial position or cash flows.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock contextRef="From2020-10-01to2021-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"&gt;A summary of the status of the Company&amp;#8217;s&#13;outstanding share purchase warrants is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Number of Shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Weighted Average Exercise Price ($)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 49%; padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Balance, September 30, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-left: 10pt; text-indent: -10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;350,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.19&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;150,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Balance, September 30, 2020 and March 31, 2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;500,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.88&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock>
    <avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock contextRef="From2020-10-01to2021-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"&gt;At March 31, 2021, the Company had share&#13;purchase warrants outstanding as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Number&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Exercise Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Expiry Date&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;350,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 7%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.19&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 7%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 52%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;June 30, 2021&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;150,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;May 6, 2024&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;500,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;</avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2020-10-01to2021-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"&gt;These amounts have been included in general&#13;and &amp;#9;administrative expenses and research and development expenses on the Company&amp;#8217;s statements of &amp;#9;operations as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Three months ended March 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Six months ended March 31,&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 38%"&gt;&lt;font style="font-size: 10pt"&gt;General and administrative&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;793,957&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;810,309&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,216,780&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,291,410&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;Research and development&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,052,199&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;890,444&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,568,690&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,673,767&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;Total share based compensation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,846,156&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,700,753&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,785,470&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,965,177&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 10pt"&gt;&lt;br style="clear: both" /&gt;&#13;&lt;/font&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2020-10-01to2021-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"&gt;The fair value of each option award granted&#13;during the six months ended March 31, 2021 and 2020 is estimated on the date of grant using the Black Scholes option pricing model based&#13;on the following weighted average assumptions:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 58%"&gt;&lt;font style="font-size: 10pt"&gt;Risk-free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.64&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.68&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Expected life of options (years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.64&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.44&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Annualized volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;96.26&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;97.61&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Dividend rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 10pt"&gt;&lt;br style="clear: both" /&gt;&#13;&lt;/font&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ProfitLoss contextRef="From2020-10-01to2021-03-31" unitRef="USD" decimals="0">-16010287</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2019-10-012020-03-31" unitRef="USD" decimals="0">-13828622</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2020-10-012021-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2020-10-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2020-10-012021-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-16010287</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2019-10-012020-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2019-10-012020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2019-10-012020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-13828622</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">-8155222</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">-7236697</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-8155222</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-7236697</us-gaap:ProfitLoss>
    <avxl:SharesIssuedUponExerciseOfOptionsShares contextRef="From2020-10-012021-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">346900</avxl:SharesIssuedUponExerciseOfOptionsShares>
    <avxl:SharesIssuedUponExerciseOfOptionsShares contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">346900</avxl:SharesIssuedUponExerciseOfOptionsShares>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">7091142</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2020-10-01to2021-03-31" unitRef="USD" decimals="0">487111</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2019-10-012020-03-31" unitRef="USD" decimals="0">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <avxl:OtherIncomeDisclosureTextBlock contextRef="From2020-10-01to2021-03-31">&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;  &lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; width: 53px"&gt;&lt;font style="font-size: 10pt"&gt;Note 3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 3px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;u&gt;Other Income&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white"&gt;Grant Income&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white"&gt;During the six months&#13;ended March 31, 2021, the Company received $497,931 of a $995,862 research grant awarded by the Michael J. Fox Foundation for Parkinson&amp;#8217;s&#13;Research. The grant will be used to fund a clinical trial in the Company&amp;#8217;s lead compound, ANAVEX&lt;sup&gt;&amp;#174;&lt;/sup&gt;2-73 for the treatment&#13;of Parkinson&amp;#8217;s disease.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white"&gt;The grant income&#13;is being deferred when received and amortized to other income as the related research and development expenditures are incurred. During&#13;the three and six months ended March 31, 2021, the Company recognized $10,820 and $10,820, respectively (2020: $0 and $0, respectively)&#13;of this grant on its statements of operations within grant income.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white"&gt;During the year&#13;ended September 30, 2017, the Company was awarded grant funding in the amount of $597,886. The grant was received in equal quarterly installments&#13;over a period of two years ending during the year ended September 30, 2020, in exchange for a commitment to complete clinical testing&#13;for a therapeutic drug candidate for the treatment of Rett syndrome.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white"&gt;The grant income&#13;was deferred when received and amortized to other income as the related research and development expenditures were incurred. During the&#13;three and six months ended March 31, 2020, the Company recognized $74,944 and $149,888, respectively of this grant on its statements of&#13;operations within grant income.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white"&gt;Research and Development&#13;Incentive Income&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white"&gt;Research and development&#13;incentive income represents the receipt by the Company&amp;#8217;s Australian subsidiary, of the Australian research and development incentive&#13;credit, (the &amp;#8220;ATO R&amp;#38;D Credit&amp;#8221;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white"&gt;During the three&#13;and six months ended March 31, 2021, the Company recorded research and development incentive income of $960,879 (AUD 1,244,133) and $2,230,195&#13;(AUD 2,980,095) (2020: $717,328 (AUD 1,203,000) and $1,660,543 (AUD 2,548,000)), respectively, in respect of the ATO R&amp;#38;D Credit for&#13;eligible research and development expenses incurred during the period.&lt;/p&gt;</avxl:OtherIncomeDisclosureTextBlock>
    <avxl:EquityOfferingAgreementsTextBlock contextRef="From2020-10-01to2021-03-31">&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;  &lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; width: 53px"&gt;&lt;font style="font-size: 10pt"&gt;Note 4&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 3px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;u&gt;Equity Offering Agreements&lt;/u&gt; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;2019 Purchase Agreement&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;On June 7, 2019, the Company entered into&#13;a $50,000,000 purchase agreement (the &amp;#8220;2019 Purchase Agreement&amp;#8221;) with Lincoln Park, as amended on July 1, 2020, pursuant to&#13;which the Company had the right to sell and issue to Lincoln Park, and Lincoln Park was obligated to purchase, up to $50,000,000 in value&#13;of its shares of common stock from time to time over a three-year period until July 1, 2022.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;In consideration for entering into the 2019&#13;Purchase Agreement, the Company issued to Lincoln Park 324,383 shares of common stock as a commitment fee during the year ended September&#13;30, 2019 and agreed to issue up to 162,191 shares pro rata, when and if, Lincoln Park purchased, at the Company&amp;#8217;s discretion, the&#13;$50,000,000 aggregate commitment.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;During the six months ended March 31, 2021,&#13;the Company issued to Lincoln Park an aggregate of 4,086,209 (2020 &amp;#8211; 6,014,425) shares of common stock under the 2019 Purchase Agreement,&#13;including 4,007,996 (2020: 5,964,584) shares of common stock for an aggregate purchase price of $24,111,198 (2020: $15,365,492) and 78,213&#13;(2020: 49,841) commitment shares.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;At March 31, 2021, no amount remained available&#13;under the 2019 Purchase Agreement (September 30, 2020: $24,111,198).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;Sales Agreement&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;The Company entered into a Controlled Equity&#13;Offering Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020 (the &amp;#8220;Sales Agreement&amp;#8221;) with Cantor&#13;Fitzgerald&amp;#160;&amp;#38; Co. and SVB Leerink LLC (together the &amp;#8220;Sales Agents&amp;#8221;), pursuant to which the Company may offer and sell&#13;shares of common stock registered under an effective registration statement from time to time through the Sales Agents (the &amp;#8220;Offering&amp;#8221;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;Upon delivery of a placement notice based&#13;on the Company&amp;#8217;s instructions and subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell the Shares&#13;by methods deemed to be an &amp;#8220;at the market offering&amp;#8221; offering, in negotiated transactions at market prices prevailing at the&#13;time of sale or at prices related to such prevailing market prices, or by any other method permitted by law, including negotiated transactions,&#13;subject to the prior written consent of the Company. The Company is not obligated to make any sales of Shares under the Sales Agreement.&#13;The Company or Sales Agents may suspend or terminate the offering of Shares upon notice to the other party, subject to certain conditions.&#13;The Sales Agents will act as agent on a commercially reasonable efforts basis consistent with their normal trading and sales practices&#13;and applicable state and federal law, rules&amp;#160;and regulations and the rules&amp;#160;of Nasdaq.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;The Company has agreed to pay the Sales Agents&#13;commissions for their services of up to 3.0% of the gross proceeds from the sale of the Shares pursuant to the Sales Agreement. The Company&#13;also agreed to provide the Sales Agents with customary indemnification and contribution rights. During the six months ended March 31,&#13;2021, 3,552,313 shares were sold pursuant to the Offering for gross proceeds of $37,823,241 (net proceeds of $36,688,544 after deducting&#13;offering expenses).&lt;/p&gt;</avxl:EquityOfferingAgreementsTextBlock>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="From2020-10-01to2021-03-31">&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;  &lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; width: 53px"&gt;&lt;font style="font-size: 10pt"&gt;Note 5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 3px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;u&gt;Commitments and Contingencies&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;  &lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 56px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;font style="font-size: 10pt"&gt;a)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 10pt"&gt;Leases &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; color: gray"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"&gt;During the three and six months ended March&#13;31, 2021, the Company incurred office lease expense of $29,903 and $98,290, respectively (2020: $60,861 and $110,915, respectively).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;  &lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 56px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;font style="font-size: 10pt"&gt;b)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 10pt"&gt;Litigation&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; color: gray"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"&gt;The Company is subject to claims and legal&#13;proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there can be no guarantee that the&#13;outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will not have a material&#13;adverse effect upon the Company&amp;#8217;s consolidated financial statements. The Company does not believe that any of such pending claims&#13;and legal proceedings will have a material adverse effect on its consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;  &lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 56px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;font style="font-size: 10pt"&gt;c)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 10pt"&gt;Share Purchase Warrants&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; color: gray"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"&gt;A summary of the status of the Company&amp;#8217;s&#13;outstanding share purchase warrants is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Number of Shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Weighted Average Exercise Price ($)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 49%; padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Balance, September 30, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-left: 10pt; text-indent: -10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;350,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.19&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;150,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Balance, September 30, 2020 and March 31, 2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;500,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.88&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"&gt;At March 31, 2021, the Company had share&#13;purchase warrants outstanding as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Number&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Exercise Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Expiry Date&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;350,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 7%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.19&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 7%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 52%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;June 30, 2021&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;150,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;May 6, 2024&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;500,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"&gt;2015 Stock Option Plan&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"&gt;On September 18, 2015, the Company&amp;#8217;s&#13;board of directors approved a 2015 Omnibus Incentive Plan (the &amp;#8220;2015 Plan&amp;#8221;), which provided for the grant of stock options&#13;and restricted stock awards to directors, officers, employees and consultants of the Company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"&gt;The maximum number of our common shares reserved&#13;for issue under the plan was 6,050,553 shares, subject to adjustment in the event of a change of the Company&amp;#8217;s capitalization. At&#13;March 31, 2021, 146,371 (September 30, 2020: 146,371) options remain available for issue under the 2015 Plan.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"&gt;2019 Stock Option Plan&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"&gt;On January 15, 2019, the Board approved the&#13;2019 Omnibus Incentive Plan (the &amp;#8220;2019 Plan&amp;#8221;), which provides for the grant of stock options and restricted stock awards to&#13;directors, officers, employees, consultants and advisors of the Company. Under the terms of the 2019 Plan, 6,000,000 additional shares&#13;of Common Stock are available for issuance under the 2019 Plan, in addition to the shares available under the 2015 Plan. Any awards outstanding&#13;under the 2015 Plan or the Company&amp;#8217;s 2007 Stock Option Plan (the &amp;#8220;2007 Plan&amp;#8221;) will remain subject to and be paid under&#13;the 2015 Plan or the 2007 Plan, respectively, and any shares subject to outstanding awards under the 2015 Plan or the 2007 Plan that subsequently&#13;cease to be subject to such awards (other than by reason of settlement of the awards in shares) will automatically become available for&#13;issuance under the 2019 Plan.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"&gt;The 2019 Plan provides that it may be administered&#13;by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined by the board of directors&#13;at the time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date,&#13;then the exercise price shall not be less than 110% of fair market value of the Company&amp;#8217;s shares of common stock on the grant date.&#13;Stock options may be granted under the 2019 Plan for an exercise period of up to ten years from the date of grant of the option or such&#13;lesser periods as may be determined by the board, subject to earlier termination in accordance with the terms of the 2019 Plan. At March&#13;31, 2021, 1,856,665 (September 30, 2020: 3,161,665) options remain available for issue under the 2019 Plan.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"&gt;A summary of the status of Company&amp;#8217;s&#13;outstanding stock purchase options is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Number of Shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Weighted Average Exercise Price ($)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Weighted Average Grant Date Fair Value ($)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Aggregate intrinsic value ($)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 39%; padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Outstanding, September 30, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;8,462,933&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.58&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4,115,032&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,695,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.96&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.27&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(68,332&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.01&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(13,335&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.15&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Outstanding, September 30, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;10,076,266&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.48&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;14,982,581&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,305,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.93&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.47&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(29,167&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.44&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(346,900&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.88&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Outstanding, March 31, 2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;11,005,199&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.79&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;122,805,858&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Exercisable, March 31, 2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,513,533&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.65&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;84,890,710&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 10pt"&gt;&lt;br style="clear: both" /&gt;&#13;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"&gt;The aggregate intrinsic value is calculated&#13;as the difference between the exercise price of the underlying awards and the quoted market price of the Company&amp;#8217;s stock for the&#13;options that were in-the-money at March 31, 2021.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"&gt;During the three and six months ended March&#13;31, 2021, the Company recognized stock-based compensation expense of $1,846,156 and $2,785,470, respectively (2020: $1,700,753 and $2,965,177,&#13;respectively) in connection with the issuance and vesting &amp;#9;of stock options and warrants in exchange for services. These amounts have&#13;been included in general and &amp;#9;administrative expenses and research and development expenses on the Company&amp;#8217;s statements of &amp;#9;operations&#13;as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Three months ended March 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Six months ended March 31,&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 38%"&gt;&lt;font style="font-size: 10pt"&gt;General and administrative&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;793,957&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;810,309&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,216,780&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,291,410&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;Research and development&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,052,199&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;890,444&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,568,690&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,673,767&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;Total share based compensation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,846,156&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,700,753&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,785,470&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,965,177&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 10pt"&gt;&lt;br style="clear: both" /&gt;&#13;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"&gt;An amount of approximately $7,091,142 in&#13;stock-based compensation is expected to be recorded over the remaining term &amp;#9;of such options through fiscal 2024.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"&gt;The fair value of each option award granted&#13;during the six months ended March 31, 2021 and 2020 is estimated on the date of grant using the Black Scholes option pricing model based&#13;on the following weighted average assumptions:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 58%"&gt;&lt;font style="font-size: 10pt"&gt;Risk-free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.64&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.68&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Expected life of options (years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.64&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.44&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Annualized volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;96.26&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;97.61&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Dividend rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;</us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="From2020-10-01to2021-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"&gt;A summary of the status of Company&amp;#8217;s&#13;outstanding stock purchase options is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Number of Shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Weighted Average Exercise Price ($)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Weighted Average Grant Date Fair Value ($)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Aggregate intrinsic value ($)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 39%; padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Outstanding, September 30, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;8,462,933&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.58&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4,115,032&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,695,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.96&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.27&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(68,332&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.01&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(13,335&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.15&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Outstanding, September 30, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;10,076,266&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.48&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;14,982,581&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,305,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.93&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.47&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(29,167&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.44&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(346,900&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.88&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Outstanding, March 31, 2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;11,005,199&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.79&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;122,805,858&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Exercisable, March 31, 2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,513,533&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.65&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;84,890,710&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="From2020-10-01to2021-03-31" unitRef="USD" decimals="0">46610321</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="From2019-10-012020-03-31" unitRef="USD" decimals="0">4377441</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>avxl-20210331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.8a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: avxl.xfr; Date: 2021%2D05%2D13T17:07:21Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 8KlZs7xRiXgen8uCandcSayKWcPtxJFzKZkhv2pxfTn6nyshdtS3Wisakjw2kT4G -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:avxl="http://anavex.com/20210331" elementFormDefault="qualified" targetNamespace="http://anavex.com/20210331">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://anavex.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" id="InterimCondensedConsolidatedBalanceSheets">
	  <link:definition>00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" id="InterimCondensedConsolidatedBalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" id="InterimCondensedConsolidatedStatementsOfOperations">
	  <link:definition>00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" id="InterimCondensedConsolidatedStatementsOfCashFlows">
	  <link:definition>00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" id="InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity">
	  <link:definition>00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" id="BusinessDescriptionAndBasisOfPresentation">
	  <link:definition>00000007 - Disclosure - Business Description and Basis of Presentation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/RecentAccountingPronouncements" id="RecentAccountingPronouncements">
	  <link:definition>00000008 - Disclosure - Recent Accounting Pronouncements</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/OtherIncome" id="OtherIncome">
	  <link:definition>00000009 - Disclosure - Other Income</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/EquityOfferingAgreements" id="EquityOfferingAgreements">
	  <link:definition>00000010 - Disclosure - Equity Offering Agreements</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000011 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/RecentAccountingPronouncementsPolicies" id="RecentAccountingPronouncementsPolicies">
	  <link:definition>00000012 - Disclosure - Recent Accounting Pronouncements (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000013 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" id="BusinessDescriptionAndBasisOfPresentationDetailsNarrative">
	  <link:definition>00000014 - Disclosure - Business Description and Basis of Presentation (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" id="OtherIncomeDetailsNarrative">
	  <link:definition>00000015 - Disclosure - Other Income (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" id="EquityOfferingAgreementsDetailsNarrative">
	  <link:definition>00000016 - Disclosure - Equity Offering Agreements (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
	  <link:definition>00000017 - Disclosure - Commitments and Contingencies (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" id="CommitmentsAndContingenciesDetails1">
	  <link:definition>00000018 - Disclosure - Commitments and Contingencies (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" id="CommitmentsAndContingenciesDetails2">
	  <link:definition>00000019 - Disclosure - Commitments and Contingencies (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" id="CommitmentsAndContingenciesDetails3">
	  <link:definition>00000020 - Disclosure - Commitments and Contingencies (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" id="CommitmentsAndContingenciesDetails4">
	  <link:definition>00000021 - Disclosure - Commitments and Contingencies (Details 4)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000022 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
    <element id="avxl_NonOperatingIncomeFromGrant" name="NonOperatingIncomeFromGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ResearchAndDevelopmentIncentiveIncome" name="ResearchAndDevelopmentIncentiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" name="CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" name="CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ValueOfSharesObligatedToPurchase" name="ValueOfSharesObligatedToPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" name="NumberOfSharesObligatedToPurchaseProrataBasic" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodSharesNewIssues4" name="StockIssuedDuringPeriodSharesNewIssues4" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodValueNewIssues3" name="StockIssuedDuringPeriodValueNewIssues3" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodSharesNewIssues3" name="StockIssuedDuringPeriodSharesNewIssues3" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodValueNewIssues4" name="StockIssuedDuringPeriodValueNewIssues4" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PercentageOfGrossProceedsFromSales" name="PercentageOfGrossProceedsFromSales" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_GrossProceedsFromSaleOfCommonStock" name="GrossProceedsFromSaleOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" name="ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedUponExerciseOfOptionsShares" name="SharesIssuedUponExerciseOfOptionsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OtherIncomeDisclosureTextBlock" name="OtherIncomeDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EquityOfferingAgreementsTextBlock" name="EquityOfferingAgreementsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseAgreement1Member" name="PurchaseAgreement1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_LincolnParkCapitalFundLLCMember" name="LincolnParkCapitalFundLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EquityOfferingSalesAgreementMember" name="EquityOfferingSalesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CantorFitzgeraldAndCoMember" name="CantorFitzgeraldAndCoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrantsMember" name="PurchaseWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrants1Member" name="PurchaseWarrants1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrants2Member" name="PurchaseWarrants2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2015Member" name="StockOptionPlan2015Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionsMember" name="OptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2019Member" name="StockOptionPlan2019Member" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ParkinsonMember" name="ParkinsonMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DisclosureOtherIncomeAbstract" name="DisclosureOtherIncomeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DisclosureEquityOfferingAgreementsAbstract" name="DisclosureEquityOfferingAgreementsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>avxl-20210331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Created by Electro Filings, LLC- http://www.electrofilings.com -->
    <!-- Field: Doc-Info; Name: Source; Value: avxl.xfr; Date: 2021%2D05%2D13T17:07:21Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20210331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:href="avxl-20210331.xsd#InterimCondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20210331.xsd#InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:href="avxl-20210331.xsd#InterimCondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:href="avxl-20210331.xsd#InterimCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="avxl-20210331.xsd#InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:href="avxl-20210331.xsd#BusinessDescriptionAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncements" xlink:href="avxl-20210331.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20210331.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreements" xlink:href="avxl-20210331.xsd#EquityOfferingAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20210331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:href="avxl-20210331.xsd#RecentAccountingPronouncementsPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20210331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:href="avxl-20210331.xsd#BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20210331.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" xlink:href="avxl-20210331.xsd#EquityOfferingAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20210331.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20210331.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20210331.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20210331.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20210331.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20210331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaapIncomeTaxesReceivable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapIncomeTaxesReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="loc_us-gaapDeferredIncomeCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredIncomeCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlNonOperatingIncomeFromGrant" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&apos; EQUITY (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Business Description and Basis of Presentation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncements" xlink:title="00000008 - Disclosure - Recent Accounting Pronouncements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000009 - Disclosure - Other Income" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreements" xlink:title="00000010 - Disclosure - Equity Offering Agreements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="00000011 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:title="00000012 - Disclosure - Recent Accounting Pronouncements (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="00000013 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:title="00000014 - Disclosure - Business Description and Basis of Presentation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000015 - Disclosure - Other Income (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" xlink:title="00000016 - Disclosure - Equity Offering Agreements (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000017 - Disclosure - Commitments and Contingencies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000018 - Disclosure - Commitments and Contingencies (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="00000019 - Disclosure - Commitments and Contingencies (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="00000020 - Disclosure - Commitments and Contingencies (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="00000021 - Disclosure - Commitments and Contingencies (Details 4)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000022 - Disclosure - Commitments and Contingencies (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>avxl-20210331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Created by Electro Filings, LLC- http://www.electrofilings.com -->
    <!-- Field: Doc-Info; Name: Source; Value: avxl.xfr; Date: 2021%2D05%2D13T17:07:21Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20210331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:href="avxl-20210331.xsd#InterimCondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20210331.xsd#InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:href="avxl-20210331.xsd#InterimCondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:href="avxl-20210331.xsd#InterimCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="avxl-20210331.xsd#InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:href="avxl-20210331.xsd#BusinessDescriptionAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncements" xlink:href="avxl-20210331.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20210331.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreements" xlink:href="avxl-20210331.xsd#EquityOfferingAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20210331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:href="avxl-20210331.xsd#RecentAccountingPronouncementsPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20210331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:href="avxl-20210331.xsd#BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20210331.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" xlink:href="avxl-20210331.xsd#EquityOfferingAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20210331.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20210331.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20210331.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20210331.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20210331.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20210331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&apos; EQUITY (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:label="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:label="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_SharesIssuedUponExerciseOfOptionsShares" xlink:label="loc_avxlSharesIssuedUponExerciseOfOptionsShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUponExerciseOfOptionsShares_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_50" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Business Description and Basis of Presentation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncements" xlink:title="00000008 - Disclosure - Recent Accounting Pronouncements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000009 - Disclosure - Other Income" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreements" xlink:title="00000010 - Disclosure - Equity Offering Agreements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="00000011 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:title="00000012 - Disclosure - Recent Accounting Pronouncements (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="00000013 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:title="00000014 - Disclosure - Business Description and Basis of Presentation (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000015 - Disclosure - Other Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_ParkinsonMember" xlink:label="loc_avxlParkinsonMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_avxlParkinsonMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCurrencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AUD" xlink:label="loc_currencyAUD_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlNonOperatingIncomeFromGrant_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_110" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" xlink:title="00000016 - Disclosure - Equity Offering Agreements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_PurchaseAgreement1Member" xlink:label="loc_avxlPurchaseAgreement1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="loc_avxlEquityOfferingSalesAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlEquityOfferingSalesAgreementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="loc_avxlLincolnParkCapitalFundLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlLincolnParkCapitalFundLLCMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="loc_avxlCantorFitzgeraldAndCoMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlCantorFitzgeraldAndCoMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="loc_avxlValueOfSharesObligatedToPurchase_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlValueOfSharesObligatedToPurchase_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues4_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues4_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues3_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues3_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues3_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues3_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues4_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues4_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="loc_avxlPercentageOfGrossProceedsFromSales_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlPercentageOfGrossProceedsFromSales_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_GrossProceedsFromSaleOfCommonStock" xlink:label="loc_avxlGrossProceedsFromSaleOfCommonStock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlGrossProceedsFromSaleOfCommonStock_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_50" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000017 - Disclosure - Commitments and Contingencies (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_PurchaseWarrantsMember" xlink:label="loc_avxlPurchaseWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_60" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000018 - Disclosure - Commitments and Contingencies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_PurchaseWarrants1Member" xlink:label="loc_avxlPurchaseWarrants1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_PurchaseWarrants2Member" xlink:label="loc_avxlPurchaseWarrants2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="00000019 - Disclosure - Commitments and Contingencies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_60" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="00000020 - Disclosure - Commitments and Contingencies (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="00000021 - Disclosure - Commitments and Contingencies (Details 4)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000022 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_StockOptionPlan2019Member" xlink:label="loc_avxlStockOptionPlan2019Member_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2019Member_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_OptionsMember" xlink:label="loc_avxlOptionsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlOptionsMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_120" xlink:type="arc" order="6" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>avxl-20210331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Created by Electro Filings, LLC- http://www.electrofilings.com -->
    <!-- Field: Doc-Info; Name: Source; Value: avxl.xfr; Date: 2021%2D05%2D13T17:07:21Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AUD" xlink:label="currency_AUD" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AUD" xlink:to="currency_AUD_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AUD_lbl" xml:lang="en-US">Australia, Dollars</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_PurchaseAgreement1Member" xlink:label="avxl_PurchaseAgreement1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreement1Member" xlink:to="avxl_PurchaseAgreement1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseAgreement1Member_lbl" xml:lang="en-US">2019 Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="avxl_LincolnParkCapitalFundLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LincolnParkCapitalFundLLCMember" xlink:to="avxl_LincolnParkCapitalFundLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_LincolnParkCapitalFundLLCMember_lbl" xml:lang="en-US">Lincoln Park Capital Fund, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="avxl_EquityOfferingSalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingSalesAgreementMember" xlink:to="avxl_EquityOfferingSalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EquityOfferingSalesAgreementMember_lbl" xml:lang="en-US">Equity Offering Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="avxl_CantorFitzgeraldAndCoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CantorFitzgeraldAndCoMember" xlink:to="avxl_CantorFitzgeraldAndCoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CantorFitzgeraldAndCoMember_lbl" xml:lang="en-US">Cantor Fitzgerald &amp;amp; Co [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_PurchaseWarrantsMember" xlink:label="avxl_PurchaseWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrantsMember" xlink:to="avxl_PurchaseWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrantsMember_lbl" xml:lang="en-US">Purchase Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_PurchaseWarrants1Member" xlink:label="avxl_PurchaseWarrants1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants1Member" xlink:to="avxl_PurchaseWarrants1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrants1Member_lbl" xml:lang="en-US">Purchase Warrants 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_PurchaseWarrants2Member" xlink:label="avxl_PurchaseWarrants2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants2Member" xlink:to="avxl_PurchaseWarrants2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrants2Member_lbl" xml:lang="en-US">Purchase Warrants 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_StockOptionPlan2015Member" xlink:label="avxl_StockOptionPlan2015Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2015Member" xlink:to="avxl_StockOptionPlan2015Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2015Member_lbl" xml:lang="en-US">2015 Omnibus Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_OptionsMember" xlink:label="avxl_OptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionsMember" xlink:to="avxl_OptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionsMember_lbl" xml:lang="en-US">Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_StockOptionPlan2019Member" xlink:label="avxl_StockOptionPlan2019Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2019Member" xlink:to="avxl_StockOptionPlan2019Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2019Member_lbl" xml:lang="en-US">2019 Omnibus Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_2_lbl" xml:lang="en-US">Common Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_2_lbl" xml:lang="en-US">Additional Paid-In Capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsMember_2_lbl" xml:lang="en-US">Accumulated Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_ParkinsonMember" xlink:label="avxl_ParkinsonMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ParkinsonMember" xlink:to="avxl_ParkinsonMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ParkinsonMember_lbl" xml:lang="en-US">Parkinson [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesReceivable" xlink:to="us-gaap_IncomeTaxesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesReceivable_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses and deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeCurrent" xlink:to="us-gaap_DeferredIncomeCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeCurrent_lbl" xml:lang="en-US">Deferred grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies - Note 5</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Capital stock Authorized: 10,000,000 preferred stock, par value $0.001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Capital stock Authorized: 100,000,000 common shares, par value $0.001 per share Issued and outstanding: 70,030,620 common shares (September 30, 2020 - 62,045,198)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expenses)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="avxl_NonOperatingIncomeFromGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingIncomeFromGrant" xlink:to="avxl_NonOperatingIncomeFromGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NonOperatingIncomeFromGrant_lbl" xml:lang="en-US">Grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ResearchAndDevelopmentIncentiveIncome" xlink:to="avxl_ResearchAndDevelopmentIncentiveIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign exchange gain (loss), net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Net loss before provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense, current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss and comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Net Loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted average number of shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash Flows used in Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in non-cash working capital balances related to operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses and deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash Flows provided by Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US">Share issue costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Increase in cash and cash equivalents during the period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance beginning, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Shares issued under 2019 purchase agreement Purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Shares issued under 2019 purchase agreement Purchase shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:label="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:to="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_lbl" xml:lang="en-US">Shares issued under 2019 purchase agreement Commitment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:label="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:to="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_lbl" xml:lang="en-US">Shares issued under 2019 purchase agreement Commitment shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Shares issued upon exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_SharesIssuedUponExerciseOfOptionsShares" xlink:label="avxl_SharesIssuedUponExerciseOfOptionsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedUponExerciseOfOptionsShares" xlink:to="avxl_SharesIssuedUponExerciseOfOptionsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedUponExerciseOfOptionsShares_lbl" xml:lang="en-US">Shares issued upon exercise of options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Shares issued under Sales Agreement, net of shares issue costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Shares issued under Sales Agreement, net of shares issue costs, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance ending, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Business Description and Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="avxl_DisclosureOtherIncomeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DisclosureOtherIncomeAbstract" xlink:to="avxl_DisclosureOtherIncomeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DisclosureOtherIncomeAbstract_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_OtherIncomeDisclosureTextBlock" xlink:label="avxl_OtherIncomeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherIncomeDisclosureTextBlock" xlink:to="avxl_OtherIncomeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_OtherIncomeDisclosureTextBlock_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_DisclosureEquityOfferingAgreementsAbstract" xlink:label="avxl_DisclosureEquityOfferingAgreementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DisclosureEquityOfferingAgreementsAbstract" xlink:to="avxl_DisclosureEquityOfferingAgreementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DisclosureEquityOfferingAgreementsAbstract_lbl" xml:lang="en-US">Equity Offering Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_EquityOfferingAgreementsTextBlock" xlink:label="avxl_EquityOfferingAgreementsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingAgreementsTextBlock" xlink:to="avxl_EquityOfferingAgreementsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_EquityOfferingAgreementsTextBlock_lbl" xml:lang="en-US">Equity Offering Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements Not Yet Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of exercisable share purchase warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:label="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:to="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_lbl" xml:lang="en-US">Schedule of share purchase warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of outstanding stock purchase options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of general and administrative expenses and research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted average assumptions for fair value of each option award</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Loss per share for potentially dilutive common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="dei_LegalEntityAxis_2_lbl" xml:lang="en-US">Series [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="avxl_ValueOfSharesObligatedToPurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ValueOfSharesObligatedToPurchase" xlink:to="avxl_ValueOfSharesObligatedToPurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ValueOfSharesObligatedToPurchase_lbl" xml:lang="en-US">Total number of shares obligated to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Share issued for offering, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:to="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_lbl" xml:lang="en-US">Pro rata basic number of shares obligated to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues4" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues4_lbl" xml:lang="en-US">Number of shares issued for aggregate purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues3_lbl" xml:lang="en-US">Number of shares issued for aggregate purchase price, value</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues3_lbl" xml:lang="en-US">Number of shares issued for commitment</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues4" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues4_lbl" xml:lang="en-US">Amount of shares remain available</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="avxl_PercentageOfGrossProceedsFromSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PercentageOfGrossProceedsFromSales" xlink:to="avxl_PercentageOfGrossProceedsFromSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PercentageOfGrossProceedsFromSales_lbl" xml:lang="en-US">Percentage of gross proceeds from sales</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_GrossProceedsFromSaleOfCommonStock" xlink:label="avxl_GrossProceedsFromSaleOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_GrossProceedsFromSaleOfCommonStock" xlink:to="avxl_GrossProceedsFromSaleOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_GrossProceedsFromSaleOfCommonStock_lbl" xml:lang="en-US">Gross proceeds from sale of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceed from offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Share Purchase Warrants Balance, at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price warrants outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_lbl" xml:lang="en-US">Share Purchase Warrants Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_lbl" xml:lang="en-US">Weighted Average Exercise Price warrants granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Share Purchase Warrants Balance, at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price Balance, at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Warrants and Rights Outstanding, Maturity Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Options Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Option Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options Outstanding at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate intrinsic value Outstanding at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life of options (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Annualized volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Maximum number of common shares reserved for future issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Additional shares of common stock available for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xml:lang="en-US">Description of grant option</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Expiration period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_3_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Remaining stock based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CantorFitzgeraldAndCoMember" xlink:to="avxl_CantorFitzgeraldAndCoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_CantorFitzgeraldAndCoMember_doc" xml:lang="en-US">Represents information related to cantor fitzgerald and co.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:to="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_doc" xml:lang="en-US">Commitment shares issued shares underterms of purchase agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:to="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_doc" xml:lang="en-US">Commitment shares Issued value Underterms of purchase agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingSalesAgreementMember" xlink:to="avxl_EquityOfferingSalesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EquityOfferingSalesAgreementMember_doc" xml:lang="en-US">Represents information related to equity offering sales agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LincolnParkCapitalFundLLCMember" xlink:to="avxl_LincolnParkCapitalFundLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_LincolnParkCapitalFundLLCMember_doc" xml:lang="en-US">Information related to type of legal entity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:to="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_doc" xml:lang="en-US">Information related to number of shares obligated to purchase prorata basic.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PercentageOfGrossProceedsFromSales" xlink:to="avxl_PercentageOfGrossProceedsFromSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PercentageOfGrossProceedsFromSales_doc" xml:lang="en-US">Represents information related to percentage of gross proceeds from sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreement1Member" xlink:to="avxl_PurchaseAgreement1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PurchaseAgreement1Member_doc" xml:lang="en-US">Represents the information pertaining to purchase agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrantsMember" xlink:to="avxl_PurchaseWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PurchaseWarrantsMember_doc" xml:lang="en-US">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Information related to share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues3_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues3_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues4_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues4_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues3_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues3_doc" xml:lang="en-US">Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues4_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues4_doc" xml:lang="en-US">Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2015Member" xlink:to="avxl_StockOptionPlan2015Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockOptionPlan2015Member_doc" xml:lang="en-US">Information related to type of plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2019Member" xlink:to="avxl_StockOptionPlan2019Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockOptionPlan2019Member_doc" xml:lang="en-US">Represents the information pertaining to stock option.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ValueOfSharesObligatedToPurchase" xlink:to="avxl_ValueOfSharesObligatedToPurchase_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ValueOfSharesObligatedToPurchase_doc" xml:lang="en-US">Information related to value of shares obligated to purchase initially.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_2_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_2_lbl" xml:lang="en-US">Payments of Financing Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_2_lbl" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherIncomeDisclosureTextBlock" xlink:to="avxl_OtherIncomeDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OtherIncomeDisclosureTextBlock_2_lbl" xml:lang="en-US">Number of shares issued for aggregate purchase price [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingAgreementsTextBlock" xlink:to="avxl_EquityOfferingAgreementsTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EquityOfferingAgreementsTextBlock_2_lbl" xml:lang="en-US">Shares issued under 2015 Purchase Agreement - Commitment shares (in shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>avxl-20210331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Created by Electro Filings, LLC- http://www.electrofilings.com -->
    <!-- Field: Doc-Info; Name: Source; Value: avxl.xfr; Date: 2021%2D05%2D13T17:07:21Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20210331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:href="avxl-20210331.xsd#InterimCondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20210331.xsd#InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:href="avxl-20210331.xsd#InterimCondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:href="avxl-20210331.xsd#InterimCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="avxl-20210331.xsd#InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:href="avxl-20210331.xsd#BusinessDescriptionAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncements" xlink:href="avxl-20210331.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20210331.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreements" xlink:href="avxl-20210331.xsd#EquityOfferingAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20210331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:href="avxl-20210331.xsd#RecentAccountingPronouncementsPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20210331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:href="avxl-20210331.xsd#BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20210331.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" xlink:href="avxl-20210331.xsd#EquityOfferingAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20210331.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20210331.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20210331.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20210331.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20210331.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20210331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaapIncomeTaxesReceivable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapIncomeTaxesReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="loc_us-gaapDeferredIncomeCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredIncomeCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlNonOperatingIncomeFromGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&apos; EQUITY (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:label="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:label="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_SharesIssuedUponExerciseOfOptionsShares" xlink:label="loc_avxlSharesIssuedUponExerciseOfOptionsShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUponExerciseOfOptionsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Business Description and Basis of Presentation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncements" xlink:title="00000008 - Disclosure - Recent Accounting Pronouncements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000009 - Disclosure - Other Income">
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="loc_avxlDisclosureOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_OtherIncomeDisclosureTextBlock" xlink:label="loc_avxlOtherIncomeDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureOtherIncomeAbstract" xlink:to="loc_avxlOtherIncomeDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreements" xlink:title="00000010 - Disclosure - Equity Offering Agreements">
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_DisclosureEquityOfferingAgreementsAbstract" xlink:label="loc_avxlDisclosureEquityOfferingAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_EquityOfferingAgreementsTextBlock" xlink:label="loc_avxlEquityOfferingAgreementsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureEquityOfferingAgreementsAbstract" xlink:to="loc_avxlEquityOfferingAgreementsTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="00000011 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:title="00000012 - Disclosure - Recent Accounting Pronouncements (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="00000013 - Disclosure - Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherShareBasedCompensationActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:label="loc_avxlScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_avxlScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:title="00000014 - Disclosure - Business Description and Basis of Presentation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000015 - Disclosure - Other Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="loc_avxlDisclosureOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureOtherIncomeAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_ParkinsonMember" xlink:label="loc_avxlParkinsonMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_avxlParkinsonMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCurrencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AUD" xlink:label="loc_currencyAUD" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlNonOperatingIncomeFromGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" xlink:title="00000016 - Disclosure - Equity Offering Agreements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_DisclosureEquityOfferingAgreementsAbstract" xlink:label="loc_avxlDisclosureEquityOfferingAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureEquityOfferingAgreementsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_PurchaseAgreement1Member" xlink:label="loc_avxlPurchaseAgreement1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="loc_avxlEquityOfferingSalesAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlEquityOfferingSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="loc_avxlLincolnParkCapitalFundLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlLincolnParkCapitalFundLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="loc_avxlCantorFitzgeraldAndCoMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlCantorFitzgeraldAndCoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="loc_avxlValueOfSharesObligatedToPurchase" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlValueOfSharesObligatedToPurchase" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues4" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues4" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues3" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues3" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues4" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues4" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="loc_avxlPercentageOfGrossProceedsFromSales" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlPercentageOfGrossProceedsFromSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_GrossProceedsFromSaleOfCommonStock" xlink:label="loc_avxlGrossProceedsFromSaleOfCommonStock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlGrossProceedsFromSaleOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000017 - Disclosure - Commitments and Contingencies (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_PurchaseWarrantsMember" xlink:label="loc_avxlPurchaseWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000018 - Disclosure - Commitments and Contingencies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_PurchaseWarrants1Member" xlink:label="loc_avxlPurchaseWarrants1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_PurchaseWarrants2Member" xlink:label="loc_avxlPurchaseWarrants2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="00000019 - Disclosure - Commitments and Contingencies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="00000020 - Disclosure - Commitments and Contingencies (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="00000021 - Disclosure - Commitments and Contingencies (Details 4)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000022 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_StockOptionPlan2019Member" xlink:label="loc_avxlStockOptionPlan2019Member" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2019Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20210331.xsd#avxl_OptionsMember" xlink:label="loc_avxlOptionsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140014989367272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>May 11, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ANAVEX LIFE SCIENCES CORP.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001314052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,038,920<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140014989418600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 75,859,339<span></span>
</td>
<td class="nump">$ 29,249,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Incentive and tax receivables</a></td>
<td class="nump">7,328,090<span></span>
</td>
<td class="nump">4,849,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and deposits</a></td>
<td class="nump">386,809<span></span>
</td>
<td class="nump">443,839<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">83,574,238<span></span>
</td>
<td class="nump">34,542,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,658,052<span></span>
</td>
<td class="nump">3,989,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">3,618,779<span></span>
</td>
<td class="nump">3,316,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeCurrent', window );">Deferred grant income</a></td>
<td class="nump">487,111<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Liabilities</a></td>
<td class="nump">7,763,942<span></span>
</td>
<td class="nump">7,305,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Capital stock Authorized: 100,000,000 common shares, par value $0.001 per share Issued and outstanding: 70,030,620 common shares (September 30, 2020 - 62,045,198)</a></td>
<td class="nump">70,032<span></span>
</td>
<td class="nump">62,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">251,427,781<span></span>
</td>
<td class="nump">186,851,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(175,687,517)<span></span>
</td>
<td class="num">(159,677,230)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">75,810,296<span></span>
</td>
<td class="nump">27,236,569<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 83,574,238<span></span>
</td>
<td class="nump">$ 34,542,197<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28183603&amp;loc=d3e692-112598<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140014989354120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">70,030,620<span></span>
</td>
<td class="nump">62,045,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">70,030,620<span></span>
</td>
<td class="nump">62,045,198<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140014991782952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 2,233,745<span></span>
</td>
<td class="nump">$ 1,720,142<span></span>
</td>
<td class="nump">$ 3,704,401<span></span>
</td>
<td class="nump">$ 3,072,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">6,720,841<span></span>
</td>
<td class="nump">6,053,047<span></span>
</td>
<td class="nump">14,646,360<span></span>
</td>
<td class="nump">12,401,715<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="num">(8,954,586)<span></span>
</td>
<td class="num">(7,773,189)<span></span>
</td>
<td class="num">(18,350,761)<span></span>
</td>
<td class="num">(15,473,891)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expenses)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrant', window );">Grant income</a></td>
<td class="nump">10,820<span></span>
</td>
<td class="nump">74,944<span></span>
</td>
<td class="nump">10,820<span></span>
</td>
<td class="nump">149,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ResearchAndDevelopmentIncentiveIncome', window );">Research and development incentive income</a></td>
<td class="nump">960,879<span></span>
</td>
<td class="nump">717,328<span></span>
</td>
<td class="nump">2,230,195<span></span>
</td>
<td class="nump">1,660,543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income, net</a></td>
<td class="nump">9,216<span></span>
</td>
<td class="nump">70,180<span></span>
</td>
<td class="nump">7,657<span></span>
</td>
<td class="nump">116,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gain (loss), net</a></td>
<td class="num">(154,563)<span></span>
</td>
<td class="num">(325,960)<span></span>
</td>
<td class="nump">178,071<span></span>
</td>
<td class="num">(272,848)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">826,352<span></span>
</td>
<td class="nump">536,492<span></span>
</td>
<td class="nump">2,426,743<span></span>
</td>
<td class="nump">1,654,483<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before provision for income taxes</a></td>
<td class="num">(8,128,234)<span></span>
</td>
<td class="num">(7,236,697)<span></span>
</td>
<td class="num">(15,924,018)<span></span>
</td>
<td class="num">(13,819,408)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Income tax expense, current</a></td>
<td class="num">(26,988)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(86,269)<span></span>
</td>
<td class="num">(9,214)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (8,155,222)<span></span>
</td>
<td class="num">$ (7,236,697)<span></span>
</td>
<td class="num">$ (16,010,287)<span></span>
</td>
<td class="num">$ (13,828,622)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="nump">68,594,867<span></span>
</td>
<td class="nump">58,353,954<span></span>
</td>
<td class="nump">66,421,380<span></span>
</td>
<td class="nump">56,544,037<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonOperatingIncomeFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonOperatingIncomeFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ResearchAndDevelopmentIncentiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ResearchAndDevelopmentIncentiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140014989390936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows used in Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (16,010,287)<span></span>
</td>
<td class="num">$ (13,828,622)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,785,470<span></span>
</td>
<td class="nump">2,965,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in non-cash working capital balances related to operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Incentive and tax receivables</a></td>
<td class="num">(2,478,750)<span></span>
</td>
<td class="num">(1,509,202)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and deposits</a></td>
<td class="nump">57,030<span></span>
</td>
<td class="nump">195,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(331,002)<span></span>
</td>
<td class="nump">126,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">302,205<span></span>
</td>
<td class="nump">1,062,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred grant income</a></td>
<td class="nump">487,111<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(15,188,223)<span></span>
</td>
<td class="num">(10,988,051)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows provided by Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common shares</a></td>
<td class="nump">61,934,439<span></span>
</td>
<td class="nump">15,365,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Share issue costs</a></td>
<td class="num">(1,134,697)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">998,802<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">61,798,544<span></span>
</td>
<td class="nump">15,365,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Increase in cash and cash equivalents during the period</a></td>
<td class="nump">46,610,321<span></span>
</td>
<td class="nump">4,377,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">29,249,018<span></span>
</td>
<td class="nump">22,185,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">$ 75,859,339<span></span>
</td>
<td class="nump">$ 26,563,071<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140014984928744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Sep. 30, 2019</a></td>
<td class="nump">$ 52,652<span></span>
</td>
<td class="nump">$ 153,633,807<span></span>
</td>
<td class="num">$ (133,396,760)<span></span>
</td>
<td class="nump">$ 20,289,699<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance beginning, shares at Sep. 30, 2019</a></td>
<td class="nump">52,650,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued under 2019 purchase agreement Purchase shares</a></td>
<td class="nump">$ 5,965<span></span>
</td>
<td class="nump">15,359,527<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">15,365,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued under 2019 purchase agreement Purchase shares, shares</a></td>
<td class="nump">5,964,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2', window );">Shares issued under 2019 purchase agreement Commitment shares</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="num">(49)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2', window );">Shares issued under 2019 purchase agreement Commitment shares, shares</a></td>
<td class="nump">49,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,965,177<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,965,177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(13,828,622)<span></span>
</td>
<td class="num">(13,828,622)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2020</a></td>
<td class="nump">$ 58,666<span></span>
</td>
<td class="nump">171,958,462<span></span>
</td>
<td class="num">(147,225,382)<span></span>
</td>
<td class="nump">24,791,746<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance ending, shares at Mar. 31, 2020</a></td>
<td class="nump">58,664,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2019</a></td>
<td class="nump">$ 57,082<span></span>
</td>
<td class="nump">165,891,753<span></span>
</td>
<td class="num">(139,988,685)<span></span>
</td>
<td class="nump">25,960,150<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance beginning, shares at Dec. 31, 2019</a></td>
<td class="nump">57,080,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued under 2019 purchase agreement Purchase shares</a></td>
<td class="nump">$ 1,571<span></span>
</td>
<td class="nump">4,365,969<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,367,540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued under 2019 purchase agreement Purchase shares, shares</a></td>
<td class="nump">1,570,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2', window );">Shares issued under 2019 purchase agreement Commitment shares</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2', window );">Shares issued under 2019 purchase agreement Commitment shares, shares</a></td>
<td class="nump">14,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,700,753<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,700,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,236,697)<span></span>
</td>
<td class="num">(7,236,697)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2020</a></td>
<td class="nump">$ 58,666<span></span>
</td>
<td class="nump">171,958,462<span></span>
</td>
<td class="num">(147,225,382)<span></span>
</td>
<td class="nump">24,791,746<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance ending, shares at Mar. 31, 2020</a></td>
<td class="nump">58,664,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Sep. 30, 2020</a></td>
<td class="nump">$ 62,047<span></span>
</td>
<td class="nump">186,851,752<span></span>
</td>
<td class="num">(159,677,230)<span></span>
</td>
<td class="nump">27,236,569<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance beginning, shares at Sep. 30, 2020</a></td>
<td class="nump">62,045,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued under 2019 purchase agreement Purchase shares</a></td>
<td class="nump">$ 4,008<span></span>
</td>
<td class="nump">24,107,190<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">24,111,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued under 2019 purchase agreement Purchase shares, shares</a></td>
<td class="nump">4,007,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2', window );">Shares issued under 2019 purchase agreement Commitment shares</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2', window );">Shares issued under 2019 purchase agreement Commitment shares, shares</a></td>
<td class="nump">78,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued upon exercise of options</a></td>
<td class="nump">$ 347<span></span>
</td>
<td class="nump">998,455<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">998,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedUponExerciseOfOptionsShares', window );">Shares issued upon exercise of options, shares</a></td>
<td class="nump">346,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued under Sales Agreement, net of shares issue costs</a></td>
<td class="nump">$ 3,552<span></span>
</td>
<td class="nump">36,684,992<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">36,688,544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued under Sales Agreement, net of shares issue costs, shares</a></td>
<td class="nump">3,552,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,785,470<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,785,470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(16,010,287)<span></span>
</td>
<td class="num">(16,010,287)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2021</a></td>
<td class="nump">$ 70,032<span></span>
</td>
<td class="nump">251,427,781<span></span>
</td>
<td class="num">(175,687,517)<span></span>
</td>
<td class="nump">75,810,296<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance ending, shares at Mar. 31, 2021</a></td>
<td class="nump">70,030,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2020</a></td>
<td class="nump">$ 66,964<span></span>
</td>
<td class="nump">213,766,108<span></span>
</td>
<td class="num">(167,532,295)<span></span>
</td>
<td class="nump">46,300,777<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance beginning, shares at Dec. 31, 2020</a></td>
<td class="nump">66,962,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued under 2019 purchase agreement Purchase shares</a></td>
<td class="nump">$ 662<span></span>
</td>
<td class="nump">6,649,134<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,649,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued under 2019 purchase agreement Purchase shares, shares</a></td>
<td class="nump">661,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2', window );">Shares issued under 2019 purchase agreement Commitment shares</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2', window );">Shares issued under 2019 purchase agreement Commitment shares, shares</a></td>
<td class="nump">21,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued upon exercise of options</a></td>
<td class="nump">$ 347<span></span>
</td>
<td class="nump">998,455<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">998,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedUponExerciseOfOptionsShares', window );">Shares issued upon exercise of options, shares</a></td>
<td class="nump">346,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued under Sales Agreement, net of shares issue costs</a></td>
<td class="nump">$ 2,037<span></span>
</td>
<td class="nump">28,167,950<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">28,169,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued under Sales Agreement, net of shares issue costs, shares</a></td>
<td class="nump">2,037,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,846,156<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,846,156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,155,222)<span></span>
</td>
<td class="num">(8,155,222)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2021</a></td>
<td class="nump">$ 70,032<span></span>
</td>
<td class="nump">$ 251,427,781<span></span>
</td>
<td class="num">$ (175,687,517)<span></span>
</td>
<td class="nump">$ 75,810,296<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance ending, shares at Mar. 31, 2021</a></td>
<td class="nump">70,030,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment shares issued shares underterms of purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment shares Issued value Underterms of purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedUponExerciseOfOptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedUponExerciseOfOptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140015082321560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Description and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Business Description and Basis of Presentation</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; width: 53px"><font style="font-size: 10pt">Note 1</font></td>
    <td style="width: 3px">&#160;</td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><u>Business Description and Basis of Presentation</u></font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">Business</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">Anavex Life Sciences Corp. (&#8220;Anavex&#8221;
or the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics
by applying precision medicine to central nervous system (&#8220;CNS&#8221;) diseases with high unmet need. Anavex analyzes genomic data
from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment
of neurodegenerative and neurodevelopmental diseases. The Company&#8217;s lead compound ANAVEX<sup>&#174;</sup>2-73 is being developed
to treat Alzheimer&#8217;s disease, Parkinson&#8217;s disease and potentially other central nervous system diseases, including rare diseases,
such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein
2 (&#8220;MECP2&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">Basis of Presentation</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">These unaudited interim condensed consolidated
financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;)
and accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim reporting. Accordingly,
certain information and note disclosures normally included in the annual financial statements in accordance with U.S. GAAP have been condensed
or omitted pursuant to such rules and regulations. In the opinion of management, the disclosures are adequate to make the information
presented not misleading.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">These accompanying unaudited interim condensed
consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management
are necessary for fair presentation of the information contained herein. The consolidated balance sheet as of September 30, 2020 was derived
from the audited annual financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited interim
condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes
thereto included in the Company&#8217;s annual report on Form 10-K for the year ended September 30, 2020 filed with the SEC on December
28, 2020. The Company follows the same accounting policies in the preparation of interim reports.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">Operating results for the six months ended
March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending September 30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">Liquidity</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">All of the Company&#8217;s potential drug
compounds are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful
or, if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial
revenues. To date, we have not generated any revenues from our operations. The Company expects the business to continue to experience
negative cash flows for the foreseeable future and cannot predict when, if ever, our business might become profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">The Company believes that its existing cash
and cash equivalents, along with existing financial commitments from third parties, will be sufficient to meet its cash commitments for
up to three years after the date that these interim condensed consolidated financial statements are issued. The process of drug development
can be costly, and the timing and outcomes of clinical trials is uncertain.&#160;The assumptions upon which the Company has based its
estimates are routinely evaluated and may be subject to change.&#160;The actual amount of the Company&#8217;s expenditures will vary depending
upon a number of factors including but not limited to the design, timing and duration of future clinical trials, the progress of the Company&#8217;s
research and development programs and the level of financial resources available. The Company has the ability to adjust its operating
plan spending levels based on the timing of future clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">Other than our rights related to the Sales
Agreement (as defined below in Note 4), there can be no assurance that additional financing will be available to us when needed or, if
available, that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional financing on
a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">In December 2019, a novel strain of coronavirus,
COVID-19, was reported to have surfaced in Wuhan, China. In March 2020, the World Health Organization declared COVID-19 to be a global
pandemic as a result of the rapid spread of the virus beyond its point of origin.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">The global outbreak of COVID-19 continues
to rapidly evolve as of the date these interim condensed consolidated financial statements are issued. As such, it is uncertain as to
the full magnitude that the outbreak will have on the Company&#8217;s financial condition and future results of operations. Management
is actively monitoring the global situation on its business, including on its clinical trials and operations and financial condition.
The effects of COVID-19 did not have a material impact on the Company&#8217;s result of operations or financial condition for the period
ended March 31, 2021. However, given the daily evolution of the COVID-19 situation, and the global responses to curb its spread, the Company
is not able to estimate the effects COVID-19 may have on its future results of operations or financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">Use of Estimates</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; color: gray">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">The preparation of financial statements in
accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
at the date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly
evaluates estimates and assumptions related to accounting for research and development costs, valuation and recoverability of deferred
tax assets, asset impairment, stock-based compensation, and loss contingencies. The Company bases its estimates and assumptions on current
facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which
form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are
not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">Principles of Consolidation</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">These consolidated financial statements include
the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited., a company incorporated under
the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex Canada Ltd., a company incorporated
under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">Fair Value Measurements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; color: gray">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">The fair value hierarchy under GAAP is based
on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair
value which are the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">Level 1 - &#9;&#160;quoted
prices (unadjusted) in active markets for identical assets or liabilities;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">Level 2 - &#160;&#160;observable
inputs other than Level 1, quoted prices for similar assets or liabilities in active &#9;&#9;markets, quoted prices for identical or similar
assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value
drivers are observable; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">Level 3 - &#9;&#160;assets
and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant to the fair
value of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">The book value of cash and cash equivalents
and accounts payable and accrued liabilities approximate their fair values due to the short-term maturity of those instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">At March 31, 2021 and September 30, 2020,
the Company did not have any Level 3 assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">Basic and Diluted Loss per Share</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; color: gray">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">Basic income/(loss) per common share is computed
by dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the
period. Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of
(1) the weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options
and warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the
diluted net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation
of diluted net loss per share because their effect would be anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">As of March 31, 2021, loss per share excludes
11,505,199 (September 30, 2020 &#8211; 10,576,266) potentially dilutive common shares related to outstanding options and warrants, as
their effect was anti-dilutive.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140014991346296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; width: 53px"><font style="font-size: 10pt">Note 2</font></td>
    <td style="width: 3px">&#160;</td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><u>Recent Accounting Pronouncements</u></font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><i>Recent Accounting Pronouncements Not
Yet Adopted</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The Company does not expect the adoption
of recently issued accounting pronouncements to have a significant impact on its results of operations, financial position or cash flows.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (c)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140015075217816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_DisclosureOtherIncomeAbstract', window );"><strong>Other Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_OtherIncomeDisclosureTextBlock', window );">Other Income</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; width: 53px"><font style="font-size: 10pt">Note 3</font></td>
    <td style="width: 3px">&#160;</td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><u>Other Income</u></font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">Grant Income</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">During the six months
ended March 31, 2021, the Company received $497,931 of a $995,862 research grant awarded by the Michael J. Fox Foundation for Parkinson&#8217;s
Research. The grant will be used to fund a clinical trial in the Company&#8217;s lead compound, ANAVEX<sup>&#174;</sup>2-73 for the treatment
of Parkinson&#8217;s disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">The grant income
is being deferred when received and amortized to other income as the related research and development expenditures are incurred. During
the three and six months ended March 31, 2021, the Company recognized $10,820 and $10,820, respectively (2020: $0 and $0, respectively)
of this grant on its statements of operations within grant income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">During the year
ended September 30, 2017, the Company was awarded grant funding in the amount of $597,886. The grant was received in equal quarterly installments
over a period of two years ending during the year ended September 30, 2020, in exchange for a commitment to complete clinical testing
for a therapeutic drug candidate for the treatment of Rett syndrome.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">The grant income
was deferred when received and amortized to other income as the related research and development expenditures were incurred. During the
three and six months ended March 31, 2020, the Company recognized $74,944 and $149,888, respectively of this grant on its statements of
operations within grant income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">Research and Development
Incentive Income</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">Research and development
incentive income represents the receipt by the Company&#8217;s Australian subsidiary, of the Australian research and development incentive
credit, (the &#8220;ATO R&#38;D Credit&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; background-color: white">During the three
and six months ended March 31, 2021, the Company recorded research and development incentive income of $960,879 (AUD 1,244,133) and $2,230,195
(AUD 2,980,095) (2020: $717,328 (AUD 1,203,000) and $1,660,543 (AUD 2,548,000)), respectively, in respect of the ATO R&#38;D Credit for
eligible research and development expenses incurred during the period.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureOtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureOtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OtherIncomeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OtherIncomeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140014991292792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offering Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_DisclosureEquityOfferingAgreementsAbstract', window );"><strong>Equity Offering Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_EquityOfferingAgreementsTextBlock', window );">Equity Offering Agreements</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; width: 53px"><font style="font-size: 10pt">Note 4</font></td>
    <td style="width: 3px">&#160;</td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><u>Equity Offering Agreements</u> </font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">2019 Purchase Agreement</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">On June 7, 2019, the Company entered into
a $50,000,000 purchase agreement (the &#8220;2019 Purchase Agreement&#8221;) with Lincoln Park, as amended on July 1, 2020, pursuant to
which the Company had the right to sell and issue to Lincoln Park, and Lincoln Park was obligated to purchase, up to $50,000,000 in value
of its shares of common stock from time to time over a three-year period until July 1, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">In consideration for entering into the 2019
Purchase Agreement, the Company issued to Lincoln Park 324,383 shares of common stock as a commitment fee during the year ended September
30, 2019 and agreed to issue up to 162,191 shares pro rata, when and if, Lincoln Park purchased, at the Company&#8217;s discretion, the
$50,000,000 aggregate commitment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">During the six months ended March 31, 2021,
the Company issued to Lincoln Park an aggregate of 4,086,209 (2020 &#8211; 6,014,425) shares of common stock under the 2019 Purchase Agreement,
including 4,007,996 (2020: 5,964,584) shares of common stock for an aggregate purchase price of $24,111,198 (2020: $15,365,492) and 78,213
(2020: 49,841) commitment shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">At March 31, 2021, no amount remained available
under the 2019 Purchase Agreement (September 30, 2020: $24,111,198).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">Sales Agreement</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">The Company entered into a Controlled Equity
Offering Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020 (the &#8220;Sales Agreement&#8221;) with Cantor
Fitzgerald&#160;&#38; Co. and SVB Leerink LLC (together the &#8220;Sales Agents&#8221;), pursuant to which the Company may offer and sell
shares of common stock registered under an effective registration statement from time to time through the Sales Agents (the &#8220;Offering&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">Upon delivery of a placement notice based
on the Company&#8217;s instructions and subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell the Shares
by methods deemed to be an &#8220;at the market offering&#8221; offering, in negotiated transactions at market prices prevailing at the
time of sale or at prices related to such prevailing market prices, or by any other method permitted by law, including negotiated transactions,
subject to the prior written consent of the Company. The Company is not obligated to make any sales of Shares under the Sales Agreement.
The Company or Sales Agents may suspend or terminate the offering of Shares upon notice to the other party, subject to certain conditions.
The Sales Agents will act as agent on a commercially reasonable efforts basis consistent with their normal trading and sales practices
and applicable state and federal law, rules&#160;and regulations and the rules&#160;of Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">The Company has agreed to pay the Sales Agents
commissions for their services of up to 3.0% of the gross proceeds from the sale of the Shares pursuant to the Sales Agreement. The Company
also agreed to provide the Sales Agents with customary indemnification and contribution rights. During the six months ended March 31,
2021, 3,552,313 shares were sold pursuant to the Offering for gross proceeds of $37,823,241 (net proceeds of $36,688,544 after deducting
offering expenses).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureEquityOfferingAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureEquityOfferingAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_EquityOfferingAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_EquityOfferingAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140015082097912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; width: 53px"><font style="font-size: 10pt">Note 5</font></td>
    <td style="width: 3px">&#160;</td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><u>Commitments and Contingencies</u></font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 56px">&#160;</td>
    <td style="font: 12pt Times New Roman, Times, Serif; width: 24px"><font style="font-size: 10pt">a)</font></td>
    <td style="font: 12pt Times New Roman, Times, Serif"><font style="font-size: 10pt">Leases </font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; color: gray">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">During the three and six months ended March
31, 2021, the Company incurred office lease expense of $29,903 and $98,290, respectively (2020: $60,861 and $110,915, respectively).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 56px">&#160;</td>
    <td style="font: 12pt Times New Roman, Times, Serif; width: 24px"><font style="font-size: 10pt">b)</font></td>
    <td style="font: 12pt Times New Roman, Times, Serif"><font style="font-size: 10pt">Litigation</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; color: gray">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">The Company is subject to claims and legal
proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there can be no guarantee that the
outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will not have a material
adverse effect upon the Company&#8217;s consolidated financial statements. The Company does not believe that any of such pending claims
and legal proceedings will have a material adverse effect on its consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 56px">&#160;</td>
    <td style="font: 12pt Times New Roman, Times, Serif; width: 24px"><font style="font-size: 10pt">c)</font></td>
    <td style="font: 12pt Times New Roman, Times, Serif"><font style="font-size: 10pt">Share Purchase Warrants</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; color: gray">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">A summary of the status of the Company&#8217;s
outstanding share purchase warrants is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="3" style="text-align: center"><font style="font-size: 10pt">Number of Shares</font></td>
    <td style="text-align: center">&#160;</td>
    <td colspan="3" style="text-align: center"><font style="font-size: 10pt">Weighted Average Exercise Price ($)</font></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 49%; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Balance, September 30, 2019</font></td>
    <td style="width: 1%; padding-left: 10pt; text-indent: -10pt">&#160;</td>
    <td style="width: 8%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">350,000</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">4.19</font></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Granted</font></td>
    <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">150,000</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">3.17</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Balance, September 30, 2020 and March 31, 2021</font></td>
    <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">500,000</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3.88</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">At March 31, 2021, the Company had share
purchase warrants outstanding as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Number</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Exercise Price</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Expiry Date</font></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">350,000</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 7%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">4.19</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 7%">&#160;</td>
    <td style="width: 52%; text-align: right"><font style="font-size: 10pt">June 30, 2021</font></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">150,000</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">3.17</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">May 6, 2024</font></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">500,000</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">2015 Stock Option Plan</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">On September 18, 2015, the Company&#8217;s
board of directors approved a 2015 Omnibus Incentive Plan (the &#8220;2015 Plan&#8221;), which provided for the grant of stock options
and restricted stock awards to directors, officers, employees and consultants of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">The maximum number of our common shares reserved
for issue under the plan was 6,050,553 shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization. At
March 31, 2021, 146,371 (September 30, 2020: 146,371) options remain available for issue under the 2015 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">2019 Stock Option Plan</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">On January 15, 2019, the Board approved the
2019 Omnibus Incentive Plan (the &#8220;2019 Plan&#8221;), which provides for the grant of stock options and restricted stock awards to
directors, officers, employees, consultants and advisors of the Company. Under the terms of the 2019 Plan, 6,000,000 additional shares
of Common Stock are available for issuance under the 2019 Plan, in addition to the shares available under the 2015 Plan. Any awards outstanding
under the 2015 Plan or the Company&#8217;s 2007 Stock Option Plan (the &#8220;2007 Plan&#8221;) will remain subject to and be paid under
the 2015 Plan or the 2007 Plan, respectively, and any shares subject to outstanding awards under the 2015 Plan or the 2007 Plan that subsequently
cease to be subject to such awards (other than by reason of settlement of the awards in shares) will automatically become available for
issuance under the 2019 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">The 2019 Plan provides that it may be administered
by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined by the board of directors
at the time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date,
then the exercise price shall not be less than 110% of fair market value of the Company&#8217;s shares of common stock on the grant date.
Stock options may be granted under the 2019 Plan for an exercise period of up to ten years from the date of grant of the option or such
lesser periods as may be determined by the board, subject to earlier termination in accordance with the terms of the 2019 Plan. At March
31, 2021, 1,856,665 (September 30, 2020: 3,161,665) options remain available for issue under the 2019 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">A summary of the status of Company&#8217;s
outstanding stock purchase options is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Number of Shares</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Weighted Average Exercise Price ($)</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Weighted Average Grant Date Fair Value ($)</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Aggregate intrinsic value ($)</font></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 39%; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Outstanding, September 30, 2019</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right"><font style="font-size: 10pt">8,462,933</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right"><font style="font-size: 10pt">3.58</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right"><font style="font-size: 10pt">4,115,032</font></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,695,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">2.96</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">2.27</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Forfeited</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(68,332</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3.01</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Exercised</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(13,335</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">3.15</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Outstanding, September 30, 2020</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">10,076,266</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3.48</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">14,982,581</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,305,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5.93</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">4.47</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Forfeited</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(29,167</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1.44</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Exercised</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(346,900</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">2.88</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Outstanding, March 31, 2021</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">11,005,199</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3.79</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">122,805,858</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Exercisable, March 31, 2021</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">7,513,533</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">3.65</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">84,890,710</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 10pt"><br style="clear: both" />
</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">The aggregate intrinsic value is calculated
as the difference between the exercise price of the underlying awards and the quoted market price of the Company&#8217;s stock for the
options that were in-the-money at March 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">During the three and six months ended March
31, 2021, the Company recognized stock-based compensation expense of $1,846,156 and $2,785,470, respectively (2020: $1,700,753 and $2,965,177,
respectively) in connection with the issuance and vesting &#9;of stock options and warrants in exchange for services. These amounts have
been included in general and &#9;administrative expenses and research and development expenses on the Company&#8217;s statements of &#9;operations
as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="7" style="text-align: center"><font style="font-size: 10pt">Three months ended March 31,</font></td>
    <td>&#160;</td>
    <td colspan="7" style="text-align: center"><font style="font-size: 10pt">Six months ended March 31,</font></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">2021</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">2020</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">2021</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">2020</font></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 38%"><font style="font-size: 10pt">General and administrative</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 10pt">793,957</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 10pt">810,309</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 10pt">1,216,780</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 10pt">1,291,410</font></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">Research and development</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">1,052,199</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">890,444</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">1,568,690</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">1,673,767</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">Total share based compensation</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">1,846,156</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">1,700,753</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">2,785,470</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">2,965,177</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 10pt"><br style="clear: both" />
</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">An amount of approximately $7,091,142 in
stock-based compensation is expected to be recorded over the remaining term &#9;of such options through fiscal 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">The fair value of each option award granted
during the six months ended March 31, 2021 and 2020 is estimated on the date of grant using the Black Scholes option pricing model based
on the following weighted average assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">2021</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">2020</font></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%"><font style="font-size: 10pt">Risk-free interest rate</font></td>
    <td style="width: 8%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">0.64</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">%</font></td>
    <td style="width: 8%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">1.68</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">%</font></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Expected life of options (years)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5.64</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5.44</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Annualized volatility</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">96.26</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">97.61</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Dividend rate</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0.00</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0.00</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140015075443464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zB6lChZMEpAj" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Recent
Accounting Pronouncements Not Yet Adopted</i></font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on its results
of operations, financial position or cash flow.</font></p>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140014989646232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock', window );">Schedule of exercisable share purchase warrants outstanding</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">A summary of the status of the Company&#8217;s
outstanding share purchase warrants is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="3" style="text-align: center"><font style="font-size: 10pt">Number of Shares</font></td>
    <td style="text-align: center">&#160;</td>
    <td colspan="3" style="text-align: center"><font style="font-size: 10pt">Weighted Average Exercise Price ($)</font></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 49%; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Balance, September 30, 2019</font></td>
    <td style="width: 1%; padding-left: 10pt; text-indent: -10pt">&#160;</td>
    <td style="width: 8%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">350,000</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">4.19</font></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Granted</font></td>
    <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">150,000</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">3.17</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Balance, September 30, 2020 and March 31, 2021</font></td>
    <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">500,000</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3.88</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock', window );">Schedule of share purchase warrants outstanding</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">At March 31, 2021, the Company had share
purchase warrants outstanding as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Number</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Exercise Price</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Expiry Date</font></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">350,000</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 7%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">4.19</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 7%">&#160;</td>
    <td style="width: 52%; text-align: right"><font style="font-size: 10pt">June 30, 2021</font></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">150,000</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">3.17</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">May 6, 2024</font></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">500,000</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of outstanding stock purchase options</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">A summary of the status of Company&#8217;s
outstanding stock purchase options is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Number of Shares</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Weighted Average Exercise Price ($)</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Weighted Average Grant Date Fair Value ($)</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Aggregate intrinsic value ($)</font></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 39%; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Outstanding, September 30, 2019</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right"><font style="font-size: 10pt">8,462,933</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right"><font style="font-size: 10pt">3.58</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right"><font style="font-size: 10pt">4,115,032</font></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,695,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">2.96</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">2.27</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Forfeited</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(68,332</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3.01</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Exercised</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(13,335</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">3.15</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Outstanding, September 30, 2020</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">10,076,266</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3.48</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">14,982,581</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,305,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5.93</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">4.47</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Forfeited</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(29,167</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1.44</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Exercised</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(346,900</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">2.88</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Outstanding, March 31, 2021</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">11,005,199</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3.79</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">122,805,858</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Exercisable, March 31, 2021</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">7,513,533</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">3.65</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">84,890,710</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of general and administrative expenses and research and development expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">These amounts have been included in general
and &#9;administrative expenses and research and development expenses on the Company&#8217;s statements of &#9;operations as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="7" style="text-align: center"><font style="font-size: 10pt">Three months ended March 31,</font></td>
    <td>&#160;</td>
    <td colspan="7" style="text-align: center"><font style="font-size: 10pt">Six months ended March 31,</font></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">2021</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">2020</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">2021</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">2020</font></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 38%"><font style="font-size: 10pt">General and administrative</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 10pt">793,957</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 10pt">810,309</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 10pt">1,216,780</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 10pt">1,291,410</font></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">Research and development</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">1,052,199</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">890,444</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">1,568,690</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">1,673,767</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">Total share based compensation</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">1,846,156</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">1,700,753</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">2,785,470</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">2,965,177</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 10pt"><br style="clear: both" />
</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted average assumptions for fair value of each option award</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">The fair value of each option award granted
during the six months ended March 31, 2021 and 2020 is estimated on the date of grant using the Black Scholes option pricing model based
on the following weighted average assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">2021</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">2020</font></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%"><font style="font-size: 10pt">Risk-free interest rate</font></td>
    <td style="width: 8%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">0.64</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">%</font></td>
    <td style="width: 8%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">1.68</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">%</font></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Expected life of options (years)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5.64</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5.44</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Annualized volatility</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">96.26</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">97.61</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Dividend rate</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0.00</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0.00</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 10pt"><br style="clear: both" />
</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140015075437624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Description and Basis of Presentation (Details Narrative) - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Loss per share for potentially dilutive common shares</a></td>
<td class="nump">11,505,199<span></span>
</td>
<td class="nump">10,576,266<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140014987222280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrant', window );">Grant income</a></td>
<td class="nump">$ 10,820<span></span>
</td>
<td class="nump">$ 74,944<span></span>
</td>
<td class="nump">$ 10,820<span></span>
</td>
<td class="nump">$ 149,888<span></span>
</td>
<td class="nump">$ 597,886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">960,879<span></span>
</td>
<td class="nump">717,328<span></span>
</td>
<td class="nump">2,230,195<span></span>
</td>
<td class="nump">1,660,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_AUD', window );">Australia, Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">1,244,133<span></span>
</td>
<td class="nump">$ 1,203,000<span></span>
</td>
<td class="nump">$ 2,980,095<span></span>
</td>
<td class="nump">$ 2,548,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_ParkinsonMember', window );">Parkinson [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">$ 497,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonOperatingIncomeFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonOperatingIncomeFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_AUD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_AUD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_ParkinsonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_ParkinsonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140014991852456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offering Agreements (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 07, 2019</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member', window );">2019 Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ValueOfSharesObligatedToPurchase', window );">Total number of shares obligated to purchase</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Share issued for offering, shares</a></td>
<td class="nump">324,383<span></span>
</td>
<td class="nump">4,086,209<span></span>
</td>
<td class="nump">6,014,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NumberOfSharesObligatedToPurchaseProrataBasic', window );">Pro rata basic number of shares obligated to purchase</a></td>
<td class="nump">162,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues4', window );">Number of shares issued for aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,007,996<span></span>
</td>
<td class="nump">5,964,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues3', window );">Number of shares issued for aggregate purchase price, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,111,198<span></span>
</td>
<td class="nump">$ 15,365,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues3', window );">Number of shares issued for commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,213<span></span>
</td>
<td class="nump">49,841<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues4', window );">Amount of shares remain available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 24,111,198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember', window );">Equity Offering Sales Agreement [Member] | Cantor Fitzgerald &amp;amp; Co [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Share issued for offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,552,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_PercentageOfGrossProceedsFromSales', window );">Percentage of gross proceeds from sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_GrossProceedsFromSaleOfCommonStock', window );">Gross proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,823,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceed from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,688,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_GrossProceedsFromSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_GrossProceedsFromSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NumberOfSharesObligatedToPurchaseProrataBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to number of shares obligated to purchase prorata basic.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NumberOfSharesObligatedToPurchaseProrataBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_PercentageOfGrossProceedsFromSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information related to percentage of gross proceeds from sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_PercentageOfGrossProceedsFromSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodSharesNewIssues3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodSharesNewIssues3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodSharesNewIssues4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodSharesNewIssues4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodValueNewIssues3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodValueNewIssues3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodValueNewIssues4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodValueNewIssues4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ValueOfSharesObligatedToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to value of shares obligated to purchase initially.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ValueOfSharesObligatedToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_CantorFitzgeraldAndCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_CantorFitzgeraldAndCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140014984843352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Purchase Warrants [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share Purchase Warrants Balance, at beginning</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price warrants outstanding at beginning</a></td>
<td class="nump">$ 3.88<span></span>
</td>
<td class="nump">$ 4.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod', window );">Share Purchase Warrants Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice', window );">Weighted Average Exercise Price warrants granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share Purchase Warrants Balance, at ending</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Balance, at ending</a></td>
<td class="nump">$ 3.88<span></span>
</td>
<td class="nump">$ 3.88<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140014987679560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 1)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member', window );">Purchase Warrants 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 4.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants and Rights Outstanding, Maturity Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member', window );">Purchase Warrants 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants and Rights Outstanding, Maturity Date</a></td>
<td class="text">May  06,  2024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140014991836888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 2) - 2015 Omnibus Incentive Plan [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding at beginning</a></td>
<td class="nump">10,076,266<span></span>
</td>
<td class="nump">8,462,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding at beginning</a></td>
<td class="nump">$ 3.48<span></span>
</td>
<td class="nump">$ 3.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value Outstanding at beginning</a></td>
<td class="nump">$ 14,982,581<span></span>
</td>
<td class="nump">$ 4,115,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
<td class="nump">1,305,000<span></span>
</td>
<td class="nump">1,695,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Granted</a></td>
<td class="nump">$ 5.93<span></span>
</td>
<td class="nump">$ 2.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Granted</a></td>
<td class="nump">$ 4.47<span></span>
</td>
<td class="nump">$ 2.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options Forfeited</a></td>
<td class="num">(29,167)<span></span>
</td>
<td class="num">(68,332)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Forfeited</a></td>
<td class="nump">$ 1.44<span></span>
</td>
<td class="nump">$ 3.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Option Exercised</a></td>
<td class="num">(346,900)<span></span>
</td>
<td class="num">(13,335)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercised</a></td>
<td class="nump">$ 2.88<span></span>
</td>
<td class="nump">$ 3.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding at ending</a></td>
<td class="nump">11,005,199<span></span>
</td>
<td class="nump">10,076,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding at ending</a></td>
<td class="nump">$ 3.79<span></span>
</td>
<td class="nump">$ 3.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value Outstanding at ending</a></td>
<td class="nump">$ 122,805,858<span></span>
</td>
<td class="nump">$ 14,982,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable</a></td>
<td class="nump">7,513,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 3.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value Exercisable</a></td>
<td class="nump">$ 84,890,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140014987223368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">$ 1,846,156<span></span>
</td>
<td class="nump">$ 1,700,753<span></span>
</td>
<td class="nump">$ 2,785,470<span></span>
</td>
<td class="nump">$ 2,965,177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">793,957<span></span>
</td>
<td class="nump">810,309<span></span>
</td>
<td class="nump">1,216,780<span></span>
</td>
<td class="nump">1,291,410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">$ 1,052,199<span></span>
</td>
<td class="nump">$ 890,444<span></span>
</td>
<td class="nump">$ 1,568,690<span></span>
</td>
<td class="nump">$ 1,673,767<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140014991052056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 4)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.64%<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">5 years 7 months 21 days<span></span>
</td>
<td class="text">5 years 5 months 9 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Annualized volatility</a></td>
<td class="nump">96.26%<span></span>
</td>
<td class="nump">97.61%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140014991781656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Lease expense</a></td>
<td class="nump">$ 29,903<span></span>
</td>
<td class="nump">$ 98,290<span></span>
</td>
<td class="nump">$ 60,861<span></span>
</td>
<td class="nump">$ 110,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">1,846,156<span></span>
</td>
<td class="nump">$ 1,700,753<span></span>
</td>
<td class="nump">2,785,470<span></span>
</td>
<td class="nump">$ 2,965,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Remaining stock based compensation</a></td>
<td class="nump">$ 7,091,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,091,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member', window );">2015 Omnibus Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Maximum number of common shares reserved for future issuance</a></td>
<td class="nump">6,050,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,050,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member', window );">2015 Omnibus Incentive Plan [Member] | Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Maximum number of common shares reserved for future issuance</a></td>
<td class="nump">146,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member', window );">2019 Omnibus Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Maximum number of common shares reserved for future issuance</a></td>
<td class="nump">1,856,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,856,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,161,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares of common stock available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Description of grant option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The exercise price will be determined by the board of directors at the time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair market value of the Company&#8217;s shares of common stock on the grant date<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_OptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_OptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>35
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MY$J+M!(#01IGY3][K0)Q)G '%P1N)7#?":AW0>!5 J_H:$E6=.LSTVP\E.)
MI'D;W,Q%$9M"#;V),S.,:RWA:0PZ/?;%"Y>D0U3$)%=#6X.G>6('E?ZQU+L7
M]'WR160Z4F2:A3Q\J[>!I09R3T"/+FKXA<D[XM&/Q'5<VL+C7Y,?"6U5OZ'Q
MZO!XA9V'AN?OR49I"3/N'\2R6UMV"\ON!<O/(LAA'6CR_;CG;0''Y=3I?$,H
M>C5%#[69 $)88,P2MFO#P/5;EBB.</1KCOYMT5AR&8O03","$[DU,+C3:>+\
M\N'#E<$?U&R#V]AFL0I8<D*<P>W6E8*[?7,1I/L:Z?Y_(?WD3%X&PKVN1.FA
M1GI ;?Q<RO=$V"CB;IV.\]#Q'(2+.DUJ<U"O::9C?02PA)-%GFZX;,UON(GC
MT(XWZ#M]#.DLV]);D%9\%YN, F%;L+0U3%>,)HO)T_0O\L=\-B5K?SY=^-,U
M\;^NEG<8I]MPNK=P^C"P$@9U#LG]E?S.CZVDN)4#$?1HU^EA\Y\V"9EZMY#-
MLT#(O9#,% ,?R5K#;"-"$E_D@ SD(FP/*^Z^>,(@FQ1/\21]"E^U-%8<2'6<
M[0K.]K5ZQ?'G^\WY+5F3]BF>M^OP:2[+$LHL5'9";27#':^0-1L!Q?/WV6J%
M883AW G9/M]PGX7(.BP(H%"$R<'#TA C;+8#BF?PBG"=LB0AC[F"QZI]+'$?
M+7-LZZ3-9D#Q#%X!35,N=V9V_0H..H*YG^Y9UAX[W/#:KDZ;38'B>?P4JP@*
M=!0(M[D&Y#:;@7O39@ H*9P>UEH$SY VBJJ7?,VUTBP+(8:M%6?IW"N<S;GH
M93QP'._^P85]ZN6<RCXKQ,V@%.<310*3E,J:O+Y;GX$F1>5O-Z^7!R@H9V!,
M%4GX%J3.W0 ^+\LS2=G08E^4]1NAX9!07$9PCN/2O #/MT+H4\-\H#X9CO\#
M4$L#!!0    ( +>#K5*+4_C$4P0  &0-   8    >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&ULC9=M3^,X$(#_BE6M=*P$Q';>4:E4VIZV$LLB"G>?W<1M+?*V
MMD/A?OV-DY*^).GR 6HG,^-GQO;,9+C-Y:O:<*[1>YIDZG:PT;JXL2P5;7C*
MU'5>\ S>K'*9,@U3N;94(3F+*Z4TL2C&GI4RD0U&P^K9HQP-\U(G(N./$JDR
M39G\N.-)OKT=D,'G@R>QWFCSP!H-"[;F"ZY?BD<),ZNQ$HN49TKD&9)\=3L8
MDYL)\8Q")?&/X%MU,$;&E66>OYK)/+X=8$/$$QYI8X+!SQN?\"0QEH#C]\[H
MH%G3*!Z./ZW_73D/SBR9XI,\^5?$>G,[" 8HYBM6)OHIW_[@.X=<8R_*$U7]
M1]N=+!Z@J%0Z3W?*0)"*K/YE[[M '"@0IT>![A3H5Q7LG8)=.5J356Y-F6:C
MH<RW2!IIL&8&56PJ;?!&9&8;%UK"6P%Z>C1_>)X]S7^BR:^'Z>QA,9N:T>+7
M_7PZ?H;)W?A^_#"9H<6/V>QY@2Y>,E;&0O/X.[I"+XLINOCV?6AI #'FK&BW
MZ%V]*.U9]">3U\@FEXAB2CK4)^?5%[P =5RIXV-U"]QO8D";&-#*GMUC;U)*
MR3-]QI+=6+(K2TZ?):8VB&4QBLR _R[%&TO M.J*46W*JTR9V_8V\MW #6T[
M'%IOA]%H"]*0.B$F02-X1.LTM,Y9VGD6 1O<H@I9LW>XEQ$'Y&7".XEK<^XA
ML4T#'.(3X+:<$SBA[>!N7K?A=<_R/DI>,!$C_@Y)3'%58<>\R)7HCK#;XK #
M#WA/<-MBCF,'!]MP1.LUM-Y9VN=<LP2-E>+=<%YKU<!V?8?:P0E>6]!V7(>2
MT.\&]!M _RO''MT+MA2)T.)TTX^L!HW5X*S;XRC*2SCQJ& ?YB!UN1ZT/?+<
M +OTQ/,.N3 (L>MT.QXVB.&?$&7)8Y3T.5Y3AAV4)/#]T^/3(6<3#[:RFY+@
M?6K&9SFG?,5ABV*TE@SV2611GG;&<V?G^,+YA) 3T@ZYGBM)#NH'^<(Q[SU#
M.T#2SAR^9X?.Z8YW"=K8]6A/JB/['$_H'U)S(0PI5-3H%8U+O<FE^(_'-XA@
M?(GK/P013J&Y4!LFN;J$,RP19/"2HV_X&F.""B[KEVBNE#E#)@5!=Z0T#$2V
MOD$^&(+:Y-$38^@"RI;FZ1(L?-8NJ*$>O<2.>TG"H+N.TG8\,+9;86N+ 8#3
MDR#(OIR1\_5L'$.QAVX+XF8R[Y7(H+)5<>R$M5L4U"4.]?V@=1+;H@12LTO\
M@R1P#+VO:N1\68/K7:9EPJ!+,0V=B(3NI&U7J2M8W@M\H#C%[9)U0\_WJ=UW
M@_95C9PO:_4-6IASN<F3F$OU%YI!ZZ _.K';U0K:!H)IZ)U"MR4I\'JNUU/9
MR+ZTD:_4MH-+7]V#+[O@M1J:GM+7(=E3^ZR#%MA\?T"+N1:90@E?@2J^]B$,
MLF[IZXG.BZHK7N8:>NQJN('/("Z- +Q?Y;G^G)A&N_FP&OT/4$L#!!0    (
M +>#K5*JP8PON@(  !$(   8    >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
ME99=;]HP%(;_BA7MHI4ZXB1\K0(D"E1#:BEJVNUBVH5)#L1J8F>V ]U^_6PG
MC: %"EP0VSGO\7->&YO>AHL7F0 H])JE3/:=1*G\VG5EE$!&9(/GP/2;)1<9
M4;HK5J[,!9#8BK+4]3%NNQFAS!GT[-A<#'J\4"EE,!=(%EE&Q-\;2/FF[WC.
MV\ C727*#+B#7DY6$()ZSN="]]PZ2TPS8))RA@0L^\[0NQYU3;P-^$%A([?:
MR%2RX/S%=*9QW\$&"%*(E,E ]&,-(TA3DTAC_*ER.O641KC=?LM^:VO7M2R(
MA!%/?])8)7VGZZ 8EJ1(U2/??(>JGI;)%_%4VF^TJ6*Q@Z)"*IY58DV0458^
MR6OEPY; :QX0^)7 /U405(+ %EJ2V;+&1)%!3_ -$B9:9S,-ZXU5ZVHH,ZL8
M*J'?4JU3@^GL:?(XO4>CA]EX,@LG8],*'^ZFX^&3[MP,[X:ST02%WR>3IQ!=
M/#-2Q%1!?(DNYD0 4PDH&I'T$GU%7Y"+9*)'9<]5FLW,X$85QTW)X1_@N">B
M@0+O"OG8]_;(1\?E(>1:CJT<[\I=[4AMBU_;XMM\P:%\BBC0FU4AOD2WE!$6
M49*B.9?4[KY?PX540N_!WT<F"^K) CM9\\!D<[US00B(D5[NZ.6J,A&10B5<
MT'\0[_.SS-FR.<UO=3WP</GIN>MMYTX(W,%NUMC-\[!S(M":I 7LPRUS=;8H
M< -C[QWK9U$[H*T:M'44=,2S3*_9.>:V#GKVWMU3(G>HVS5U^PSJH]ZV3_+V
MLZ@=RDY-V3G?6RIEL=_7S@>W.A@'N.V_M_5CH(YIMKQOW?V\W9JW>SZOOMVD
M(BRF;+4/NGLJ],?  ]#NUH%M+DM]^JTHDRB%I9;B1D?G$.4%5'84S^T9ON!*
MWPBVF>@[&X0)T.^7G*NWCKD6ZG\!@_]02P,$%     @ MX.M4HY ^0I<!0
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MJ9J?%"OJ?/AA$R5YR+ECY%E<8P^*ATHIOX-AK3/\K?ECI<,%DDB'"6&C2Z'
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M8G-2%ZOVG8+/15T7R_;P423P6&L,X//[HJA?3IK7%'8OOES\ U!+ P04
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M,3 '9]%#HB,MYS5,5-QFWLLW2S%MMEMXN*JQS;I(C,D=,7/4;D<3)J7EP09
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MKR5*LX'6EX)FBN;!'- .\]-_ 5!+ P04    " "W@ZU2*5?3^M8&  #7$
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MEDA^7=?/VDE(X;1*C$A\ ?>MV>VQ)%\6X)<:_M76$LY#WA*"VTNXTU4CZF?
M#=+(#%3M="#@S2H*HXC_0=.K$H.JMR3ZS3\V21)=GC#'J_'E&1:MV\,'56,Y
MUG OS&,(PH+ /5@)H E4^0P^DU%(UFPKT ;B..S5;C^!N1<9OQOJ*-P"V,0E
MB!J!6]M*^G)D"I?&7^" QO6V5(5P:![W]^Z%T#;T/G9=U? DRE8&.@>%H;5[
M823*Y[#35878L0EWCY ;78%#0B)Y_M5/TH! J!B-;Y^E,-!@GG0&;>U4.78Y
MF<-/-:I#+LND$<Q'2*@^(919R@C[3($.7@=ZFD<.0W8<!U@F:;C<+$\Y0 GA
M+\IQ?G,I(6O9/"EG!WR^'F3C9+65)EA&OHXXQ%P:;-;GP8<R7B=A?!'W5ANC
M 3T4(1SVLO99R\,IT#X;&:;.C3VC>HK/+RUDRNZ,I#BQY\$X7Z) ')39D3-S
M^.[%$ZL^0^69R/N#/((EUA-)&/R)6(IZ9 <CF8;19ATFT06\I1+FOHCC2UB'
M49R&:;(Z.Q7V%B&8(;=?:*(P0,-EFQ%\-!.=AQ<7:V_F':S"BW4:KC;I2?U4
M1Q.T0RLW1NT8_!LLC#B.,4V;7N^;>!4NUZLPO4C..$GGFS")ET&WG%Z$FS0^
M&Y>+-S^']^XXGE!K;'6-58]CF@X"&$_Q)%0IMJ4,_J__\':H-_#UQ@!?,)_-
MX4&4Z/J+R+]/L!I6^!UFWNBRQ"^>/X.!/X^U]+RTYB+?4,D2%QU&U$6A0;<=
M$PGN_R@&&IL0Y)'J*3'>(=5I$_R@W'\+;/\R@V]$U5PBU#D;>/C]%CY(PO@(
M'S[<H6)=2%3NPW9D@>B_5S]A4GC-I!6BU>0]FR$:#4Y4$=:.LCZ./F%84A(E
M^=#4K7;$Q<'P#/**$I$+=5MX$&/ DUCU^>B]F,-O#>K-9(FV#"'&-#:EV'DK
MM794QW3VR@+<]R6^4#7":_F@9[VO[?8_"!XZ6D7/*K^ ))PIOP_MC'%.J'8"
MGL+(,XA7.(#!%J.+.=(9DA4),H5L)<6M<[.C-CSK/N+A6D^='MY#FC^U+-!)
M/ZR,J*WH/7&]./<RL:NDQJ)B]NH#/XERL @8B J&O4:6_?BS+1;&2':B-"0Q
M=(<*1G/5><=HFF'SDPI<+<6!H/9$=0)Q&!P%'DV@]H,A/7X"<N/EXRS.)^VL
M+&5\.KXK\2@9G^6TH+C/PHA<C[(X#\8Z$<+KA+86;S89K5%UJ)JXDS3UF1F;
MH?KLZK!SS$>J$<8]A^-JVTGCD )'=>:A3.P?%!UH4("8INBHR ]G:79*E$A*
M>,6RNB8*I4;4!L6P!3 Z?(S 7D4I9A<$H@RBPSM*2<G@_' /L,G&4&XPSP'/
M\*8IU8ZU<A_SQES2J:3T.38M27G>*]I2O/04G\G:+@$_"YN)3]/4[=F=_I#0
M8)"/6RG@@6(MZZ3)Y<%;:9ZX9E&Q/U4LY]$_^S(IC+9\L-BA9MNQ#LUY+OE\
MU)43.OQ258SA!J*T>HS7Z"<\GKUN?XZROXOAO16;()-5K7(,H[]8>E9Q1FU;
M_L#G5OLGCR2!'Z'+<+5*PF4\G-X.R,5@-<Z*8Y^&<4;Q.XH-#?OE>;A)EF&2
MQO"VYBX?+Z[#]683KM(41(YUC^25$6_613#4O?R,C6&E/9M_Z5JT&%TVL5H+
MOE)35>+\]_?.X>MP:W_O+ZLOV_V5'X-0('-#*7,4C>;GJYD/7O_B=,-7UZUV
M&'Q^W$N!Q4H;<#W7>%'J7LC \+>,F_\!4$L#!!0    ( +>#K5) ![Y>F0H
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MN9R$^!CP3>'.':PA5+(AN@N;3_DL&8:$4*/T@4'PZQY7J'4@XC1^=YQ)+QF
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M;4$: 5Q?":&'B7$P/I;/_P902P,$%     @ MX.M4CEVHT1U @  H04  !D
M  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL?53;;MLP#/T5PD\;T%6V<^E:
M. ::=,4&K%O08-O#L ?%9F*ALN1)<M/VZT?)KI<-25YL77@.#TF1V4Z;!ULA
M.GBJI;*SJ'*NN6+,%A76W)[K!A7=;+2IN:.MV3+;&.1E -62I7$\9347*LJS
M<+8T>:9;)X7"I0';UC4WSW.4>C>+DNCUX%YL*^</6)XU?(LK=-^:I:$=&UA*
M4:.R0BLPN)E%U\G58NSM@\%W@3N[MP8?R5KK![_Y5,ZBV M"B87S#)Q^C[A
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MH!N2;GH]7MIUY=E*#U[0^TQ1P4&J*J^KMDJVJ]BR/>['IN'+C>]/#6^C/!A
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M)4"\7Q/"CQ,9H+XZCO\"4$L#!!0    ( +>#K5(8H]P:+P0  !<.   9
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;,V7;6_;-A#'O\K!V(86R"Q13Y8Z
MQT!J+UN&M#7J=7M1[ 4MTS(1271)RFZ'??@=)45^D*QDW5[,0&+1NCO][G\D
MCQKOA7Q0&\8T?,[27%T/-EIO7UF6BC<LHVHHMBS'.VLA,ZIQ*!-+;26CJ](I
M2RW'M@,KHSP?3,;E;W,Y&8M"ISQG<PFJR#(JO[QFJ=A?#\C@\8?W/-EH\X,U
M&6]IPA9,?]C.)8ZL)LJ*9RQ77.0@V?IZ<$->S<C(.)06OW&V5T?78%)9"O%@
M!G>KZX%MB%C*8FU"4/S:L2E+4Q,).3[500?-,XWC\?5C]-LR>4QF216;BO1W
MOM*;ZT$X@!5;TR+5[\7^9U8GY)MXL4A5^1_VM:T]@+A06F2U,Q)D/*^^Z>=:
MB",'XEUP<&H'Y[D.;NW@/M?!JQV\4IDJE5*'&=5T,I9B#])88S1S48I9>F/Z
M/#=U7VB)=SGZZ<F/GPJNO\"[]9I)GB=PDTC&L*Y:P8L9TY2G"MY2*:DISTOX
M'CXL9O#BFY=C2^/330PKKI_TNGJ2<^%)OQ3Y$.S1%3@VB3K<I_WN;Z@<@DN,
MNT,ZW&?/=[=/W2V4K-'-:71SRGC>A7@F"9@7,M[@I#NH!A_?L&S)Y!_P%]SS
M'*N3PYS*!YC2+=<TA=LB7UW!_?VTL>R!<1L8MX1Q+\#@I$_I4E1%@ANL5IY4
M.#1?G8S?Z0V3H#<TAU.GCTC+X$ZS3/41>0V1URO/K\(DFQ<F0Q!K4!LJF0*Q
M3'E"-5N!%K"MU>N:2E7TH(QNMJ[=Q+>KS]C:=7#Y#9??RS67(F9LI6 M109W
M2A4TCQD("0N:,D-:+8@N)O\?,@4-4]#+M##: $<6U 5W<J2H%N-5+5L73!72
M/X)Q'<\-W0:E6E-M,\\. \>.3NUF;;O )I[G^-VIC9K41D_)#3C!J-F:>?PO
MYL.HQ4<"AT2D&R]L\,)>O+?G/$=%H FN:</6<,%6\KB+;AIVJ&R/HB@X4[EM
MYT>!YX=>=QI1DT;TGZ=Q!3N:%IW91*UY[G@$/U%XED[;D/ANX'N1TYT/L0]-
MR?[JC&*195R;W:RSB=@MC4>A0\[6Q:S#S(M"[\)\(D?=E/2"WV2BP&WV "Z9
M.7P!W6$GI<NT4_ ZYK&0]CEOVZ15E%/D0R,C_9WL_ 1@-D+5W=&F--=8@5NN
M_TR8I.D*OJ/9]@?SA^WD.1V-'%H:^;_T-')H:J2_JWW-3CVM8YYLU;[ON$=S
M\A3GT,O($\V,R1@%P..YF7")%$KAXCYN<,K4LA.J/[([M.UO^R0[]#;2W]Q^
MND!EB,U*QJ,_GG'CAT[(H#7I75S,V.@NK=-#7R)/-B8#5/$\5K&38=1F"((P
M]+WS3=LZ.H2;5R8\<28\5Y"R-;K:PQ%*+JNWD&J@Q;8\ER^%QE-^>;G!-S<F
MC0'>7PNA'P?FJ-^\"T[^!E!+ P04    " "W@ZU20?EC>0T#  !M"0  &0
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M]="<+]@FU5^+W3_\D%!0QDN*5)E?M#O8>CV4;)0NLH,S$&0BW_^SQ\-"G#A
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MR]( GB^*0C\/R@FJL_WH/U!+ P04    " "W@ZU2J=-Y_QT#  !#"@  &0
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MUHT /I\+H5]NC('Z^\WH7U!+ P04    " "W@ZU2^?(N<PL#  "+$   #0
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M7,940-(":P%:(^<:!7B-'&P4(#9RLE& V<C11@%J(V<;!;B-'&X4(#=RNE&
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M6;MF1C7VX"^ZG]_9)U!+ 0(4 Q0    ( +>#K5('04UB@0   +$    0
M          "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ MX.M
M4N&:]67O    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N
M>&UL4$L! A0#%     @ MX.M4IE<G",0!@  G"<  !,              ( !
MS0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "W@ZU2<D,N.-T#
M   E#@  &               @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N
M>&UL4$L! A0#%     @ MX.M4HM3^,13!   9 T  !@              ("!
M(0P  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( +>#K5*J
MP8PON@(  !$(   8              " @:H0  !X;"]W;W)K<VAE971S+W-H
M965T,RYX;6Q02P$"% ,4    " "W@ZU2CD#Y"EP%  #($P  &
M    @(&:$P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @
MMX.M4GSGU^L'!0  A1   !@              ("!+!D  'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;%!+ 0(4 Q0    ( +>#K5*B.]AW,@@   0S   8
M          " @6D>  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M    " "W@ZU2;8TMPQ\/  !N*   &               @('1)@  >&PO=V]R
M:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ MX.M4O;9BCYN @  ?P4
M !@              ("!)C8  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+
M 0(4 Q0    ( +>#K5*T[?)MQ@0  -@+   8              " @<HX  !X
M;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " "W@ZU2*5?3^M8&
M  #7$   &0              @('&/0  >&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;%!+ 0(4 Q0    ( +>#K5) ![Y>F0H   D;   9              "
M@=-$  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ MX.M
M4C&.;F># @  AP4  !D              ("!HT\  'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6Q02P$"% ,4    " "W@ZU2?-IBW;L%   X#P  &0
M        @(%=4@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0
M   ( +>#K5(Y=J-$=0(  *$%   9              " @4]8  !X;"]W;W)K
M<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ MX.M4A0MK!(5 P  1@H
M !D              ("!^UH  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q0
M2P$"% ,4    " "W@ZU2&*/<&B\$   7#@  &0              @(%'7@
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( +>#K5)!^6-Y
M#0,  &T)   9              " @:UB  !X;"]W;W)K<VAE971S+W-H965T
M,3<N>&UL4$L! A0#%     @ MX.M4C<"OF#5 @  *PD  !D
M ("!\64  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " "W
M@ZU2MQ:OMC($  #G#P  &0              @(']:   >&PO=V]R:W-H965T
M<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( +>#K5*ITWG_'0,  $,*   9
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M  !X;"]S='EL97,N>&UL4$L! A0#%     @ MX.M4I>*NQS     $P(   L
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64$L%!@     > !X "0@  'N"      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>77</ContextCount>
  <ElementCount>207</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>17</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="avxl-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="avxl-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets</Role>
      <ShortName>INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="avxl-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="avxl-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="avxl-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="avxl-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity</Role>
      <ShortName>INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="avxl-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Business Description and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation</Role>
      <ShortName>Business Description and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="avxl-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/RecentAccountingPronouncements</Role>
      <ShortName>Recent Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="avxl-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Other Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/OtherIncome</Role>
      <ShortName>Other Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="avxl-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Equity Offering Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/EquityOfferingAgreements</Role>
      <ShortName>Equity Offering Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="avxl-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="avxl-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Recent Accounting Pronouncements (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/RecentAccountingPronouncementsPolicies</Role>
      <ShortName>Recent Accounting Pronouncements (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://anavex.com/role/RecentAccountingPronouncements</ParentRole>
      <Position>12</Position>
    </Report>
    <Report instance="avxl-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>13</Position>
    </Report>
    <Report instance="avxl-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Business Description and Basis of Presentation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative</Role>
      <ShortName>Business Description and Basis of Presentation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="avxl-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Other Income (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/OtherIncomeDetailsNarrative</Role>
      <ShortName>Other Income (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/OtherIncome</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="avxl-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Equity Offering Agreements (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative</Role>
      <ShortName>Equity Offering Agreements (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/EquityOfferingAgreements</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="avxl-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="avxl-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Commitments and Contingencies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails1</Role>
      <ShortName>Commitments and Contingencies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="avxl-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Commitments and Contingencies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails2</Role>
      <ShortName>Commitments and Contingencies (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="avxl-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Commitments and Contingencies (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails3</Role>
      <ShortName>Commitments and Contingencies (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="avxl-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Commitments and Contingencies (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails4</Role>
      <ShortName>Commitments and Contingencies (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="avxl-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>avxl-20210331.xml</File>
    <File>avxl-20210331.xsd</File>
    <File>avxl-20210331_cal.xml</File>
    <File>avxl-20210331_def.xml</File>
    <File>avxl-20210331_lab.xml</File>
    <File>avxl-20210331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>40
<FILENAME>0001731122-21-000829-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001731122-21-000829-xbrl.zip
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M@PN'SEH./9-T1CCL\^K%$FK+IT/NVJ[[<Z:W<CKT5DZ1WC0%Z_,4\W"N?"<
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M@C.=^G@()DPC4"LQ;H4)<3T0:@2[#8Q8(I\0D.@^3&,A?HI!AI86>_[INK0
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M(C=?7YX7>9G"A=\Y+*C(M@+L56_J,XF+]XUAEV-R[S29J8]? [IJ:BA36,Y
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MG3DG<*K,.(XU)NFP@]5[H!VP_^!_<BORB3@1V.<X4 5=QIX/#W*808+C*!?
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M;PF-42^9FOI0A7E+UJ:P:&E.'(P7C]&$PR *F)D4NB6R%22J%S.$LWT,@I;
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M<9]/O/Y@07^V!PL%1J [!_T!H!D)1AXIG"T<]&AA%S6N=L&(&7L9.R5[UC%
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MF]C4GP:U?#$EM^F<J9 2;ZD[$RLSD@:R?'1T+-B5 W!LCV'UV&==O*(NM@\
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M01%3-*D%FSCY(/\[!'SR/U!+ P04    " "W@ZU25HR6(.T0  !=# $ %0
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MO&JT33V%(9<YL17"=A'7.T5*KD*8U,X@7D?BU9%X.>V>6RPN=@RP\W2+ 9V
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M0?M!4M5A6A7)2BZ]BS>$<EVNV^'HK7C?JR!Y14[8K$T,R2'*N],5<!">\$^
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MU-'<9B-O\#2OV#)*J?[X#*U$M0F7[LF12]YS]H?U=_3)_P%02P,$%     @
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MQZ*<:4(224/$_MC,+^S#MVNRP/%%DK.EO,+>*"E< ,0@&H>%XF?O8-#+U(:
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MZ=5/[NP960NAJR=E#;3>H6(I8,>%&O$.B@86ZNFVRH<AY51I8\GH#"J#%*E
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M>CE &2I;:=TA::R,$54@G_#\1/JT!6&^'JEM O2LA0>6X31?PS;J-2Y-#RG
MN_G;1>K.O>E-&6(AW"@%;8J!MQZN26Z_5=K'Y FUEMN89@Z(N+3W]XQ ! (Y
MPX+Z-HVCX$7^=X?M%DTQ0+96C$I:;J,HRP #W2T%'[H]@CZG.?H[811AN@+T
M=&[P2,)US$-<^>I+'?E3I--Z$8D3^J"^4XE.P_%V5[T1S;!]<6#&PNXZ=&+#
MBA+Y@5$1#<W99'#$Y@+*=TQY3O91GU#7A>57.@KURELT?RLDJ$5Z&.&^8UGN
M O=W5'<3R;]E0=[!/8;T)E@[@/+HQKY^B>8NC>/+E#*YPX$&WK(4/T9]D(IJ
M0VY5A'=\[R:W"=DU!!=972N4PTKONE']8KF*TQ="OA#Z% 5$,X/%0A@1),'?
MFUTDT1\DE,'J(M.R_1 8O3X_@V6B9E,/JY$K S@ I]'0-%39JIE0'(MU- Z7
M41+QK1OQ!F+C!3H>L\.:Y[%XCNZ)Q.E*W/8MJ<"-Z$WC%7G19]R6U4T<OP8E
M6S3+UDOYW="9;)1*/$UT(S:09AX<H0: HW1$M4Q#\SN)%H_\N5S\Q(;H@B"\
M*0S-4XKF.*(R6E^LDC ;G6D1;\<% C(B9TD>A5&\YC;E"PG65.3'EKEV2<C3
MQW/CMBZ##R\PY<FW>(I>T<ZS)=\7T45YC5.VTVB\,9NC$:8W1L%@1MN8VK0'
M&;^!Q'.\%BLP/I16:<[&<83C^ 65U8)\;.6NF(=G27B^F85G?.FX$!N&?#.<
MG[W<IZPMF&I+YL2+39FL[D/P]M+FN!BY#I>C:Y+FJ8^R42N <J(]I7+=_6Z-
M(QE5CV^#>F!Q,^V?L14Q?DBE=UQK%'ZB^IE!4_/S/?LKP\'&!^CU+\:KR(]C
M.79#J9W+L6H!,^5-IEKW_+3&CVH%B#%9_RPCZ_)'G* F$ZQ<V".TUW5/%NUQ
MJW ;.S!^XS0C#<8K'\Q8G$"I*4;AM;<TXR&)OEV3!8XOV)R=O\R>HP8X%#_#
M25=A$JZS(">41S?]QHEV-G>:DT69CF=>W!A_B"/QTA_SL8I-<]6Y5#^/LY-"
M6_&K$\$^!N]68(B4;<#<\S?(4+)>/K QNTD[DY8%H#RM3D. 3)_*ATDISZ/#
M%M:-/!@M*VG#Z/T!6:4BO2_(-KB\ W*PJ.97%S<ORLIT21RGDMUGYI4ITVJ#
MF7NVE-OP=FLH-K#2(J!\XOS9GX5=,UA%!C3FG&!^V3M06=6!!3B;Q+92K)K1
M!G%[MR9;BZRP*HC3\!Q>4>!HTM.%9UD-J!^5,3ZVK.Z"KX8ILXFULN.#@<!A
MPG9RA;7!5C.&>+&@XKGL3=S)BD:!8^@UW_CX,* ).IR^@:=1I0]W+3;0L%/+
M.@;J1GI_:B>[-P1]75;?\-,I,]#NP0:@1M@A" RJBS$^+=V0.;;#Z1MJ&E6&
M63K8$ZQ:UD[V&W&"7L,9)4L<)0@_X2CFF_\308S)R,\!\8(M:7^A:9;5U[PB
MMZ]*51LN9]"R5Z&"53\+#$A9R]E9*E2,(NJ0BA",QJ9$QKDG I525'[.Q@,\
MQ#!1*6O#Y0Q4]BI4H.IG@0$J:SG;H/I% R,.L3)XA[,#WF>]2B(>=G2[9DOE
MH,P*,&#W3\/O>]?5J%;?YJN2V3M4MY58LQ4KT5INVP%!J"K&M1%Z7CL)_?2B
MCH.UBW'9N7S?,=,[-4M?N/16A8,9(6-K9 J2%MR'\@V!>AWU _0,/;PT"(N*
MD*@)6"Q+;Y/I6NRZ[QWX$0IV_@+U* W1_Y3&D%+A#+.Q5%$>+O6,J9XA=6T7
MF+(/XTH>C%XE64[7PIJ(<)S[1YP4EST^I\D3R7(2RJV9L7MK>/U[,4JW;=91
M!O/0RL&^:^]0>?41=/5\<WDC'GTJWQ'!S$B0190D$^9DF*P-:A?[_U;<PYK)
M:UCEXWZW?&]?N>WF7RBWSSM"Z(#FPY$^)8)D*T"U2-N E"RHX$$E$Q)<RH08
M^VU4?N'Z7"5R&]YM5[6J?@4&0MF8#LQ HU[OBP$/RMHZ H)W]X1EVXY2[=:"
MG=(D+-7NF+951%F)6T__;@2#,\)==H3]^'<AU9Y8!X=-L;4/L.@W)O]<Y>ZZ
MT(/ZC*)3Y;=9YY+>;&W[YU_M[P(,$(R!M<A0\SL,X_NPFULFZ!$CG[\)]KPB
M@8A[YU_5VG.:S=S!U>_%7NZ6C3K*)#>P;N\NF2>%U6&D_S"C>< >+A2A7M?(
MMW4A8$CT#V0EMMBX;3H)0&Q(Z9<S7>^X1G7?Z%><\P1B+^<XUXUV>W:7XW*H
M4O419,L+!NL#!>[XLN7"C*?/D 6@6@D'J"P#\4* H';7\>W*8=USS]2)"^K7
MUYPZ:J!'R<Z;C$6>TIN)SN[@C3\/+N:K]"4].HT0O4/WXWJ"H_Q_'"MPE>0T
M2K(H$+?LIN^L=GU[.M+5S3;1V&Y6]LI'LU+9SF7/ZNIZ5)(7B<5?^<@5!YA9
M>7XI[I--U"7*FO9IM!J::LQQJJ@&S IU.MUT[O-(,32N1ILVDD#9 %-XS&-*
M &ITCM^T@T;M>-7OSV@>7>>A;O.>C?Y=FDO\R#?F+G%$I_2=!TL!R@I,T\33
MS=^](NR/-9A$[UZ+(#C%CC7BO$@POS+#<)G2.8GR->M237#\I#7MTP W--68
M@UA1C9N!>BH':B(6H],$!O:JJ//%"X[]&79]_HNB"7RXY(/% #5@)VKD49WS
M@3+LSYP\C>)#W71PAL&48+#^3&&IAW:ZW:(@IX-S:T6M4X@K2P$W%VZK@7JJ
MJ_ -!M"[VH%2(:_SW$ A]FJ6VZJ!1YWC!DGP>F:X;=0>.K]9F0/ BR9/T3^
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MWW/&/K:%JV.AF*Q\ <^:-6S![ /Q:H63"*?IDK(63C91')=+AYEP-RBL)PL
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M +SI1F<[+ 3+3+$8^)4"Q;6ECLF#'ZI9!&GF1V7/)3GL].'Y&ZI<S88)Z0;
M;R6HP:TH&$,V?PU4MX;1@&L+JH HP6D8C+_1L\>2,?5(-Q6+-&'X9%YQR#8/
M3_66P"\YJ(W3MJ(Z *1SU$N/X[;M@=^&:(VCO#HTR[/U<DY[>\ A,C8B6_RB
M;B$FXKM=8B(&_>DOUOAF\ILQ,1'YQW8SQI7"KVMJ >^U&45W!#]Z5#,^/7\)
MV<7R%SM^GZ7 3BXUUYQ-)1Q-';5O3A@W%_;J!K]#R1JRON@]FFFSVG8+A=I!
M#O8&Z_]NPN2:.K,141G$]J(9OD<._9L]'I.G?H8EQ2219%)[S]!A(EJ5:E_
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H;"TR,#(Q,#,S,5]P<F4N>&UL4$L%!@     &  8 B@$  ,"V      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
